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Abstract 
 
Intracellular regulation of sustained contraction stimulated by L-type Ca2+ channel 
activation in swine carotid smooth muscle 
 
Hillevi K. Ets 
Robert S. Moreland 
 
 
Sustained vascular smooth muscle (VSM) contraction is important for 
maintaining organ perfusion and systemic blood pressure at homeostatic levels.  L-type 
Ca2+ channels (LTCCs) on the surface of VSM cells are believed to contribute to 
sustained contraction, however the intracellular signaling downstream of LTCCs is not 
well understood, particularly in large conduit arteries.  
The purpose of this project was to determine how prolonged force is sustained in 
large artery VSM downstream of LTCC activation.  Intact VSM tissue dissected from the 
swine carotid artery was mounted to a force transducer and contracted sub-maximally 
with an LTCC agonist, Bay K8644.  Inhibitors against LTCC activity	and	downstream	kinases	known	to	be	involved	with	VSM	contraction	myosin light chain (MLC) kinase, 
p42/44 mitogen-activated protein (MAP) kinase, protein kinase C (PKC), Rho kinase 
(ROCK), and p21-activated kinase (PAK1) were used individually and in combinations 
to elucidate signaling that maintains long-term force.  Isometric force was recorded as the 
physiological output of the experiment.  
Surprisingly, the known modulatory pathways of VSM contraction by calcium 
sensitization and thin filament regulation were not activated during sustained contraction 
with Bay K8644.  Their involvement was assessed by measuring phosphorylation of the 
	 ix	
myosin binding subunit of MLC phosphatase (MYPT1), the PKC-potentiated inhibitory 
peptide (CPI-17), and the thin filament-associated protein caldesmon.  The most 
intriguing finding was that inhibition of MAP kinase led to a significant increase in Bay 
K8644-induced force and MLC phosphorylation, while inhibition of MLC kinase resulted 
in significantly increased MAP kinase activity.  Such an effect has not been previously 
described and was of great interest given the absence of known force modulatory 
pathways.  The involvement of PAK1 was investigated as a possible mechanism for the 
effects between MLC kinase and MAP kinase.  Inhibiting PAK1 led to decreased MLC 
phosphorylation, decreased MAP kinase phosphorylation, and decreased contractile 
force. 
The collective results suggest the presence of a novel force regulatory mechanism 
involving PAK1 and its effects on p42/44 MAP kinase and MLC kinase during prolonged 
force in carotid artery VSM stimulated by LTCC opening. 
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Introduction 
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Vascular smooth muscle.  
The vasculature is a closed system of tubes containing blood that is propelled by 
the pumping action of the heart.  The majority of the vasculature contains a medial layer 
of smooth muscle termed vascular smooth muscle (Figure 1A) that can contract or relax 
to alter the diameter of a vessel and thus pressure of the blood within.  There are two 
major divisions of the vasculature, the arterial side that carries blood away from the heart 
and the venous side that returns blood to the heart; the focus of this project is the arterial 
vasculature.  Arteries are classified according to the size and function of the vessel 
(Figure 1B).  Large conduit arteries such as the aorta and carotid have a thick layer of 
smooth muscle tightly integrated with elastin and collagen fibers (Arribas, Hinek et al. 
2006) that dampen pulsatory oscillations in pressure (the difference between systolic and 
diastolic pressure) of blood leaving the heart (McEniery, Wilkinson et al. 2007).  The 
elasticity of large arteries allows them to absorb the high pressure of a systolic 
contraction and rebound this energy during diastolic contraction thus evening out 
pressure (Saphirstein and Morgan 2013).  This function is important to protect smaller 
vessels from damaging effects of high pressure. Smaller arteries, also called resistance 
vessels, are a major determinant of systemic blood pressure.  Their ability to constrict or 
dilate in response to intraluminal pressure gives them a great deal of control over total 
peripheral resistance and therefore mean arterial pressure (Davis 2011).   
Proper functioning of vascular smooth muscle ensures tissue perfusion by 
increasing the efficiency of the cardiovascular system.  Its dysfunction in small resistance 
vessels is strongly implicated in hypertension (Bohr and Webb 1984, Han, Hu et al. 2006, 
Martens and Gelband 1998, Mendelsohn 2005).  In large arteries, loss of contractility is 
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associated with a thickening and stiffening of the vessel wall.  This reduces compliance 
of the vessel and indicates increased risk of cardiovascular events such as heart attack and 
stroke.  Identifying how these functional changes occur begins with understanding the 
normal mechanism of contraction.   
  
Mechanism of contraction. 
The primary function of any muscle is to contract.  Vascular smooth muscle 
contraction involves transduction of an extracellular signal to the intracellular contractile 
filaments: actin and myosin.  This stimulation to contract is termed excitation-contraction 
coupling.  Excitation occurs either by “electromechanical coupling” or 
“pharmacomechanical coupling" (AV Somlyo and Somlyo 1968), both of which result in 
an increase in intracellular Ca2+ concentration as demonstrated in Figure 2 (R Webb 
2003).  Electromechanical coupling is initiated by membrane depolarization that opens 
voltage-gated Ca2+ channels on the cell surface, allowing an influx of Ca2+ from the 
extracellular environment to the intracellular space.  Pharmacomechanical coupling 
occurs when a ligand binds to a G protein-coupled receptor on the cell membrane that 
initiates an intracellular signaling cascade.  The G-alpha subunit activates membrane-
bound phospholipase C (PLC) that cleaves phosphatidylinositol 4,5-bisphosphate (PIP2) 
into two molecules: inositol triphosphate (IP3) and diacylglycerol (DAG) (Berridge and 
Irvine 1984, Nishizuka 1984).  IP3 binds to IP3 receptors on the surface of the 
sarcoplasmic reticulum (SR), triggering the release of intracellular Ca2+ stores (Foskett, 
White et al. 2007).  Whether the increase in Ca2+ is the result of electromechanical or 
pharmacomechanical coupling, once in the cytosol, Ca2+ binds to the calcium binding 
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protein calmodulin (CaM) in a ratio of 4 Ca2+: 1 CaM (Adelstein, Conti et al. 1980).  The 
Ca2+/CaM complex activates myosin light chain (MLC) kinase that can then 
phosphorylate its substrate, the regulatory MLC, at the Serine19 residue (Barron, Barany 
et al. 1980).  MLC phosphorylation activates the myosin molecule and allows for cross-
bridge cycling to occur (Horowitz, Menice et al. 1996, R Webb 2003). 
 
Intracellular Ca2+ stores and Ca2+ handling 
 An increase in intracellular Ca2+ is a critical step for vascular smooth muscle 
contraction, thus the movement and storage of Ca2+ is of great importance (Davis and 
Hill 1999).  The sarcoplasmic reticulum (SR, called the endoplasmic reticulum (ER) in 
non-muscle cells) is the organelle that sequesters Ca2+ within the cell.  The plasma 
membrane and the membrane of the SR contain receptors and channels that regulate Ca2+ 
release and uptake (Figure 3).  IP3 generated from cleaving of PIP2 binds to IP3 
receptors, releasing Ca2+ from the SR (Nelson, Cheng et al. 1995).  Ca2+ is taken back 
into the SR by the sarco/endoplasmic reticulum Ca2+ ATPase (SERCA).  A similar 
ATPase exists in the plasma membrane, called the plasma membrane Ca2+ ATPase 
(PMCA) that pumps Ca2+ from the cytosol into the extracellular space (Thornloe and 
Nelson 2005).  These two pumps, the SERCA and PMCA, require energy in the form of 
ATP to move Ca2+ against its concentration gradient in order to regulate Ca2+ in the 
cytosol.  Store-operated Ca2+ channels (SOCC) allow Ca2+ into the sarcoplasmic 
reticulum from the extracellular space, entirely bypassing the cytosol (Ng and Gurney 
2001).  There is evidence that the Na+/Ca2+ exchanger (NCX) also performs this function 
(Blaustein and Lederer 1999).  In addition, nonselective cation channels in the plasma 
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membrane allow Ca2+ into the cell in response to receptor-ligand interaction, stretch, or 
depletion of SR Ca2+ stores (Thornloe and Nelson 2005). 
 Evidence suggests that, in smooth muscle cells, extracellular Ca2+ entering 
through voltage-gated Ca2+ channels is the primary source for Ca2+ that leads to 
contraction.  Intracellular Ca2+ stored in the SR acts as a negative feedback for 
contraction in smooth muscle cells by activating K+ channels that hyperpolarize the cell 
and promote relaxation (Perez, Bonev et al. 2001, Zhuge, Fogarty et al. 2002).   
 
Cross-bridge cycling 
Cross-bridge cycling is the physical interaction between actin and myosin 
filaments that accounts for cell shortening and the production of force (Hai and Murphy 
1989), as illustrated in Figure 4.  Myosin molecules consist of two heavy chain proteins 
coiled together and hinged.  The hinge part of the molecule is wrapped by two light chain 
proteins, the 20-kDa regulatory light chain and the 17-kDa essential light chain.  The 
regulatory light chain has two phosphorylatable sites at Threonine18 and Serine19 
residues, which are the sites of phosphorylation primarily studied and believe to account 
for activation of myosin (Hai and Kim 2005).  Dual phosphorylation has been 
experimentally observed but is considered a pathophysiological event (Takeya, Wang et 
al. 2014, Walsh 2011).  Although the precise role and regulation of the essential light 
chain is not known, if it is removed from the myosin molecule, contraction fails to occur 
(Hasegawa and Morita 1992).  It is theorized that the essential light chain provides 
structural integrity to the myosin molecule (Hasegawa and Morita 1992).  
Phosphorylation of the regulatory MLC at Serine19 by MLC kinase causes a 
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conformational change in the head portion of the myosin molecule that has intrinsic 
ATPase activity and contains a binding site for the actin filament (Chacko and Rosenfeld 
1982).  The myosin head attaches to the actin filament and rotates, physically pulling on 
the actin filament.  This event is called the power stroke and is the smallest unit of 
contraction (Dillon, Aksoy et al. 1981).  Asynchronous power strokes occurring along the 
length of myosin and actin filaments within a cell allow the cell to shorten or develop 
force.  To initiate relaxation of the smooth muscle cell, the MLC is dephosphorylated by 
the MLC phosphatase resulting in inactivation of the myosin molecule and cessation of 
the cross bridge cycle (Barany, Rokolya et al. 1991).  MLC phosphatase is a 
heterotrimeric protein consisting of a Type 1 phosphatase (PP1c), a myosin-binding 
subunit (MYPT1), and a third subunit of unknown function (Hartshorne, Ito et al. 1998).   
 
Extracellular influences. 
 Vascular smooth muscle cells are tightly integrated into the structure of the vessel 
wall.  The components of the vessel wall affect vascular smooth muscle contraction by 
secreting vasoactive substances (endothelial cells) or by altering the stiffness of the tissue 
(extracellular matrix).   
 
Endothelial cells 
Endothelial cells that line the interior of vessels modulate force by chemical 
crosstalk with vascular smooth muscle cells.  What were originally known as endothelial-
derived relaxing factors have now been identified as nitric oxide (NO), hydrogen sulfide 
(H2S), and prostacyclin (also called prostaglandin 2 or PGI2) (Coletta, Papapetropoulos et 
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al. 2012, Yang, Wu et al. 2008).  NO is synthesized from the amino acid L-arginine by 
endothelial nitric oxide synthase (eNOS).  Because it is a gas, NO rapidly diffuses from 
the endothelial cell into the smooth muscle cell where it promotes relaxation by 
increasing production of cGMP (Dudzinski, Igarashi et al. 2006).  This in turn activates 
PKG that causes the reuptake of Ca2+ by into the SR and the opening of Ca2+-activated 
K+ channels.  These actions decrease the intracellular concentration of Ca2+, reducing 
activation of MLC kinase and promoting relaxation.  PGI2 is a lipid-soluble molecule 
synthesized from prostaglandin H by prostacyclin synthase (Kukovetz, Holzmann et al. 
1979).  As a lipid molecule, PGI2 easily crosses the plasma membrane into the smooth 
muscle cell.  It promotes relaxation by increasing production of cAMP that activates PKA 
leading to dephosphorylation of MLC (Kukovetz, Holzmann et al. 1979).  These relaxing 
factors are considered to be critical for maintaining blood pressure because their absence 
or dysfunction lead to hypertension (Dananberg, Sider et al. 1993, Groneberg, König et 
al. 2010, Ribeiro, Antunes et al. 1992, Sandoo, van Zanten et al. 2010).  The endothelial 
cells also produce the vasoconstrictor endothelin-1 (ET-1) (Hosokawa, Aiuchi et al. 2002, 
Yanagisawa, Kurihara et al. 1988).  ET-1 released by endothelial cells binds to G protein-
coupled receptors on the surface of vascular smooth muscle cells, initiating a cascade that 
releases Ca2+ from the SR via IP3 receptors (Bouallegue, Daou et al. 2007). 
 
Extracellular matrix 
 The components of extracellular matrix affect vascular smooth muscle contraction 
by altering the milieu in which the cells contract.  It is composed primarily of elastin and 
collagen and also contains proteoglycans and glycoproteins (Jacob 2003).  These 
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structural components provide a scaffold against which the vascular smooth muscle cells 
can contract and generate force.  The contraction of one or a few muscle cells can be 
transmitted to and sensed by neighboring muscle cells in a tissue via cell-cell junctions, a 
phenomenon known as mechanotransduction (D'Angelo and Meininger 1994, Hill and 
Meininger 2012, Ingber 2006).  Thus the concerted actions of the individual cells result in 
measurable contractile force in a tissue or organ.  Remodeling of ECM is common in 
hypertension (Jacob 2003).  Stiffening of the ECM affects the contractility of vascular 
smooth muscle (Arribas, Hinek et al. 2006, Lemarie, Tharaux et al. 2009).  Proteolytic 
enzymes called matrix metalloproteinases (MMPs) degrade the ECM and have 
demonstrated importance in vascular remodeling seen during ageing and disease states 
like hypertension (Jacob 2003, Kuzuya and Iguchi 2003, S Liu, Bae et al. 2015).  They 
contribute to the remodeling of the ECM observed in hypertension (Raffetto and Khalil 
2008). 
 
Intracellular signaling. 
The magnitude of force developed by vascular smooth muscle in response to 
stimuli can be modulated by intracellular signaling pathways that alter sensitivity of the 
contractile components to Ca2+ (Ca2+ sensitization), relieve inhibition on myosin ATPase 
(thin filament regulation), and change cytoskeletal actin dynamics (actin polymerization).   
 
Ca2+ sensitization  
Inhibition of the MLC phosphatase allows the regulatory MLC to remain 
phosphorylated without additional cytosolic Ca2+.  Hence the contractile machinery is 
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"sensitized" to Ca2+ already present in the cytosol.  MLC phosphatase can be inhibited by 
two kinases: protein kinase C (PKC) and Rho-associated kinase (ROCK).  PKC activated 
by DAG during electromechanical and pharmacomechanical coupling phosphorylates a 
17-kDa substrate known as the C-potentiated inhibitory protein (CPI-17).  
Phosphorylation at the threonine38 residue of CPI-17 inhibits the catalytic activity of 
MLC phosphatase by binding to the PP1c subunit (Eto, Ohmori et al. 1995).  On the other 
hand, ROCK phosphorylates the myosin-binding MYPT1 subunit, inhibiting MLC 
phosphatase activity (K Kimura, Ito et al. 1996).  ROCK is typically activated by GTP-
bound RhoA following GPCR activation however there is evidence that ROCK can also 
be activated during membrane depolarization (Janssen, Tazzeo et al. 2004, Mita, 
Yanagihara et al. 2002, Ratz, Berg et al. 2005, Urban, Berg et al. 2003) and Ca2+ channel 
opening (Fernandez-Tenorio, Porras-Gonzalez et al. 2012, Ureña and Lopez-Barneo 
2012).  The mechanism of Ca2+-dependent ROCK activation is unknown and has led to 
the alternative hypothesis that ROCK is constitutively active in vascular smooth muscle 
because of the relatively high level of MYPT1 phosphorylation observed in unstimulated 
smooth muscle cells (Alvarez, Miner et al. 2010).  Ca2+ sensitization is considered an 
important modulatory pathway of vascular smooth muscle contractility and its 
dysfunction has been implicated in the pathogenesis of hypertension (Abe, Shimokawa et 
al. 2004, Doggrell 2005, Seko, Ito et al. 2003, Uehata, Ishizaki et al. 1997). 
 
Thin filament regulation 
 Another mechanism for enhancing vascular smooth muscle contraction involves 
actin and its associated proteins calponin and caldesmon (Figure 5, right side).  
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Caldesmon is situated on the actin filament and exerts an inhibitory effect on contraction 
by inhibiting actin-activated myosin ATPase activity, the biochemical activity 
responsible for muscle shortening and the development of force (Ngai and Walsh 1984).  
Phosphorylation of caldesmon by p42/44 MAP kinase relieves this inhibition (Adam and 
Hathaway 1993).  Caldesmon appears to act as a “brake” on smooth muscle contraction, a 
hypothesis confirmed by siRNA and antisense oligonucleotide knockdown of caldesmon 
in swine carotid artery smooth muscle that showed an increase in shortening velocity, an 
index of cross-bridge cycling (Earley, Su et al. 1998, Smolock, Trappanese et al. 2009, 
Trappanese 2012).  Loss of caldesmon led to increased contraction and sensitivity to 
contractile agonists.  The importance of this is demonstrated by the fact that, in human 
and animal models of pregnancy, expression of caldesmon greatly increases while 
expression of caldesmon-phosphorylating kinases such as p42/44 MAP kinase decrease 
in the myometrium (Y Li, Je et al. 2003, Word, Stull et al. 1993).  The net effect of 
increased caldesmon and decreased ability to phosphorylate caldesmon is a quiescent 
myometrium during gestation.  Shortly before labor, caldesmon levels dramatically 
decrease while levels of caldesmon-regulating kinases increase (Y Li, Je et al. 2003).  
This is thought to be in preparation of the myometrium for labor when maximal 
contractions are needed.  It is likely that additional research will yield other contributions 
of thin filament-associated proteins to contraction.  
 
Actin cytoskeleton dynamics 
In addition to the contractile actin filaments, it has been demonstrated that the 
cytoskeletal (non-contractile) actin is involved in force development (Cipolla, Gokina et 
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al. 2002, Gerthoffer and Gunst 2001, Staiculescu, Galiñanes et al. 2013).  Cytoskeletal 
actin exists as either a globular monomer (G-actin) or a filamentous polymer (F-actin), 
which is stochastic and continually polymerizing and depolymerizing (Tang and 
Anfinogenova 2008).  Filamentous actin provides the interior scaffold of all cells, 
including smooth muscle cells (Dominguez and Holmes 2011).  The connection of this 
scaffold to the extracellular matrix and neighboring cells is important for 
mechanotransduction within a given tissue (Hill and Meininger 2012, Ingber 2006).  The 
contractile filaments cannot produce measurable force unless they are tethered to the cell 
membrane and, by extension, the extracellular matrix and neighboring cells (Figure 6).  
This has been proposed as a mechanism for maintaining vascular tone (Cipolla, Gokina et 
al. 2002, Gunst and Zhang 2008, Staiculescu, Galiñanes et al. 2013).  Rather than 
continually using ATP molecules to phosphorylate MLC during a contraction, actin 
polymerization and remodeling of the cytoskeleton provides rigidity to a contracted cell 
(Lehman and Morgan 2012).  The ratio of F:G actin has been studied as an index of actin 
polymerization.  It has been shown to increase during airway (Gunst, Tang et al. 2003) 
and vascular smooth muscle contraction (Chen, Pavlish et al. 2008).  While the 
involvement of the actin cytoskeleton is outside the scope of this thesis, its growing 
importance in the field of smooth muscle research cannot go unmentioned.  
 
While these force modulatory mechanisms are known to be important to vascular 
smooth muscle contraction, they do not explain all observed phenomena such as that of 
vascular smooth muscle tone. 	
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Vascular smooth muscle tone 
A unique feature of vascular smooth muscle is that of basal or resting tone, best 
described as the amount of intrinsic force generated in the absence of a stimulus (Folkow 
1989).  Tone is the background against which chemical signals cause contraction or 
relaxation.  It is also known as intrinsic tone, basal tone, myogenic tone, and spontaneous 
tone (Meininger and Davis 1992).  In an organism, this tone is best represented by the 
myogenic response, the ability of a vessel to constrict in response to an increase in 
luminal pressure and dilate in response to a decrease in pressure (Davis 2011).  At the 
cellular level, a feature of tone is that the intracellular concentration of Ca2+ is higher than 
during relaxation but significantly lower than during a stimulated contraction, an event 
known as the “latch state” (Rubart, Patlack et al. 1996).	 
 
The myogenic response 
 The myogenic response is observed throughout the vascular tree however there is 
an inverse relationship between diameter of the vessel and its myogenic response (Davis 
and Hill 1999).  The microcirculation is most responsive to changes in intraluminal 
pressure because of its thick layer of smooth muscle (relative to total vessel diameter) and 
the absence of collagen and elastin.  The myogenic response is likely caused by 
depolarization of the plasma membrane and subsequent activation of voltage-gated Ca2+ 
channels, also known as L-type Ca2+ channels (Meininger and Davis 1992). 
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The latch state 
The ability of smooth muscle to maintain force during a state of low levels of 
intracellular Ca2+ and MLC phosphorylation, termed the latch state (Hai and Murphy 
1989), is demonstrated in Figure 7.  Stimulation of a smooth muscle tissue produces a 
large rise in Ca2+ levels (-x-) followed closely by an increase in MLC phosphorylation 
levels (--).  These events are followed by an increase in force (-o-) that plateaus as Ca2+ 
and MLC phosphorylation levels decrease to near basal levels.  This has led to the 
hypothesis that during sustained stimulation and contraction, force is maintained by 
dephosphorylated, slowly cycling "latchbridges".  It is not entirely clear how the latch 
state is maintained, but it may involve the carefully maintained balance of Ca2+ influx 
and efflux through calcium channels in the plasma membrane as well as intracellular 
kinase feedback mechanisms.  One such channel that has demonstrated importance in 
vascular tone is the L-type Ca2+ channel (Cobine, Callaghan et al. 2007, Moosmang, 
Schulla et al. 2003, Thornloe and Nelson 2005). 
 
L-type Ca2+ channels 
L-type calcium channels (LTCCs) are voltage-gated, dihydropyridine-sensitive 
ion channels present in the cell membrane of all excitable cells, including smooth muscle 
cells.  The “L” indicates long-lasting, kinetically slow channel activity.  The primary 
channel type in adult vascular smooth muscle tissue is the L-type which are present in 
differentiated, contractile smooth muscle cells but not in dedifferentiated, proliferative 
smooth muscle cells (Gollasch, Haase et al. 1998).  Their expression level mirrors that of 
smooth muscle α-actin, a well-established marker for differentiated smooth muscle cells.  
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In fact, down-regulation of LTCC leads to a loss of smooth muscle contractility 
(Kudryavtseva, Herum et al. 2014).  LTCCs are composed of 5 subunits: the pore-
forming α1 subunit, the disulfide-linked α2 and δ subunits, an intracellular β subunit, and a 
transmembrane γ subunit, depicted in Figure 8 (Catterall 2000).  On any given cell, the 
population of LTCCs are heterogeneous, meaning they have different thresholds of 
activation and deactivation (Fransen, Van Hove et al. 2012).  Some channels activate fast 
and are believed to be responsible for a rapid initiation of contraction.  Other channels 
activate slowly and are thought to sustain tonic contractions (Ureña and Lopez-Barneo 
2012).  LTCCs open in response to subtle changes in membrane voltage and do not 
require an action potential to be activated (Fleischmann and Murray 1994, Navedo, 
Amberg et al. 2005).  In this way, LTCCs create a “calcium window” that provides a 
small, sustained influx of Ca2+ into the cell which is thought to be important for 
maintaining tone (Fransen, Van Hove et al. 2012).  
 
LTCCs and kinases. 
The demonstrated importance of LTCCs in maintaining vascular tone was the 
point of departure for this study.  Because the influx of Ca2+ through LTCCs is 
recognized as a critical part of maintaining vascular smooth muscle tone, we sought to 
mimic a state of increased tone by using an LTCC agonist, Bay K8644, then correlate the 
elevation in force with intracellular signaling cascades.  The purpose of this study was to 
determine the intracellular events required to develop tone in a conduit vessel in response 
to opening of LTCCs.  The kinases of interest discussed in detail below are MLC kinase, 
MAP kinase, Rho kinase, and p21-activated kinase.  Figure 9 shows the reported and 
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proposed interactions among the proteins of interest.  This thesis will attempt to show 
that the central regulator of prolonged carotid vascular smooth muscle contraction is p21-
activated kinase or PAK1.  The dashed lines of Figure 9 represent the proposed 
interactions between the kinases.  PAK1 is activated by autophosphorylation.  Once 
activated, PAK1 regulates the activity of both MLC kinase and MAP kinase in order to 
maintain contractile force but prevent uncontrolled contraction.  
 
Myosin light chain kinase (MLC kinase) is a unique serine/threonine kinase 
because unlike most kinases, which have multiple substrates, the only known 
physiological substrate is the 20 kDa MLC.  MLC kinase consists of a catalytic domain, a 
calmodulin-binding domain, an actin-binding site, and several phosphorylation sites 
(Stull, Lin et al. 1998).  It is activated when bound to the Ca2+/calmodulin complex 
(Gallagher, Herring et al. 1991).  In the absence of Ca2+/calmodulin binding to MLC 
kinase, then MLC kinase can be phosphorylated at Serine1760 which reduces MLC kinase 
activity (Conti and Adelstein 1981).  MLC kinase expression has been shown to increase 
during the development of hypertension in spontaneously hypertensive rats (Han, Hu et 
al. 2006).  The change in expression is partially controlled by MAP kinase signaling, as 
inhibiting MAP kinase in vivo decreased MLC kinase expression and blood pressure.  
Though MLC kinase is considered quintessential for contractile force, there are 
other kinases that appear to have increasingly prominent roles in regulating and 
maintaining force.   
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p42/44 mitogen-activated protein kinase (p42/44 MAPK), also known as 
extracellular signal-regulated kinase 1/2 (ERK 1/2), is a serine/threonine kinase in the 
MAP kinase superfamily.  The canonical MAP kinase signaling cascade features MAP 
kinase that is phosphorylated by MAP kinase kinase (MEK), which in turn is activated by 
a MEK kinase (Figure 10) (Cargnello and Roux 2011).  Dual phosphorylation of MAP 
kinase at threonine and tyrosine residues in the activation loop causes a conformational 
change that stabilizes the active conformation and relieves steric hindrances of substrate 
binding.  Phosphorylated MAP kinase translocates to the nucleus resulting in activation 
of nuclear transcription factors and increased protein production.  MAP kinases are 
deactivated by dephosphorylation, typically by the dual-specificity phosphatases known 
as MAP kinase phosphatases (MKPs).  Because MAP kinase activity is most commonly 
associated with cell growth and proliferation, it is widely studied in organismal 
development and cancer (Dhillon, Hagan et al. 2007).   
In smooth muscle cells, MAP kinase activity has been shown to modulate 
contraction and force.  MAP kinase increases Ca2+ sensitivity in rat tail artery (Tsai and 
Jiang 2005) and contributes to Ca2+ sensitization in intestinal smooth muscle (Ihara, Yu et 
al. 2015).  These findings have been confirmed with the use of specific inhibitors, but a 
mechanism for how these effects are mediated has not been elucidated.  In addition to 
contributing to Ca2+ sensitization, MAP kinase regulates the thin filament-associated 
protein caldesmon by phosphorylation, thus relieving caldesmon’s inhibitory effect on 
contraction (Childs and Mak 1993).  Caldesmon phosphorylation can be activated by 
stretch (Franklin, Wang et al. 1997) or by contractile agonists such as KCl, 
phenylephrine, histamine, acetylcholine, angiotensin II, phorbol esters, and several 
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neurotransmitters (Dessy, Kim et al. 1998, Florian and Watts 1998, Hershenson, Chao et 
al. 1995, Katoch and Moreland 1995, Rosen, Ginty et al. 1994).  Inhibiting MEK, and 
preventing MAP kinase activation, decreased tone in rat middle cerebral arteries 
suggesting it plays a role in maintaining tone (Lagaud, Lam et al. 1999).  It is clear that 
MAP kinase activity or lack thereof has a profound effect on smooth muscle contraction.  
Though it is not the main kinase determining contractile force, its involvement in 
contraction is of great interest.   
 
The final protein of interest is p21-activated kinase 1 (PAK1), a serine/threonine 
kinase expressed throughout the body.  PAK1 consists of a protein binding domain, an 
autoinhibitory domain, and a catalytic kinase domain (Figure 11) (Sheehan, Ke et al. 
2007).  There are many extracellular signals that result in PAK1 activation including 
carbachol, lysophosphatidic acid, epidermal growth factor, and phorbol 12-myristate 13-
acetate (activator of PKC) (Menard and Mattingly 2003).  PAK1 exists in its inactivated 
form as a dimer in the cytosol and binding of GTP-bound Rac1 or Cdc42 activates PAK1 
by relieving dimerization and allowing autophosphorylation of the PAK1 monomers 
(Knaus, Wang et al. 1998).  Once activated, PAK1 can phosphorylate a number of 
substrates depending on the cell type and the initiating extracellular signal.  
In non-muscle cells, PAK1 mediates cell growth, proliferation, motility, and actin 
cytoskeleton dynamics.  Injection of PAK1 into quiescent cells induces membrane 
ruffling and F-actin polymerization, two events associated with cell migration (Sells, 
Knaus et al. 1997).  More recently, PAK1 has been shown to phosphorylate cortactin, an 
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F-actin binding protein important for the formation of podosomes and lamellapodia, 
particularly in macrophages (B Webb, Zhou et al. 2006).  
In addition to mediating proliferation and growth, PAK1 has specialized roles in 
muscle cells.  In skeletal muscle, PAK1 activity is critical for insulin-induced GLUT4 
recruitment and actin remodeling (Tunduguru, Chiu et al. 2014) and eliminating PAK1 or 
inhibiting its activity in skeletal muscle prevents these insulin-dependent effects.  In 
cardiac muscle, PAK1 profoundly affects intracellular Ca2+ homeostasis by regulating 
transcription of sarcoplasmic reticulum Ca2+-ATPase (Y Wang, Tsui et al. 2014) as well 
as LTCC activity (Ke, Lei et al. 2007).  These insights have led to the investigation of 
PAK1 as a therapeutic target for cardiac hypertrophy and heart failure (W Liu, Zi et al. 
2011). 
PAK1 activity has several effects in smooth muscle.  PAK1 has been shown to 
inhibit MLC kinase activity (Sanders, Matsumura et al. 1999), MLC phosphorylation, 
and contraction in Triton X-100-permeabilized carotid artery and taenia coli smooth 
muscle from guinea pig (Wirth, Schroeter et al. 2003).  PAK1 has been shown to 
phosphorylate the thin filament-associated protein caldesmon in vitro, though it is 
unknown if this finding has physiologic relevance (Foster, Shen et al. 2000).  PAK1 
regulates the network of vimentin, an intermediary filament protein, during smooth 
muscle contraction (Q Li, Spinelli et al. 2006).  Vimentin disassembles during 
contraction in order to facilitate a cytoskeletal rearrangement that favors force 
development.  A global PAK1 knockout in mice resulted in a decreased responsiveness in 
airway smooth muscle (Hoover, Zhang et al. 2012).  In intestinal smooth muscle tissue, 
PAK1 increases MYPT1 phosphorylation at the Threonine696 residue thereby increasing 
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MLC phosphorylation and force (Chu, Pham et al. 2013).  PAK1 has also been shown to 
phosphorylate and activate MAP kinase kinase, MEK (Frost, Steen et al. 1997), which is 
of particular interest in this study as it may explain how MAP kinase regulates 
contraction.  Overall these findings suggest an important role for PAK1 in muscle 
contraction.  
 
The purpose of this project was to mimic a state of increased tone in vascular 
smooth muscle tissue by sub-maximally activating LTCCs in order to elucidate the 
intracellular events responsible for developing long-term contraction or tone.  
Surprisingly, the known modulatory pathways of force—calcium sensitization via CPI-17 
and MYPT1 phosphorylation and thin filament regulation via caldesmon disinhibition—
were not involved.  Though MLC kinase is the primary kinase responsible for initiating 
contraction, maintaining contractile force appears to require a complex regulatory 
mechanism that involves MLC kinase, MAP kinase, and PAK1.  The results revealed that 
these kinases all effect phosphorylation of MLC, either directly or indirectly, and 
therefore contribute to force.  PAK1 appears to be a regulator of MAP kinase and MLC 
kinase activity because inhibiting PAK1 led to decreased activity of these kinases, 
visualized with Western blots of phosphorylatable activation sites or downstream 
substrates.  Defining this pathway will lead to a better understanding of vascular smooth 
muscle tone which is required in order to identify changes in pathological states.   
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Figure 1. The vasculature.  
A.  
 
 
B. 
 
Intima (endothelial cells) 
Adventitia (connective tissue) 
Media (smooth muscle cells) 
Large conduit artery 
    - thick muscle layer 
    - highly elastic 
    - absorbs high pressure  
of blood leaving the heart 
Small resistance arteries 
    - thick muscle layer 
    - little collagen and elastin 
    - regulate total peripheral 
resistance 
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Figure 1. The vasculature. 
A. Cross section of a vessel wall showing the medial smooth muscle layer situated 
between the intimal endothelial cells that line the vessel lumen and the adventitial 
connective tissue that offers structural support to the blood vessel.  The smooth muscle 
layer receives input to contract or relax from the endothelial cells in the lumen as well as 
nerve endings in the adventitia.  
B.  Branching of the vascular tree from a large artery into smaller arteries.  
Conduit vessels contain smooth muscle integrated with collagen and elastin in order to 
withstand the high pressure of blood leaving the heart.  Small resistance vessels have a 
thick layer of smooth muscle relative to total vessel diameter that allows for 
autoregulation of blood flow.  (Courtesy of Servier Medical Art)  
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Figure 2. Electromechanical and pharmacomechanical coupling. 
 
  
(RhoGEFs; Fig. 1). Because RhoGEFs facilitate activa-
tion of RhoA, they regulate the duration and intensity
of signaling via heterotrimeric G protein receptor
coupling. There are !70 RhoGEFs in the human ge-
nome, and three RhoGEFs have been identified in
smooth muscle: PDZ-RhoGEF, LARG (leukemia-asso-
ciated RhoGEF), and p115-RhoGEF. Increased expres-
sion and/or activity of RhoGEF proteins could aug-
ment contractile activation of smooth muscle and
therefore play a role in diseases where an augmented
response contributes to the pathophysiology (hyper-
tension, asthma, etc.).
Several recent studies suggest a role for additional
regulators of MLC kinase and MLC phosphatase (13–
16). Calmodulin-dependent protein kinase II pro-
motes smooth muscle relaxation by decreasing the
sensitivity of MLC kinase for Ca2". Additionally, MLC
FIG. 1.
Regulation of smooth muscle contraction. Various agonists (neurotransmitters, hormones, etc.) bind to
specific receptors to activate contraction in smooth muscle. Subsequent to this binding, the prototypical
response of the cell is to increase phospholipase C activity via coupling through a G protein. Phospholipase
C produces two potent second messengers from the membrane lipid phosphatidylinositol 4,5-bisphosphate:
diacylglycerol (DG) and inositol 1,4,5-trisphosphate (IP3). IP3 binds to specific receptors on the sarcoplasmic
reticulum, causing release of activator calcium (Ca2!). DG along with Ca2! activates PKC, which phosphor-
ylates specific target proteins. In most smooth muscles, PKC has contraction-promoting effects such as
phosphorylation of Ca2! channels or other proteins that regulate cross-bridge cycling. Activator Ca2! binds
to calmodulin, leading to activation of myosin light chain kinase (MLC kinase). This kinase phosphorylates
the light chain of myosin, and, in conjunction with actin, cross-bridge cycling occurs, initiating shortening
of the smooth muscle cell. However, the elevation in Ca2! concentration within the cell is transient, and the
contractile response is maintained by a Ca2!-sensitizing mechanism brought about by the inhibition of
myosin phosphatase activity by Rho kinase. This Ca2!-sensitizing mechanism is initiated at the same time that
phospholipase C is activated, and it involves the activation of the small GTP-binding protein RhoA. The
precise nature of the activation of RhoA by the G protein-coupled receptor is not entirely clear but involves
a guanine nucleotide exchange factor (RhoGEF) and migration of RhoA to the plasma membrane. Upon
activation, RhoA increases Rho kinase activity, leading to inhibition of myosin phosphatase. This promotes
the contractile state, since the light chain of myosin cannot be dephosphorylated.
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Figure 2.  Electromechanical and pharmacomechanical coupling. 
Ligand binding to a receptor in the plasma membrane leads to activation of G 
proteins that stimulate production of phospholipase C (PLC) and inositol triphosphate 
(IP3).  IP3 binds to receptors on the sarcoplasmic reticulum causing release of Ca2+ into 
the cytosol.  Ion channels in the plasma membrane allow influx of Ca2+.  Ca2+ binds to 
calmodulin and the Ca2+/calmodulin complex activates MLC kinase, leading to MLC 
phosphorylation the formation of crossbridges, and active crossbridge cycling (R Webb 
2003).  Reprinted with permission from The American Physiological Society. 
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Figure 3. Ca2+ handling in vascular smooth muscle. 
 
 
 
 
  
dihydropyridine-sensitive L-type VDCCs dominate in the
majority of SMs, the expression pattern and current density
of other VDCC types may differ among SM preparations.
This is consistent with the documented expression of non L-
or T-type channels in renal arterioles (Hansen et al. 2000)
and a differential molecular expression of pore-forming
VDCC subunits in regions of the renal resistance vasculature
(Hansen et al. 2001). L-type VDCCs play a dominant role in
SM, but the presence of other VDCC types may be of func-
tional importance for a number of SMs.
Nonselective cation channels
Nonselective cation channels have been described in al-
most every cell type to date with varying permeabilities to
Ca2+, Na+, and K+ ions (Clapham et al. 2001; Montell et al.
2002; Clapham 2003). The molecular basis of this wide vari-
ety of cation channels has been tentatively ascribed to the di-
verse family of transient receptor potential (TRP) ion
channels, initially discovered in Drosophila vision signaling
(Montell and Rubin 1989). TRP ion channels are formed by
the homo- or heterotetrameric assembly of pore-forming sub-
units, each subunit having a predicted 6-transmembrane
domain topology (Fig. 1). In SM, a number of Ca2+-
permeable, nonselective cation channels have been identified.
These include (i) receptor-activated, (ii ) SR Ca2+ store-
depletion-activated, (iii) stretch-activated, and, more re-
cently, (iv) tonically active cation channels (Fig. 2).
Unlike VDCCs in SM that demonstrate a high selectivity
for Ca2+ ions over monovalent cations, the majority of in-
ward current through nonselective cation channels under
physiological conditions is mediated by the influx of
extracellular Na+. Although it has been well established that
these different channel types are permeable to Ca2+ ions, it
remains in question whether they contribute significantly to
increases in intracellular Ca2+ and (or) to contractile Ca2+ in
SM. Regardless of their ability to provide Ca2+ for contrac-
tion, nonselective cation channels do provide a depolarizing
influence, which can lead to activation of VDCCs mediating
extracellular Ca2+ entry and contraction.
Receptor-activated channels in SM can be divided into 2
groups: (i ) ligand-gated channels activated directly by ligand
binding to the channel (the major player identified as
purinergic P2X receptor channels), and (ii ) channels acti-
vated by agonists, which bind 7-transmembrane domain re-
ceptors, activate G proteins, and thereby elicit channel
opening, receptor-operated cation channels (ROCCs).
P2X receptor channels
ATP-activated ligand-gated channels in SM were first
identified by Benham and Tsien (1987) in rabbit ear artery
SM cells. The inward currents were rapidly activated by
ATP, mediated by cations, and declined in the continued
presence of ATP as a result of channel desensitization. Later,
P2X receptor channels were cloned from rat vas deferens
SM and heterologously expressed, demonstrating ATP-
activated currents analogous to those in SM (Valera et al.
1994). The P2X family of ligand-gated ion channels now in-
cludes at least 7 identified genes (Ralevic and Burnstock
1998), of which a number have been identified in various
SMs (Brake et al. 1994; Garcia-Guzman et al. 1996; Soto et
al. 1996; Vial and Evans 2000; Gitterman and Evans 2000;
Lewis et al. 2000; Mironneau et al. 2001). Although other
P2X family members are expressed in these SMs, P2X1
channels are the major contributor to ATP-gated currents
(Ralevic and Burnstock 1998). P2X1 channels are also well
established as mediators of excitatory junction potentials
(Byrne and Large 1984; Sneddon and Burnstock 1984; Brain
et al. 2002; Lamont and Wier 2002). Excitatory junction po-
tentials are elicited by the release of neurotransmitter ATP
from nerves, providing a depolarizing stimulus to the mus-
cle. Summation of excitation junction potentials in SM with
increasing nerve stimulation can provide sufficient depolar-
ization to elicit VDCC activation. The dominant role of
P2X1 channels in SM has been confirmed by the lack of
ATP-evoked currents and nerve-mediated, ATP-dependent
contractions in the vas deferens and urinary bladder of P2X1
knockout (KO) mice (Mulryan et al. 2000; Vial and Evans
2000).
© 2005 NRC Canada
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Fig. 2. Smooth muscle (SM) excitatory ion channels. SM depolarization is mediated by Cl–-selective channels (IC1– ), tonically active
cation channels (Icat), stretch-activated channels (SAC), purinergic ligand-gated channels (P2X), store-operated cation channels (SOCC),
and receptor-operated cation channels (ROCC). These channels provide membrane depolarization leading to activation of Ca2+ selec-
tive, voltage-dependent Ca2+ channels (VDCC), which provide Ca2+ for SM contraction.
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Figure 3. Ca2+ handling in vascular smooth muscle. 
Cellular stretch activates Cl- channels, nonselective cation channels, stretch-activated 
channels (SAC), P2X receptors, store-operated Ca2+ channels (SOCC), and receptor-
operated cation channels (ROCC) thereby depolarizing the cell membrane sufficient to 
activate voltage-gated Ca2+ channels.  The Ca2+ entering through voltage-gated Ca2+ 
channels is the major contributor to smooth muscle cell contraction.  Ca2+ is also released 
from the SR through IP3 and ryanodine receptors (RyR) but this is considered less 
influential in contraction (Thornloe and Nelson 2005).  Reprinted with permission from 
NRC Research Press.  
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Figure 4. The crossbridge cycle. 
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Figure 4. The crossbridge cycle.  
(I) Adenosine triphosphate (ATP) binds to the S-1 globular head of myosin resulting in 
the dissociation of myosin and actin. 
(II) The S-1 head of the myosin molecule has intrinsic ATPase activity and rapidly 
hydrolyzes the ATP molecule to ADP and Pi. 
(III) In the presence of Ca2+ the MLC is phosphorylated which activates the myosin 
molecule.  
(IV) Myosin binds to an actin molecule in the thin filament. Release of the Pi from the S-
1 head of myosin causes the myosin head bound to the actin filament resulting in a 
conformational change from a 90° to a 45° movement, in a motion known as the power 
stroke. 
(V) Release of the adenosine diphosphate (ADP) molecule resets myosin to receive 
another ATP molecule though some investigators in the field posit that ADP is not 
released in order to maintain what is known as a latchbridge (an attached non-cycling 
crossbridge) (Langeron, Bouhemad et al. 2003). 
Reprinted with permission from the Oxford University Press. 
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Figure 5. Pathways that modulate vascular smooth muscle contraction. 
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Figure 5. Pathways that modulate vascular smooth muscle contraction. 
Binding of a ligand to a cell-surface receptor or activation of voltage-gated Ca2+ 
channels lead to an increase in cytosolic [Ca2+].  Ca2+ binds to calmodulin in order to 
activate MLC kinase that phosphorylated MLC (left side of figure).  In addition to this 
primary pathway, the smooth muscle contractile proteins receive input from regulatory 
mechanisms that affect their sensitivity to intracellular Ca2+, inhibition by thin filament-
associated proteins, and cytoskeletal actin remodeling.  Ca2+ sensitization is governed by 
the activities of Rho kinase and PKC that inhibit MLC phosphatase activity.  Additionally 
PKC may activate MAP kinase that phosphorylates the thin filament-associated protein 
caldesmon (right side of figure).  Phosphorylation of caldesmon, and potentially calponin, 
also contributes to contraction.  The purpose of these modulatory pathways is to finely 
regulate vascular smooth muscle contraction (Salamanca and Khalil 2005).  Reprinted 
with permission from Elsevier. 
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Figure 6. Actin cytoskeleton dynamics in vascular smooth muscle. 
 
 
  
between an open state in which it can bind to actin filaments as
well as to talin and !-actinin, and a closed conformation in
which it does not bind to either of these proteins, thus enabling
it to reversibly form connections between actin filaments and
membrane adhesion sites (24, 29). Vinculin binds to paxillin
and is recruited with paxillin to the adhesion complexes of
tracheal smooth muscle cells during contractile stimulation
(95). The expression of mutant vinculin peptides that inhibit
the activation of endogenous vinculin prevents the stimulus-
induced contraction of tracheal smooth muscle (69). The con-
trolled formation and dissolution of actin filament/adhesion
complex linkages by !-actinin, vinculin, and other proteins
may be an important mechanism for regulating the cytoskeletal
organization of the smooth muscle cell and enable the trans-
mission of contractile tension (61, 62).
The formation of macromolecular complexes at the leading
edge of crawling or spreading cells depends on a carefully
orchestrated process involving the stepwise assembly of an
adhesion complex, and the assembly of this adhesion complex
is required for the initiation of localized actin filament poly-
merization and dissolution. The cytoskeletal processes that
occur in smooth muscle during contractile activation may serve
parallel functions to some of the processes that occur during
cell migration: mechanical force generated either internally by
the contractile apparatus or externally by strain imposed on the
cell may stimulate the assembly of adhesion complexes that
catalyze the formation of a cortical network of actin filaments,
anchor the actin filament network to integrin proteins at adhe-
sion sites, and strengthen the network of newly formed actin
filaments. The formation of this cortical cytoskeletal structure
might serve to form a more rigid submembranous structure that
is capable of transmitting the force generated by the activation
of contractile proteins to the extracellular matrix filaments and
across the tissue (Fig. 4).
Actin Depolymerizing Proteins (ADF/Cofilin) in the
Regulation of Actin Dynamics in Smooth Muscle Tissues
Studies of actin dynamics in vitro and in cells have shown
that the polymerization of actin is regulated by proteins that
control the availability of a pool of monomeric (G) actin for
incorporation into actin filaments, and the availability of
free “barbed” or “plus” ends of actin filaments that can
undergo polymerization (22, 77). The family of ADF (actin
depolymerization factor)/cofilin proteins can regulate both
of these processes. These proteins have therefore been
termed “actin-dynamizing” proteins because of their critical
role in regulating the actin filament remodeling that enables
the rapid adaptation of the actin cytoskeleton to localized
cellular functions (11, 23, 30).
The important role of ADF/cofilin proteins in cell migration
is well established (10, 23, 30). During cell migration, new
actin filaments are generated at the leading edge of the cell, and
actin filaments at the rear of the actin network are disassem-
bled. Cofilin plays an essential role in both the actin polymer-
ization and depolymerization processes during cell movement:
It binds to actin filaments and severs them, thereby promoting
actin disassembly and the formation of new barbed ends, which
enables the nucleation of new actin filaments by the Arp2/3
complex. Cofilin also contributes to actin filament assembly by
replenishing the actin monomer pool required for polymeriza-
tion (11, 23, 75, 98).
Cofilin activity is regulated through phosphorylation and
dephosphorylation of its NH2-terminal Ser3. Serine 3 phos-
phorylation abolishes the ability of cofilin to bind to F-actin
and thus inhibits its severing function (2, 10, 83, 87). The
dephosphorylation of cofilin is mediated by the cofilin-specific
phosphatases slingshot and chronophin (70). Phosphorylated
cofilin binds to the intracellular scaffolding protein 14-3-3
(56), which acts to sequester it. Displacement from 14-3-3 can
result in the activation of cofilin by cofilin-specific phospha-
tases. Cofilin is abundantly expressed in vascular smooth
muscle cells and tissues, where it has been implicated in the
regulation of vascular smooth muscle cell migration (109). It
also plays a role in regulating the expression of smooth muscle
differentiation markers in vascular tissues (3, 64).
Recent evidence suggests that cofilin also plays a critical
role in regulating actin dynamics during the contraction and
relaxation of smooth muscle tissues. In tracheal smooth muscle
tissues, stimulation of the tissues with acetylcholine causes the
dephosphorylation and activation of cofilin (147). Cofilin de-
phosphorylation can be inhibited by expression of dominant-
negative inactive cofilin mutant, cofilin S3E (83). When cofilin
S3E is expressed in tracheal muscle tissues, it inhibits cofilin
dephosphorylation and prevents the increase in actin polymer-
ization stimulated by acetylcholine (147). These observations
are consistent with the postulated role of cofilin in regulating
the size of the pool of G-actin available for actin polymeriza-
tion during contraction. In cultured human airway smooth
muscle cells, cofilin is activated (dephosphorylated) in re-
sponse to forskolin and isoproterenol, suggesting a possible
Fig. 4. Integrated model for function of cytoskeletal dynamics in smooth
muscle contraction. The activation of the smooth muscle cell stimulates the
assembly of macromolecular protein complexes at cell membrane/ECM adhe-
sion junctions that regulate the formation of a subcortical network of actin
filaments and fortify connections between the actin filaments and integrin
proteins. The formation of a subcortical actin filament network strengthens the
membrane for the transmission of force generated by the actomyosin system
and enables adaptation of the smooth muscle cell to external forces.
Review
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Figure 6.  Actin cytoskeleton dynamics in vascular smooth muscle. 
Cytoskeletal actin filaments (F-actin) are composed of globular actin monomers 
(G-actin).  The cytoskeletal actin filaments tether contractile actin filaments to integrins 
that physically associate with the extracellular matrix.  When the contractile apparatus 
contracts, the cell physically shortens.  The shortening is transduced through cytoskeletal 
actin filaments to the extracellular matrix and then to neighboring smooth muscle cells 
(Gunst and Zhang 2008).  Reprinted with permission from The American Physiological 
Society. 
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Figure 7. Sustained vascular smooth muscle force in the presence of low levels of Ca2+ 
and MLC phosphorylation. 
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Figure 7. Sustained vascular smooth muscle force in the presence of low levels of Ca2+ 
and MLC phosphorylation. 
The initial increase in [Ca2+] (-x-) in response to cellular stimulation is followed 
closely by an increase in MLC phosphorylation (--).  These two events precede the rise 
in force generated by the tissue (-o-), which agrees with the paradigm of smooth muscle 
contraction that an increase in cytosolic Ca2+ and an increase in MLC phosphorylation 
are required events for force development.  Interestingly as force increases and plateaus, 
[Ca2+] and MLC phosphorylation drop to supra-basal levels.  There is more Ca2+ and 
MLC phosphorylation present than in the absence of stimulation however it is 
significantly lower than during the initiation of contraction and rise of force.  This state of 
high force maintained by low levels of Ca2+, MLC phosphorylation, and crossbridge 
cycling has been termed the Latch State (Menice, Hulvershorn et al. 1997).  Reprinted 
with permission from the American Society for Biochemistry and Molecular Biology. 
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Figure 8. Structure of the L-type Ca2+ channel.  
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1. Introduction
Hypertension or high blood pressure is a multi-factorial dis-
ease that plagues more than 30% of adult Americans and about one
quarter of people worldwide [1,2]. Hypertension arises because of
complex interactions of various genes with the environment, and
is considered a leading risk factor for cardiovascular and kidney
diseases [3,4]. Hypertension with unknown etiology, also known
as essential, primary or idiopathic hypertension, accounts for 95%
of all human hypertension [2].  Blood pressure is determined by
two important physical parameters, cardiac output (CO) and total
peripheral resistance (TPR). Multiple pathways including the auto-
nomic nervous system, renin–angiotensin system, aldosterone and
other vasoactive substances affect CO and TPR to tightly regulate
blood pressure and thus ensure appropriate flow of blood to vari-
ous organs in the body [5–7]. In most clinical cases, CO is normal
whereas TPR is elevated due to an abnormal constriction of the
small arteries and arterioles [8,9]. The diameter of small arteries
and arterioles is maintained mainly by the dynamic interplay of
Ca2+ and K+ channels expressed on the plasma membrane of vascu-
lar smooth muscle cells (VSMCs) [10]. The opening of K+ channels in
response to endogenous stimuli or pharmacological agents results
in an efflux of K+ from VSMCs, hyperpolarization of the plasma
membrane, closure of Ca2+ channels, reduced intracellular Ca2+ lev-
els and eventually vasodilation. Conversely, closure of K+ channels
depolarizes the plasma membrane resulting in the opening of more
Ca2+ channels, increased intracellular Ca2+ levels, and vasoconstric-
tion. The elevated vascular tone observed in human hypertension
and in several experimental models of hypertension thus points
to abnormalities in the expression and function of Ca2+ and/or K+
channels in VSMCs [11]. Indeed, the VSMCs are more depolarized as
a consequence of the ‘ion channel remodeling’ that occurs during
chronic hypertension [12]. Several families of Ca2+ and K+ chan-
nels are expressed in VSMCs (reviewed in [13,14]). In this review,
we will only focus on three of the channel types in VSMCs that
are reported to be altered in animal models of hypertension: the
L-type Ca2+ (CaV1.2) channels, the voltage-gated K+ (KV) channels,
and the large-conductance, Ca2+-activated K+ (BK) channels. We
will limit our discussion to three important aspects of these chan-
nels: (1) their physiological role in VSMCs, (2) the alteration of these
channels in VSMCs during hypertension, and (3) their potential as
therapeutic targets for the treatment of hypertension.
2. Physiological role of vascular ion channels
VSMCs express different types of ion channels at the sacroplas-
mic  reticulum and the plasma membrane to closely regulate
intracellular Ca2+ levels, resting membrane potential (Em) and cell
contractility. In VSMCs, Em is primarily determined by K+ efflux
through several plasma membrane K+ channels, including the
voltage-gated K+ (KV) channels and the large-conductance Ca2+-
activated K+ channels, often referred to as “Maxi-K” or “Big K” (BK)
channels [10,15]. While there are also inwardly-rectifying K+ (KIR)
channels [16,17],  ATP-sensitive K+ (KATP) channels [17,18],  and two
pore domain K+ (K2P) [19,20] channels present in VSMCs that likely
also contribute to the final Em, these channels are reviewed else-
where [21]. Voltage-gated L-type Ca2+ (CaV1.2) channels open in
response to membrane depolarization. Excitation of VSMCs results
in depolarization, which leads to the voltage-dependent opening
of CaV1.2 and KV channels. The opening of CaV1.2 channels allows
Ca2+ influx, causing a rise in global Ca2+ and activation of the cellular
contractile machinery. The depolarization and the corresponding
increase in intracellular Ca2+ through CaV1.2 channels both lead to
BK channel opening, which causes a compensatory hyperpolarizing
current that closes CaV1.2 channels to buffer vasoconstriction. The
Fig. 1. Proposed topology of vascular ion channels. (A) Voltage-gated L-type Ca2+
channel (CaV1.2) subunits !1, !2, ", #, $ are depicted. PM:  plasma membrane.
(B)  Voltage-gated K+ channel (KV) ! and " subunits. (C) Large-conductance, Ca2+-
activated K+ channel (BK) ! and " subunits.
opening of KV channels also allows K+ to flow out of the cell and
hyperpolarizes the VSMCs [10,15].
In this section, we  review the structure and physiological func-
tion of these ion channels in the VSMCs and when appropriate
provide a brief comparison to the channels found in cardiomy-
ocytes.
2.1. Voltage-gated L-type Ca2+ (CaV1.2) channels
Voltage-gated, long-lasting “L”-type Ca2+ (CaV1.2) channels are
opened by depolarization, show a unitary conductance of 20–30 pS,
and are slowly inactivating. Structurally, CaV1.2 channels are mul-
timeric protein complexes, comprised of pore-forming !1 subunits
and auxiliary ", !2$ and # subunits (Fig. 1A). The !1 subunits have
four repeat domains each of which has six transmembrane sections
(S1–S6). The !1 subunits are responsible for voltage sensing, Ca2+
permeability, Ca2+-dependent inactivation, and inhibition by Ca2+
channel blockers. Cytosolic accessory " subunits, of which there are
four isoforms ("1–4), interact with the !1 subunits to modulate
channel properties such as plasma membrane targeting, channel
inactivation and voltage-dependent gating [13,22–24].  The " sub-
units are classified as membrane-associated guanylate kinases, a
class of scaffolding protein that has both guanylate kinase and Src
homology 3 domains [25,26]. In VSMCs, both "2 and "3 subunits
have been identified in bovine [27], mouse [28] and rabbit aor-
tae [29]. More recently, "3 subunits have been identified in mouse
mesenteric arteries as an important regulator of CaV1.2 subunits in
hypertension [30]. Also present in the CaV1.2 complex are auxiliary
!2$ (!2$1–4) and # subunits, though their functions are less clear.
Banister et al. observed that inhibition of the !2$-1 subunit caused
vasodilation of pressurized rat cerebral arteries and reduced CaV1.2
currents in cerebral artery VSMCs [31]. Moreover, knockdown of
!2$-1 reduced plasma membrane expression of CaV1.2, suggest-
ing that !2$-1 is important for plasma membrane expression of
functional CaV1.2 channels [31].
CaV1.2 channels open in response to depolarizing stimuli, which
allows Ca2+ to flow inside the VSMC to initiate cell contraction and
other Ca2+-dependent processes. Calcium-dependent inactivation
occurs when increasing intracellular Ca2+ causes closure of CaV1.2
channels, even when depolarization is maintained [32–34];  CaV1.2
channels can also inactivate via voltage-dependent inactivation
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Figure 8.  Structure of the L-type Ca2+ channel. 
Of the many transmembrane subunits of the L-type Ca2+ channel, the most 
important is the pore-forming α1 subunit.  It is the site of action of inhibitors such as 
nifedipine and verapamil that work by decreasing the open probability of the channel.  
Less Ca2+ influx results in a decrease in contractility.  The α2δ subunit is universal to 
voltage-gated Ca2+ channels.  It is thought to have a receptor-like function because it is 
largely extracellular.  The β subunit resides inside the plasma membrane and is thought to 
interact with intracellular kinases that regulate LTCC function (Hosey, Chien et al. 1996, 
Joseph, Thakali et al. 2013).  Reprinted with permission from Elsevier. 
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Figure 9.  Reported and proposed interactions among proteins of interest studied in this 
Thesis. 
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Figure 9.  Reported and proposed interactions among proteins of interest studied in this 
Thesis. 
Arrows indicate an excitatory effect while blunted lines indicate an inhibitory 
effect.  p21-activated kinase (PAK1) is activated by Rho kinase (ROCK) and by 
autophosphorylation.  Activated PAK1 regulates phosphorylation and activity of MLC 
kinase and MAP kinase.  Activation of MAP kinase leads to phosphorylation and 
disinhibition of caldesmon (CaD) which leads to an increase in force independent of 
MLC phosphorylation.  MLC kinase is phosphorylated resulting in a decrease in MLC 
kinase activity, however force can still be increased through Ca2+ sensitization mediated 
by PKC and ROCK as well as CaD disinhibition by MAP kinase. 
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Figure 10. Canonical MAP kinase signaling. 
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Figure 10. Canonical MAP kinase signaling. 
MAP kinases mediate cellular responses triggered by extracellular signals such as 
growth factors and cytokines.  The various isoforms share a similar pattern of activation 
beginning with an external stimulus and ending in a biological response.  The multi-step 
activation mechanism allows for amplification of the initial signal as it is transduced 
inward.  The multitude of kinase activation steps also allows for regulation of the 
pathway(s) at different levels.  This study primarily focuses on the p42/44 isoform of 
MAP kinase, also identified as extracellular signal-regulated kinase 1/2 (ERK1/2) 
(Cargnello and Roux 2011).  Adapted with permission from the American Society for 
Microbiology.   
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Figure 11. Structure of p21-activated kinase. 
 
 
 
 
  
homology with yeast Cla4 and Ste20 (83). Pak1 (!-Pak) was
first discovered in rat brain as a small GTPase-binding protein
(82). Of both the Pak groups, Pak1 is reported to be the
predominant isoform in muscle, including the heart (52). Pak1
is a 545-amino acid protein (Fig. 1) with a large NH2-terminal
binding domain and inhibitory region (aa 70-149) and a
COOH-terminal kinase region (aa 255-529) (77). Within the
NH2-terminal region is a p21-binding domain (PBD; aa 70-113)
with an embedded minimal sequence for Cdc42 and Rac-
interactive binding (CRIB; aa 75-90) (65, 67, 103). Partially
overlapping this segment is the autoinhibitory region (aa 83-
149) that forms part of the “inhibitory switch” and participates
in inhibition of COOH-terminal kinase activity in the inactive
dimerized conformation (77, 91). On the COOH-terminal side
of the inhibitory region is an acidic region whose functional
significance is not known.
The overall peptide sequence contains five proline-rich re-
gions (82) of the (PXXP) SH3-binding motif that are signifi-
cant in mediating proliferative responses. The first has been
identified as a binding site for the SH3-containing Nck adapter
protein (aa 12-18) (17, 39). COS-7 cell stimulation with plate-
let-derived growth factor induces Nck binding to Pak1, func-
tionally linking Pak1 and receptor tyrosine kinases in prolifer-
ation and cell growth. In vitro, phosphorylation of the Akt site,
Ser-21, attenuates the interaction between Nck and Pak1. The
second SH3 domain (aa 40-47) interacts with the Grb2 adapter
protein and mediates the interaction of Pak1 with the epidermal
growth factor receptor in vitro and in vivo (95). In other
studies, Ser-21 phosphorylation promotes Nck interaction and
cellular migration in nonmuscle cells (139, 140). Finally,
phosphorylation of the Cdc2/Cdk5 site (Thr-212) is involved in
neuron microtubule dynamics (10, 138). Additional autophos-
phorylation sites have been reported at Ser-57, Ser-144, Ser-
149, and Ser-198 (25), but their functional significance is not
well known. Amino acids 182-203 constitute the fourth pro-
line-rich region that represents a noncanonical Pak-interactive
exchange factor, cloned-out of library (PIX/COOL) binding
site (84). Beyond the kinase domain (aa 529-545), the COOH-
terminal end has a conserved binding site for the G"#-subunit
of heterotrimeric G proteins, which are reported to inhibit Pak1
kinase activity (76, 125).
Significant phosphorylation sites have been identified in
Pak1 for initiating and maintaining catalytic activity. Most
studied is the Thr-423 site in the kinase domain, originally
identified as a site of autophosphorylation following binding to
GTP-bound Cdc42 or Rac1 (81, 122). This site is instrumental
in sustaining relief of autoinhibition in the conformational shift
from the dimerized to monomerized states and in promoting
full catalytic activity toward substrates (41, 136). Although
autophosphorylation at Thr-423 occurs in vitro, this activity
appears to be low in vivo and instead requires phosphorylation
by the 3-phosphoinositide-dependent kinase 1 in the presence
of sphingosine for substantial kinase activation (64). Experi-
mentally, substitution of the Thr-423 to glutamate renders the
kinase constitutively active (81). Substitution of Lys-299 with
arginine results in a kinase-dead mutant with no catalytic
activity following stimulation with sphingosine or Cdc42 (16).
The presence of multiple sites for phosphorylation suggest that
the kinase has the capacity to interact with more than one
substrate, depending on specific cellular conditions.
Structurally, inactive Pak1 exists as a homodimer with an
antiparallel configuration where the COOH-terminal catalytic
domain of one Pak monomer is stabilized in the inactive state
by close proximity of the NH2-terminal region of the other (77)
(see Fig. 2). In this trans-inhibited conformation, the NH2-
terminal inhibitory switch region is associated with the C-lobe
of the kinase domain of the other monomer, and the PBDs of
the two monomers are associated together. Binding of GTP-
bound Cdc42 to the PBD initiates dissociation of the dimer into
monomers, release of the inhibitory switch from the kinase
C-lobe, and exposure of the Thr-423 site for phosphorylation.
Additional autophosphorylation occurs at multiple serine/thre-
onine sites, preventing redimerization and return to an inactive
state (91). The kinase-activated monomer can then interact
with its cellular targets.
Pak1 activators. Intracellular activators of Pak1 are not
limited to small GTPases but include a range of molecules.
Pak1 activity may also be regulated without any involvement
of protein phosphorylation. As with Cdc42/Rac1, PIX/COOL
may regulate Pak1 activity in a phosphorylation-independent
manner (8), although it is unclear whether PIX/COOL has any
effect on autophosphorylation of Pak1. In smooth muscle cells,
there is evidence for the regulation of Pak1 activity by lipid-
derived signals such as sphingosine (16), lysophosphatidic acid
(102), and phosphatidylinositol (64) and in COS-7 cells at a
site that may be identical to the GTPase-binding domain (16).
As previously discussed, receptor tyrosine kinases may acti-
vate Pak1 through interaction with Nck adapter proteins (30,
39, 112, 118). Other serine/threonine kinases phosphorylate
Pak1 at sites different from the autophosphorylation sites, such
as PKG, which acts at Ser-21, stimulating changes in cell
morphology (38). There is recent evidence that Pak1 is acti-
vated by epidermal growth factors in a prostate carcinoma-
derived cell line and that it acts through the atypical PKC-$
isoform to phosphorylate myosin II-B, providing an important
potential link between Pak1 and the cytoskeleton (36). On the
side of inactivation, two protein phosphatase 2C (PP2C)-like
serine-threonine phosphatases, POPX1 and POPX2, are asso-
ciated with Pak1 and inactivate it through dephosphorylation,
inhibiting actin stress-fiber breakdown (69, 137). In leuko-
Fig. 1. Domain structure and autophosphorylation sites of p21-activated kinase 1 (Pak1). Human Pak1 has 545 amino acids. The 7 autophosphorylation sites
are denoted by P. Catalytic domain (blue) contains 1 phosphorylation site (Thr-423). p21-Binding domain (PBD) is represented in orange. Autoinhibitory domain
(AI) is yellow. Proline-rich motifs, represented by black bars, are followed by phosphorylation sites. These 3 motifs are between amino acids 12–18, 40–47,
and 185–196, respectively. Known sites of phosphorylation by kinases are Akt (Ser-21), Cdc2/Cdk5 (Thr-212), and 3-phosphoinositide-dependent kinase 1
(Thr-423).
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Figure 11. Structure of p21-activated kinase. 
The serine/threonine kinase p21-activated kinase (PAK1) contains a number of 
autophosphorylation sites, represented by the letter P.  There is a p21-binding domain 
(PBD), an autoinhibitory domain (AI), and a catalytic domain.  Black bars represent 
proline-rich motifs.  In its inactive form, PAK1 is a homodimer such that the C-terminal 
catalytic domain of one PAK1 molecule is held in its inactive conformation by close 
proximity to the N-terminal end of another PAK1 molecule (Sheehan, Ke et al. 2007).  
Reprinted with permission from The American Physiological Society.   
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Vascular Smooth Muscle Tissue Preparation 
 Porcine carotid arteries were obtained from a local slaughterhouse and transported 
in ice-cold physiological salt solution (PSS) containing (in mM): 140 NaCl, 4.7 KCl, 
1.2MgSO4, 1.6 CaCl2, 1.2 Na2HPO4, 2 MOPS (pH7.4), and 0.02 EDTA.  The arteries 
were cleaned of excess fat and connective tissue and stored in PSS as described above 
containing 5 mM D-glucose at 4°C.  Arteries were stored for up to 4 days at 4°C in PSS.  
Previous studies have shown that storage for up to 4 days at 4°C in PSS does not result in 
a loss of tissue viability or activity (Fulginiti, Singer et al. 1993, Rembold and Murphy 
1988, Su, Smolock et al. 2004).  The medial smooth muscle layer was dissected for 
experimentation by removal of the intimal and adventitial layers.  Isolated smooth muscle 
tissue was then cut circumferentially to obtain strips approximately 2 mm wide and 6 mm 
long (Figure 12). 
 
Isometric force recordings 
 Circumferential strips of smooth muscle were mounted in double-walled glass 
muscle baths containing PSS (MOPS-buffered solution) bubbled with 100% oxygen and 
maintained at 37°C.  Tissues were stretched to the optimal length (Lo) for force 
production, approximated to be 5g of force, and allowed to equilibrate and stress-relax 
for 30-40 minutes.  Lo is defined as the length at which maximum force can be produced 
by a given tissue (Figure 13) (Herlihy and Murphy 1973).  The length of a tissue 
determines overlap between the contractile actin and myosin filaments and therefore the 
number of crossbridge interactions.  If the overlap of the thick and thin filaments is not 
optimal, the number of crossbridge interactions is decreased and maximum force cannot 
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be achieved.  There is an optimal overlap between actin and myosin filaments, hence an 
optimal length of tissue that can allow a muscle to develop maximal force.  During 
equilibration the tissues stress-relaxed to a resting tension of 1 gram.  If tissues relaxed to 
less than 1 gram of force, they were incrementally stretched until they held at 1gram 
baseline force. Following equilibration tissues were contracted with 110 mM KCl-
containing PSS (equimolar substitution of KCl for NaCl) and then allowed to relax in 
regular PSS for 20-30 minutes.  The contraction-relaxation cycle was repeated 4 times 
until a stable maximum force value was achieved.  This step confirmed viability of the 
muscle tissue and also provided a maximum force value against which experimental force 
values could be compared.  Experimental force values were normalized to maximum 
force produced upon stimulation with 110 mM KCl-PSS.  Isometric force was detected 
by Grass FT.03 force transducers and recorded using LabChart software (AD 
Instruments).  Because LTCCs are voltage-gated, experiments were conducted in PSS 
containing 15 mM KCl, rather than the typical 4.7 mM KCl.  Preliminary studies showed 
that 15 mM KCl-containing PSS alone did not result in an increase if force.   
After equilibration, tissues were treated with one of the following inhibitors for 20 
minutes: 1 µM nifedipine (L-type Ca2+ channel inhibitor), 10 µM ML-7 (MLC kinase 
inhibitor), 3 µM bisindolylmaleimide I (PKC inhibitor; henceforth referred to as Bis), 10 
µM U0126 (MAP kinase kinase inhibitor), 1 µM H-1152 (Rho kinase inhibitor), and 100 
uM IPA-3 (p21-activated kinase, PAK1, inhibitor).  Following treatment with inhibitors 
100 nM of the L-type Ca2+ channel agonist Bay K8644 was added for 120 minutes.  As 
we did not visualize Ca2+ during Bay K8644-induced contraction, we relied on existing 
evidence that Bay K8644 does in fact increase intracellular Ca2+ in vascular smooth 
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muscle tissue (Figure 14, (Alvarez, Miner et al. 2010)).  At the conclusion of the 
experiment tissues were flash frozen in a slurry of 6% trichloroacetic acid/acetone and 
dry ice with 1 mM dithiothreitol.  The tissue strips were allowed to slowly thaw to room 
temperature and then pulverized in a buffer solution of 1% SDS, 10% glycerol, 50 mM 
Tris HCl (pH 6.8), 10 mM dithiothreitol, and protease inhibitor cocktail (Sigma-Aldrich) 
using glass-glass homogenizers.  Protein content of homogenized samples was 
determined using a Lowry protein assay. 
 
MAP kinase phosphorylation 
 For detection of MAP kinase phosphorylation, 20 µg of each sample was loaded 
onto a 14% polyacrylamide separating gel and a 4% stacking gel.  Gel electrophoresis 
was carried out at 200V at room temperature until the dye front reached the bottom of the 
gel.  Proteins were then transferred to a nitrocellulose membrane at 100V for 1 hour.  
Membranes were blocked in a 1:1 solution of Odyssey Blocking Buffer (Licor) and 
phosphate buffered saline (PBS, pH 7.4) at room temperature for 1 hour then incubated in 
primary antibodies against p42/44 MAP kinase (Millipore, 1:1,000) and phosphorylated 
p42/44 MAP kinase (Promega, 1:5,000) diluted in 1:1 solution of Odyssey Blocking 
Buffer and PBS overnight at 4°C.  Membranes were washed in PBS with 0.1% Tween 5 
times for 5 minutes each.  Fluorescent secondary antibodies (Licor, goat anti-mouse 
800CW and goat anti-rabbit 680LT) were used at a 1:10,000 dilution in a 1:1 solution of 
Odyssey Blocking Buffer and PBS.  Membranes were incubated in secondary antibody at 
room temperature for 45 minutes followed by 5 washes for 5 minutes each in PBS with 
0.1% Tween.  Membranes were imaged using a Licor FC camera system and optical 
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densitometry of the bands was determined using Image Studio software (Licor).  Percent 
phosphorylation was calculated as (OD value of the phosphorylated protein band / OD 
value of the total protein band) x 100.  
  
CPI-17 phosphorylation 
 For detection of CPI-17 phosphorylation, 20 µg of each sample was loaded onto a 
14% polyacrylamide separating gel and a 4% stacking gel.  Gel electrophoresis was 
carried out at 200V at room temperature until the dye front reached the bottom of the gel.  
Proteins were then transferred to a nitrocellulose membrane at 100V for 1 hour.  
Membranes were blocked in a 1:1 solution of Odyssey Blocking Buffer (Licor) and 
phosphate buffered saline (PBS, pH 7.4) at room temperature for 1 hour then incubated in 
primary antibodies against CPI-17 (Santa Cruz, 1:800) and phosphorylated CPI-17Thr38 
(Santa Cruz, 1:800) diluted in 1:1 solution of Odyssey Blocking Buffer and PBS 
overnight at 4°C.  Membranes were washed in PBS with 0.1% Tween 5 times for 5 
minutes each.  Fluorescent secondary antibodies (Licor, goat anti-mouse 800CW and 
goat anti-rabbit 680LT) were used at a 1:10,000 dilution in a 1:1 solution of Odyssey 
Blocking Buffer and PBS.  Membranes were incubated in secondary antibody at room 
temperature for 45 minutes followed by 5 washes for 5 minutes in PBS with 0.1% 
Tween.  Membranes were imaged using a Licor FC camera system and optical 
densitometry of the bands was determined using Image Studio software (Licor).  Percent 
phosphorylation was calculated as (OD value of the phosphorylated protein band / OD 
value of the total protein band) x 100. 
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Caldesmon phosphorylation 
 For detection of caldesmon phosphorylation, 20 µg of each sample was loaded 
onto an 8% polyacrylamide separating gel and a 4% stacking gel.  Gel electrophoresis 
was carried out at 200V at room temperature until the dye front reached the bottom of the 
gel.  Proteins were then transferred to a nitrocellulose membrane at 100V for 90 minutes.  
Membranes were blocked in a 1:1 solution of Odyssey Blocking Buffer (Licor) and 
phosphate buffered saline (PBS, pH 7.4) at room temperature for 1 hour then incubated in 
primary antibodies against caldesmon (Sigma-Aldrich, 1:1,000) and phosphorylated 
caldesmonSer789 (Millipore, 1:1,000) diluted in 1:1 solution of Odyssey Blocking Buffer 
and PBS overnight at 4°C.  Membranes were washed in PBS with 0.1% Tween 5 times 
for 5 minutes each.  Fluorescent secondary antibodies (Licor, goat anti-mouse 800CW 
and goat anti-rabbit 680LT) were used at a 1:10,000 dilution in a 1:1 solution of Odyssey 
Blocking Buffer and PBS.  Membranes were incubated in secondary antibody at room 
temperature for 45 minutes followed by 5 washes for 5 minutes in PBS with 0.1% 
Tween.  Membranes were imaged using a Licor FC camera system and optical 
densitometry of the bands was determined using Image Studio software (Licor).  Percent 
phosphorylation was calculated as (OD value of the phosphorylated protein band / OD 
value of the total protein band) x 100. 
 
MYPT1 phosphorylation 
 For detection of MYPT1 phosphorylation, 20µg of each sample was loaded onto 
an 8% polyacrylamide separating gel and a 4% stacking gel.  Gel electrophoresis was 
carried out at 200V at room temperature for approximately 1 hour or until the dye front 
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reached the bottom of the gel.  Proteins were then transferred to a nitrocellulose 
membrane at 100V for 80 minutes.  Membranes were blocked in a 1:1 solution of 
Odyssey Blocking Buffer (Licor) and phosphate buffered saline (PBS, pH 7.4) at room 
temperature for 1 hour then incubated in primary antibodies against phosphorylated 
MYPT1Thr850 (Millipore, 1:1,000) and α-actin (Sigma-Aldrich, 1:10,000) diluted in 1:1 
solution of Odyssey Blocking Buffer and PBS overnight at 4°C.  Membranes were 
washed in PBS with 0.1% Tween 5 times for 5 minutes each.  Fluorescent secondary 
antibody (Licor, goat anti-mouse 800CW and goat anti-rabbit 680LT) was used at a 
1:10,000 dilution in a 1:1 solution of Odyssey Blocking Buffer and PBS.  Membranes 
were incubated in secondary antibody at room temperature for 45 minutes followed by 5 
washes for 5 minutes in PBS with 0.1% Tween.  Membranes were imaged using a Licor 
FC camera system and optical densitometry of the bands was determined using Image 
Studio software (Licor).  The membranes were stripped by vigorous shaking for 5 
minutes in Nitrocellulose Stripping Buffer (Bio-Rad) and rinsed in PBS.  Imaging 
confirmed that the previous antibody signals had been successfully removed.  Membranes 
were then incubated in primary antibodies for MYPT1 (Covance, 1:1,000) and α-actin 
(Sigma-Aldrich, 1:10,000) diluted in 1:1 solution of Odyssey Blocking Buffer and PBS 
overnight at 4°C.  The following day membranes were washed, incubated in secondary 
antibody, washed again, and imaged as described above.  Optical density of the protein 
bands of interest was analyzed by first normalizing OD of phosphorylated MYPT1 to the 
OD of the corresponding α-actin band.  The same procedure was followed to normalize 
total MYPT1 to its corresponding α-actin band.  Then the percent phosphorylation was 
determined as (OD normalized value of the phosphorylated protein band / OD normalized 
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value of the total protein band) x 100.  This procedure was used for any proteins for 
which the phosphorylated and total antibodies were of the same species and therefore 
could not be applied to the membrane concurrently.  α-actin was used to normalize as it is 
stably expressed in VSM and was not expected to change during contractile stimulation 
or in the presence of kinase inhibitors. 
 
MLC kinase phosphorylation 
 For measuring MLC kinase phosphorylation at Serine1760, 20µg of each sample 
was loaded onto an 8% polyacrylamide separating gel and a 4% polyacrylamide stacking 
gel.  Gel electrophoresis was carried out at 200V at room temperature for approximately 
1 hour until the dye front reached the bottom of the gel.  Proteins were then transferred to 
a nitrocellulose membrane at 100V for 80 minutes.  Membranes were blocked in a 1:1 
solution of Odyssey Blocking Buffer (Licor) and phosphate buffered saline (PBS, pH 7.4) 
at room temperature for 1 hour then incubated in primary antibodies against 
phosphorylated MLCKSer1760 (Invitrogen, 1:1,000) and total MLCK (Sigma-Aldrich, 
1:1,000) diluted in 1:1 solution of Odyssey Blocking Buffer and PBS overnight at 4°C.  
Membranes were washed in PBS with 0.1% Tween 5 times for 5 minutes each.  
Fluorescent secondary antibodies (goat anti-mouse 800CW and goat anti-rabbit 680LT, 
Licor) were used at a 1:10,000 dilution in a 1:1 solution of Odyssey Blocking Buffer and 
PBS.  Membranes were incubated in secondary antibody at room temperature for 45 
minutes followed by 5 washes for 5 minutes in PBS with 0.1% Tween.  Membranes were 
imaged using a Licor FC camera system and optical densitometry of the bands was 
determined using Image Studio software (Licor).  Percent phosphorylation was calculated 
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as (OD value of the phosphorylated protein band / OD value of the total protein band) x 
100. 
 
p21-activated kinase phosphorylation 
 PAK1 phosphorylation was measured at two sites, Threonine423 and Serine144.  
The Threonine423 site resides in the activation loop of PAK1.  It can be phosphorylated by 
PAK1 autophosphorylation or by phosphoinositide-dependent kinase-1 (King, Gardiner 
et al. 2000).  The Serine144 residue is in the kinase inhibitory domain.  It is 
phosphorylated by PAK1 autophosphorylation (Chong, Tan et al. 2001).  To measure 
phosphorylation, 30 µg of each sample was loaded onto a 12% polyacrylamide separating 
gel and a 4% polyacrylamide stacking gel.  Gel electrophoresis was carried out at 200V at 
room temperature for approximately 1 hour until the dye front reached the bottom of the 
gel.  Proteins were then transferred to a nitrocellulose membrane at 100V for 80 minutes.  
Membranes were blocked in a 1:1 solution of Odyssey Blocking Buffer (Licor) and 
phosphate buffered saline (PBS, pH 7.4) at room temperature for 1 hour then incubated in 
primary antibodies against either PAK1Thr423 (Cell Signaling) or PAK1Ser144 (Cell 
Signaling), along with calponin (Sigma-Aldrich) as a loading control, diluted in a 1:1 
solution of Odyssey Blocking Buffer and PBS overnight at 4°C.  Membranes were 
washed in PBS with 0.1% Tween 5 times for 5 minutes each.  Fluorescent secondary 
antibodies (goat anti-mouse 800CW and goat anti-rabbit 680LT, Licor) were used at a 
1:10,000 dilution in a 1:1 solution of Odyssey Blocking Buffer and PBS.  Membranes 
were incubated in secondary antibody at room temperature for 45 minutes followed by 5 
washes for 5 minutes in PBS with 0.1% Tween.  Membranes were imaged using a Licor 
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FC camera system and optical densitometry of the bands was determined using Image 
Studio software (Licor).  The membranes were stripped by vigorous shaking for 5 
minutes in Nitrocellulose Stripping Buffer (Bio-Rad) and rinsed in PBS.  Imaging 
confirmed that the previous antibody signals had been successfully removed.  Membranes 
were then incubated in primary antibodies for total PAK1 (Cell Signaling) and calponin 
(Sigma-Aldrich) as a loading control diluted in 1:1 solution of Odyssey Blocking Buffer 
and PBS overnight at 4°C.  The following day membranes were washed, incubated in 
secondary antibody, washed again, and imaged as described above.  Optical density of 
the protein bands of interest was analyzed by first normalizing OD of phosphorylated 
PAK1 to the OD of the corresponding calponin band.  The same procedure was followed 
to normalize total PAK1 to its corresponding calponin band.  Then the percent 
phosphorylation was determined as (OD normalized value of the phosphorylated protein 
band / OD normalized value of the total protein band) x 100.  Calponin was used in lieu 
of α-actin to normalize OD because the molecular weight of α-actin is very similar to that 
of PAK1 and in preliminary Western blots it was difficult to distinguish between the two 
bands.  Calponin is a recognized marker of smooth muscle that is stably expressed and 
not expected to change under experimental conditions. 
 
Urea/glycerol-PAGE 
 Urea/glycerol-PAGE was used to examine MLC phosphorylation.  The high urea 
content of the sample buffer dissociates MLC from the myosin heavy chain protein 
(Hathaway and Haeberle 1985).  Electrophoresis in the glycerol-containing gel separates 
phosphorylated from unphosphorylated forms of MLC as they have different 
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electrophoretic mobilities.  Tissue samples were processed for urea/glycerol-PAGE using 
the following steps.  Thawed and dehydrated tissues were placed in sample buffer 
containing 8 M urea, 18.5 mM Tris pH 8.6, 20.4 mM glycine, 0.5 M dithiothreitol, 
saturated sucrose, 0.2% bromophenol blue, 0.4 M EDTA, and Protease Inhibitor Cocktail 
(Sigma-Aldrich).  Samples were rocked at room temperature for approximately 2 hours in 
order to solubilize MLC, then stored at 4°C until subjected to gel electrophoresis.  
Phosphorylated and unphosphorylated MLC were separated in a gel containing glycerol, 
30% acrylamide with 41 mM piperazine diacrylamide, 1.55 mM Tris, 1.7 mM glycine, 
deionized water, 2.2 mM ammonium persulfate, and TEMED.  The electrophoretic 
chamber contained a lower buffer consisting of 1.55 mM Tris, 1.7 mM glycine, and water 
and an upper buffer that contained in addition to the components of the lower buffer, 2.37 
mM dithiothreitol and 2.89 mM thioglycholate.  Before sample loading the gel was 
subjected to pre-electrophoresis at 400V for 90 minutes in order to reduce any residual 
ammonium persulfate in the gel.  Samples were then loaded onto the gel, subjected to 
electrophoresis at 400V for 90 minutes, and then transferred to a nitrocellulose membrane 
at 25V for 1 hour.  Pre-electrophoresis, electrophoresis with sample, and transfer were 
conducted at room temperature.  Western blotting was carried out as described above for 
SDS-PAGE.  Membranes were blocked in a 1:1 solution of Odyssey Blocking Buffer 
(Licor) and phosphate buffered saline (PBS, pH 7.4) at room temperature for 1 hour then 
incubated in primary antibodies against total MLC (Sigma, 1:5,000) and phosphorylated 
MLCSer19 (Cell Signal, 1:1,000) diluted in a 1:1 solution of Odyssey Blocking Buffer and 
PBS overnight at 4°C.  Membranes were washed in PBS with 0.1% Tween 5 times for 5 
minutes each.  Fluorescent secondary antibodies (goat anti-mouse 800CW and goat anti-
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rabbit 680LT, Licor) were used at a 1:10,000 dilution in a 1:1 solution of Odyssey 
Blocking Buffer and PBS.  Membranes were incubated in secondary antibody at room 
temperature for 45 minutes followed by 5 washes for 5 minutes in PBS with 0.1% 
Tween.  Membranes were imaged using a Licor FC camera system and optical 
densitometry of the bands was determined using Image Studio software (Licor).  Percent 
phosphorylation was calculated as (OD value of the phosphorylated protein band / (OD 
value of the total protein band + OD value of the phosphorylated protein band)) x 100. 
 
Chemicals and inhibitors 
Chemicals and inhibitors were dissolved either in deionized water or dimethyl 
sulfoxide (DMSO) according to manufacturers’ instructions.  The following chemicals 
were used: Bay K8644 (Tocris), ML-7 (Tocris), nifedipine (Sigma-Aldrich), 
bisindolylmaleimide I (Calbiochem), U0126 (Calbiochem), H-1152 (Calbiochem), and 
IPA-3 (Cayman Chemical).  Electrophoretic reagents were purchased from Bio-Rad 
Laboratories (Hercules, CA).  All other chemicals were purchased from Fisher Scientific 
(Pittsburgh, PA).   
 
Statistical analysis 
 Results are represented as mean ± standard error of the mean.  Statistical analysis 
consisted of One-way ANOVA with multiple comparisons versus a control group (Bay 
K8644 stimulation alone) using the Holm-Sidák method.  Performing multiple 
comparisons increases the probability that a Type I error (positive result) will occur.  The 
Holm-Sidák method was chosen over the Tukey or Bonferroni procedures because it has 
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greater statistical power (Seaman, Levin et al. 1991).  A p value < 0.05 was considered 
significant. "n" values represent the number of tissues used, each from a different artery. 
 For the purposes of comparing the time course of force development between Bay 
K8644 stimulation alone and Bay K8644 in the presence of inhibitors, the One Way 
Repeated Measures ANOVA was performed.   
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Figure 12. Dissection of smooth muscle from the swine carotid artery. 
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Methods
Preparation and Apparatus.— Carotid arteries were
gently excised from hogs weighing approximately 90 kg
20-60 minutes after slaughter. They were immediately
immersed in physiological salt solution at 0QC and,
after transit to the laboratory, were trimmed of loose
connective tissue and immersed in fresh physiological
salt solution for storage, at 4°C until use. Strips
prepared from arteries generally showed consistent
responses for 2-3 days after collection.
Muscle strips were obtained in the manner shown
diagrammatically in Figure 1 (left), which is essential-
ly the technique introduced by Wolinsky and Daly (3)
for obtaining the media of rat aortas for biochemical
studies. We used the hog carotid artery because of its
large muscular media and the ease with which its
media and intima could be separated from the
adventitia (2). The less muscular central and distal
ends of the carotid artery were removed and discarded;
the remaining segment was slit longitudinally. The
media was grasped at one edge with a plain forceps,
and a strip having a rectangular cross section was
teased from the adventitial layers along naturally
occurring separations. The first strip was discarded
because parallel strips could then be removed with less
force. The thickness and the length of the strips were
proportional to the size of the artery used; the width of
the strips could be varied at will. Generally strips 8-12
mm long were teased from the arteries, and the
thickness of the unstretched strips was about 0.8 mm.
With an oxygen tension (Po2) exceeding 600 mm Hg,
oxygen diffusion was not limiting in these strips which
had a low rate of oxygen consumption (4).
Strips were mounted as shown in Figure 2A and
securely held by stainless steel-nylon clips. The lower
clip was attached to a vertical glass rod mounted on a
micrometer electrode carrier with a 35-mm drive
calibrated in units of 0.01 mm. The upper clip was
attached by a very light stainless steel jewelry chain to
FIGURE 1
Smooth mtiscle preparation obtained from hog carotid arteries. Top Left: Section of artery
from which strips were teased between the bulbous central end and the bifurcation. Middle
Left: Arterial segments were slit longitudinally. Bottom Left: Manner in which strips were
grasped and teased off. 4> = 4.5 ± 0.08" (SB) (N = S) and is the pitch of the smooth muscle
helix in the artery. Top Right: Photomicrograph of arterial cross section (Weigerts-van
Gieson stain) showing some adventitial separation; the intimal layer was greatly folded in
this constricted segment. Bottom Right: Longitudinal section of teased muscle strip (hema-
toxylin-eosin stain) showing orientation of smooth muscle nuclei.
Circulation Research, Vol. XXXIII, September 1975
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Figure 12. Dissection of smooth muscle from the swine carotid artery. 
 
The swine carotid artery was opened lengthwise.  The endothelial, intimal and 
adventitial layers were carefully teased away as shown and strips were cut 
circumferentially (Herlihy and Murphy 1973).  Reprinted with permission from Wolters 
Kluwer Health, Inc. 
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Figure 13.  Length-tension relationship in the swine carotid arterial smooth muscle. 
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Figure 13.  Length-tension relationship in the swine carotid arterial smooth muscle. 
The length-tension relationship in smooth muscle is dependent upon active 
mechanisms (contractile machinery of the cell) and passive mechanisms (structural 
proteins such as collagen and elastin).  At the optimal tissue length for force development 
(Lo), there is little contribution by the passive elements and the majority of force is 
attributed to the active contraction mechanisms via actin and myosin filaments.  This is 
why the tissues are stretched to a resting tension of approximately 1 gram.  Applying 
tension ensures that the intact muscle strip will generate force.  
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Figure 14.  Bay K8644 increases intracellular Ca2+ levels and induces contraction in 
vascular smooth muscle. 
   
 
 
  
induced by Bay K 8644 were inhibited completely (i.e. they
were not reduced all the way to the basal levels, see
Figure 2B,C). By contrast, trifluoperazine and wortmannin
abolished the Bay K 8644-induced increase in MLC phospho-
rylation and caused complete (trifluoperazine) and nearly
complete (wortmannin) relaxation (Figure 3). These data
together support the hypothesis that ROCK, MLCK and calm-
odulin participate in Bay K 8644-induced contraction, but
that these proteins may not participate in maintaining the
basal level of MLC phosphorylation.
Effect of H-1152, trifluoperazine, wortmannin and ML-7 on Bay
K 8644-induced increase in [Ca2+]i
To determine whether H-1152 and other inhibitors caused
relaxation by reducing [Ca2+]i, tissues were loaded with the
Ca2+ indicator, fura-2, and tension and calcium were simulta-
neously measured over time. Bay K 8644 induced a strong and
sustained increase in [Ca2+]i (Figure 4B) concomitantly with
an increase in tension (Figure 4A). When added during the
sustained phase of contraction, 1 mM H-1152 produced an
immediate relaxation (Figure 4C,E) without causing a reduc-
tion in [Ca2+]i (Figure 4D,F). Trifluoperazine, wortmannin and
ML-7 also caused a strong relaxation of Bay K 8644-induced
tension (Figure 4E). Like H-1152, 1 mM wortmannin did not
affect the Bay K 8644-induced increase in [Ca2+]i (Figure 4F).
However, 50 mM trifluoperazine and 3 mM ML-7 reduced the
Bay K 8644-induced increase in [Ca2+]i nearly to the basal level
(Figure 4F). Thus, the relaxation and reduction in MLC phos-
phorylation induced by H-1152 and wortmannin were not
caused by reductions in [Ca2+]i, whereas inhibition of Ca2+
entry participated in causing relaxation induced by trifluop-
erazine and ML-7.
Effect of H-1152, trifluoperazine and wortmannin
on MYPT1 phosphorylation
Myosin light chain phosphatase inhibition in smooth muscle
involves phosphorylation of MYPT1 at both T696 and T853
(human numbering scheme). To determine whether Bay K
8644 produces an increase in MLC phosphorylation by
causing MYPT1 phosphorylation, tissues were stimulated
with Bay K 8644 and frozen at steady-state contraction to
quantify by Western blot the levels of MYPT1p-T696 and
MYPT1-pT853. Unlike KCl, which produces at least a twofold
increase in MYPT1-pT853 in tonic arteries (Porter et al., 2006;
Dimopoulos et al., 2007), Bay K 8644 did not increase
MYPT1p-T853 above the basal level of ‘1’ [Figure 5B,E,H,
‘Basal (-)’ vs. ‘BayK (-)’; note that when pooling the data from
these 3 experiments, the ‘BayK (-)’ value was 1.14 ! 0.04, n =
19, and this was not significantly greater than the basal level
of ‘1’, P = 0.17]. Moreover, Bay K 8644 did not induce an
increase in MYPT1-p696 (Figure 5). Thus, the increase in MLC
phosphorylation induced by Bay K 8644 was not associated
with significant increases in MYPT1 phosphorylation.
Notably however, H-1152 (1 mM) abolished basal MYPT1-
pT853 and did not affect basal MYPT1-T696 (Figure 5). More-
over, in the presence of H-1152, Bay K 8644 did not increase
MYPT1-pT853 above the H-1152-inhibited basal level
(Figure 5A,B).
Neither trifluoperazine nor wortmannin altered MYPT1
phosphorylation in the presence or absence of Bay K 8644
(Figure 5). These data support the hypotheses that MLCK and
calmodulin do not play a role in MYPT1 phosphorylation,
that ROCK is constitutively active and that an increase in Ca2+
induced by Bay K 8644 does not increase the activity of
ROCK.
The rate of contraction induced by Bay K 8644 often dis-
played tissue-to-tissue variability. Thus, we may have missed a
potential transient increase in MYPT1 phosphorylation by
freezing tissues at a single time point once tissues had
achieved a stable steady-state contraction. We therefore
adopted a protocol where tissues generated more rapid con-
tractions that reproducibly reached a steady-state value
within 15 min. Tissues were incubated for 30 min in a nomi-
nally Ca2+-free solution (0 Ca2+; CaCl2 was omitted from the
PSS) in the presence of 100 nM Bay K 8644 plus 10 mM KCl,
then contracted by addition of 2 mM CaCl2 (Figure 6A).
Tissues were frozen at 5, 15 and 60 min and processed to
measure active RhoA, MLC phosphorylation and MYPT1
Figure 4 Examples of 30 nM Bay K 8644 (BayK)-induced tension
(A,C) and [Ca2+]i (B,D) versus time tracings, and summary tension (E)
and [Ca2+]i (F) data produced in the absence of an inhibitor (A and B
and ‘Control’ in E and F) and after addition of an inhibitor (C,D and
inhibitors in E,F). Inhibitors H-1152, trifluoperazine (TFP), wortman-
nin (Wort) and ML-7 were added to tissues once contractions
achieved a pseudo-steady state [arrows linking H-11 (H-1152) to the
tension (C) and [Ca2+]i (D) tracings]. T1 and Ca1 indicate the times at
which, respectively, pre-drug tensions and [Ca2+]i values were
recorded. T2 and Ca2 indicate the times at which, respectively, post-
drug tensions and [Ca2+]i values were recorded. Data in (E) and (F) are
means ! SE, n = 3–4. *P < 0.05 compared with control; ANOVA/
Dunnett.
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causing MYPT1 phosphorylation, tissues were stimulated
with Bay K 8644 and frozen at steady-state contraction to
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MYPT1-pT853. Unlike KCl, which produces at least a twofold
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‘Basal (-)’ vs. ‘BayK (-)’; note that when pooling the data from
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19, and this was not significantly greater than the basal level
of ‘1’, P = 0.17]. Moreover, Bay K 8644 did not induce an
increase in MYPT1-p696 (Figure 5). Thus, the increase in MLC
phosphorylation induced by Bay K 8644 was not associated
with significant increases in MYPT1 phosphorylation.
Notably however, H-1152 (1 mM) abolished basal MYPT1-
pT853 and did not affect basal MYPT1-T696 (Figure 5). More-
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The rate of contraction induced by Bay K 8644 often dis-
played tissue-to-tissue variability. Thus, we may have missed a
potential transient increase in MYPT1 phosphorylation by
freezing tissues at a single time point once tissues had
achieved a stable steady-state contraction. We therefore
adopted a protocol where tissues generated more rapid con-
tractions that reproducibly reached a steady-state value
within 15 min. Tissues were incubated for 30 min in a nomi-
nally Ca2+-free solution (0 Ca2+; CaCl2 was omitted from the
PSS) in the presence of 100 nM Bay K 8644 plus 10 mM KCl,
then contracted by addition of 2 mM CaCl2 (Figure 6A).
Tissues were frozen at 5, 15 and 60 min and processed to
measure active RhoA, MLC phosphorylation and MYPT1
Figure 4 Examples of 30 nM Bay K 8644 (BayK)-induced tension
(A,C) and [Ca2+]i (B,D) versus time tracings, and summary tension (E)
and [Ca2+]i (F) data produced in the absence of an inhibitor (A and B
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which, respectively, pre-drug tensions and [Ca2+]i values were
recorded. T2 and Ca2 indicate the times at which, respectively, post-
drug tensions and [Ca2+]i values were recorded. Data in (E) and (F) are
means ! SE, n = 3–4. *P < 0.05 compared with control; ANOVA/
Dunnett.
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Figure 14.  Bay K8644 increases intracellular Ca2+ levels and induces contraction in 
vascular smooth muscle. 
 We did not measure intracellular Ca2+ levels in this study.  Therefore, we relied 
on evidence from the literature that Bay K8644 does indeed increase intracellular Ca2+.  
In rings of vascular smooth muscle tissue, addition of Bay K8644 resulted in an increase 
in tension (A) as well as an increase in intracellular Ca2+ (B) as measured with the Ca2+ 
indicator fura-2 (Alvarez, Miner et al. 2010).  Reprinted with permission from John 
Wiley and Sons. 
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Specific Aims 
1. To determine the intracellular signaling in vascular smooth muscle cells during 
sustained sub-maximal contraction in response to opening of L-type Ca2+ channel 
stimulation. 
2. To determine the role of MAP kinase on MLC kinase activity and MLC 
phosphorylation during a sustained vascular smooth muscle contraction. 
3. To determine the involvement of p21-activated kinase in regulating p42/44 MAP 
kinase and MLC kinase activity during sustained vascular smooth muscle contraction. 
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Specific Aim 1:  
To determine the intracellular signaling in vascular smooth muscle cells during sustained 
sub-maximal contraction in response to opening of L-type Ca2+ channel stimulation. 
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Introduction. 
 Smooth muscle contraction relies on signal transduction to convey an 
extracellular event to the contractile filaments within the smooth muscle cell, termed 
excitation-contraction coupling (AP Somlyo 1985).  Contraction can be initiated by 
calcium (Ca2+) influx through plasma membrane-bound Ca2+ channels or release of Ca2+ 
from intracellular stores (Horowitz, Menice et al. 1996).  In terms of Ca2+ influx through 
membrane calcium channels, the prominent channel responsible for smooth muscle 
contraction is the L-type Ca2+ channel (LTCC) (Hockerman, Peterson et al. 1997).  This 
channel is of great interest because of its demonstrated importance in maintaining arterial 
smooth muscle contraction and its aberrant functioning in pathological conditions such as 
hypertension (Michael, Surks et al. 2008, Moosmang, Schulla et al. 2003, Navedo, Cheng 
et al. 2010). 
 Activation of LTCCs has been shown to result in vascular smooth muscle 
contraction (Kubo, Taguchi et al. 1998).  Patch-clamp recordings of individual vascular 
smooth muscle cells demonstrate that LTCCs are heterogeneous in their activating 
potentials, a result of alternative splice variants of the same gene (Liao, Yu et al. 2004).  
A given cell membrane potential will activate some, but not all, LTCCs.  This 
heterogeneity lends flexibility to the tissue as a whole and allows for Ca2+ influx into the 
cell over a range of membrane potentials.  LTCCs maintain a “Ca2+-current window” 
such that Ca2+ is constantly leaking into the cell (Fransen, Van Hove et al. 2012).  While 
too much Ca2+ would lead to cytotoxicity and cell death, the Ca2+-current window is a 
physiological state of vascular smooth muscle cells maintaining Ca2+ in non-toxic, resting 
 66 
or sub-maximal contractile concentrations (Kass and Orrenius 1999, Santana, Navedo et 
al. 2008).  The intracellular signaling downstream of Ca2+ influx through LTCCs that 
contributes to stable force maintenance in vascular smooth muscle tissue was the focus of 
Specific Aim 1.   
Intracellular signaling proteins are responsible for transducing the increase in 
intracellular Ca2+ to the physiologic endpoint of contraction (Kamm and Stull 1989).  
Examples of this are the Ca2+/calmodulin complex that activates MLC kinase, and 
changes in the activity of the MLC kinase independent of changes in Ca2+/calmodulin.  
Signaling proteins can also modify the magnitude of the force of contraction.  These 
include ROCK- and PKC-mediated inhibition of MLC phosphatase (Eto, Ohmori et al. 
1995, K Kimura, Ito et al. 1996) or disinhibition of caldesmon by MAP kinase (Childs 
and Mak 1993).  There may be as yet unidentified modifiers of contraction as research is 
performed in increasingly more smooth muscle cells and tissues and in various disease 
states.  The proteins of interest in this Aim are MLC kinase, p42/44 MAP kinase, ROCK, 
and PKC.  As explained in the general introduction, these proteins have demonstrated 
importance in VSM contraction.  It is not known specifically how these proteins are 
involved in LTCC activation-mediated contractions.  For this reason, they were examined 
in the context of a prolonged contraction in response to LTCC activation. 
The objective of this Aim was to determine the intracellular signaling events that 
occur during a sustained, sub-maximal contraction in response to stimulation and opening 
of LTCCs.  A pharmacological approach was taken to inhibit proteins of interest in the 
signaling cascade during an LTCC-stimulated contraction.  The effect(s) of the inhibitors 
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was determined by the relative magnitude or change in phosphorylation of proteins 
including the MLC, p42/44 MAP kinase, MYPT1, CPI-17, and caldesmon.   
  
Rationale. 
 Contractile pathways are typically studied under experimental conditions that 
produce maximal contraction in response to an agonist.  Additionally, studies have 
focused on the intracellular events immediately following stimulation that lead to force 
development.  By contrast, this study specifically investigated the intracellular events 
during a steady state level of force.  The long time-course of the experiment, combined 
with a dose of agonist that purposely did not lead to a maximal contraction of the tissue, 
was designed to mimic intact vascular smooth muscle tissue exhibiting an increased level 
of basal tone.  Flash-freezing the tissues during the steady-state contraction provided a 
snapshot of the intracellular events in response to opening of LTCC by pharmacological 
activation.  This approach elucidated the signaling pathways that are actively involved in 
developing prolonged force or basal tone.  
 The swine carotid artery has little-to-no spontaneous tone; therefore a 
pharmacological approach was used to mimic tone in this tissue.  In order to accomplish 
this goal, a dose-response curve of vascular smooth muscle contraction to the LTCC 
agonist Bay K8644 was performed over a range of concentrations (1, 3, 10, 30, 100 and 
300 nM; 1 and 3 µM).  Each dose was used in a time-course experiment that revealed that 
the optimal concentration for sustained, sub-maximal force was 100 nM (data not 
shown).  Bay K8644 is structurally similar to dihydropyridines and works by increasing 
the open probability of the channel’s pore-forming α1 subunit (Hockerman, Peterson et al. 
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1997).  Because LTCCs are voltage-gated calcium channels, their opening probability is 
enhanced with increasing depolarization of the plasma membrane (Alonso, Rico et al. 
1989, Fransen, Van Hove et al. 2012, Gopalakrishnan, Park et al. 1985).  As Fransen et al 
(2012) showed increasing [K+] in the extracellular solution increases the force of 
contraction achieved with the same dose of Bay K8644.  The PSS prepared in our 
laboratory contains a final concentration of 4.7 mM K+, which is not sufficient to allow 
Bay K8644 to stimulate channel opening and therefore contraction.  For this reason, all 
experiments utilized a PSS wherein NaCl was substituted with equimolar KCl to achieve 
a final [K+] of 15 mM.  Preliminary experiments showed that this concentration of K+ did 
not produce an increase in force in the absence of Bay K8644, nor did it increase MLC 
phosphorylation (data not shown).  The unstimulated basal tissues in the following 
experiments were bathed in PSS containing 15 mM K+, the effects of which were 
indistinguishable from normal PSS containing 4.7 mM K+. 
The inhibitors used in this Aim were chosen for their specificity according to the 
reported binding affinities (Ki) or half-maximal inhibitor concentration (IC50) that 
indicate specificity and potency of the inhibitors (English and Cobb 2002, Saitoh, 
Ishikawa et al. 1987, Tamura, Nakao et al. 2005, Toullec, Pianetti et al. 1991).  All 
inhibitors used in this Aim have been previously shown to exhibit relatively specific 
actions against the specific enzyme studied using Triton-X100 detergent permeabilized or 
intact smooth muscle tissues (Gorenne, Su et al. 2004, Katoch, Su et al. 1999).  Inhibitors 
were added to the muscle bath 20 minutes prior to addition of Bay K8644 to allow for 
permeation into the tissue. 
 69 
 Nifedipine is a dihydropyridine LTCC inhibitor that is used clinically to treat 
hypertension and angina pectoris (E Kimura, Tanaka et al. 1980, Moskowitz, Piccini et 
al. 1979, Olivari, Bartorelli et al. 1979).  It acts by decreasing the open probability of the 
pore-forming α1 subunit of the channel (Tikhonov and Zhorov 2009).  Nifedipine is 
highly specific, with a Ki of 1nM (Towart 1982).  Nifedipine-treated tissues were used as 
a negative control for the Bay K8644-stimulated tissues as the actions of these two 
molecules directly oppose one another.   
 ML-7 is an analog of the older compound ML-9 that has been shown to inhibit 
MLC kinase-mediated phosphorylation of MLC by competing with the ATP-binding site 
of MLC kinase (Saitoh, Ishikawa et al. 1987).  It exhibits an affinity for MLC kinase 
(Ki=0.3 µM) and at higher concentrations, is able to inhibit PKA (Ki=21 µM) and PKC 
(Ki=42 µM) though the concentration of ML-7 used in this study (10 µM) would not be 
expected to have this confounding effect.  Because MLC kinase activation is considered 
an essential step for smooth muscle contraction, inhibition of MLC kinase with ML-7 
was another negative control.   
 Bisindolylmaleimide I, also known as BIM1, GF 109203X, and Gö 6850, but 
referred to henceforth as Bis, is a pan-PKC inhibitor.  It is highly selective for most 
known isoforms of PKC, namely α, β1, β2, γ, δ, and ε, with IC50 values between 8 and 20 
nM using isolated cells and purified proteins (Toullec, Pianetti et al. 1991).  Because it is 
not known exactly which PKC isoforms are involved in smooth muscle contraction, an 
inhibitor that acts across most isoforms is a natural choice.  Bis was developed from the 
potent but poorly selective serine/threonine kinase inhibitor staurosporine.    
 70 
 U0126 is an inhibitor of p42/44 MAP kinase activity.  It targets the upstream 
molecule MAP kinase kinase, or MEK, and works by competing for ATP binding.  
U0126 was chosen over the similar inhibitor PD98059 because U0126 inhibits both 
MEK1 and MEK2 with near equal potency (Ki=70 nM and 60 nM, respectively), where 
PD98059 is far more specific for MEK1 than MEK2 (Ki=4 µM and 50 µM, respectively) 
(English and Cobb 2002).  Although U0126 is generally considered a MAP kinase kinase 
inhibitor, it will be referred to henceforth as the MAP kinase inhibitor for the sake of 
simplicity as this is the end-point of interest.   
 H-1152 is a ROCK inhibitor that acts by competing with ATP binding.  With a Ki 
of 1.6 nM, it is more potent than older ROCK inhibitors Y27632 (Ki=140 nM) and 
HA1077 (Ki=330 nM) (Tamura, Nakao et al. 2005).  H-1152 poorly inhibits PKA, PKC, 
and MLC kinase (Ki=0.63, 9.27, and 10.1 µM, respectively). Thus, there is little concern 
for non-specific effects.    
 
Results. 
Bay K8644-stimulated isometric force 
Isometric force development of vascular smooth muscle tissue was recorded in 
response to stimulation with Bay K8644 in the presence and absence of inhibitors.  
Addition of 100 nM Bay K8644 resulted in a steady increase in force for the first 60 
minutes that leveled off and increased extremely slowly for the next 60 (Figure 15).  The 
magnitude of force development was normalized to the maximum force produced by each 
tissue strip in response to the application of PSS containing 110 mM KCl (% maximal 
KCl).  Bay K8644-induced force was approximately 60-70% of maximal KCl force.  To 
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study the importance of various signaling proteins in vascular smooth muscle contraction, 
inhibitors against LTCCs (nifedipine, 1 µM), MLC kinase (ML-7, 10 µM), PKC 
(bisindolylmaleimide I, or Bis, 3 µM), MAP kinase kinase (U0126, 10 µM) and Rho 
kinase (H-1152, 1 µM) were added 20 minutes prior to stimulation with Bay K8644.  The 
effects of the inhibitors on Bay K8644-induced force are shown in Figure 16.  Pre-
treatment with nifedipine (Figure 16A) or ML-7 (Figure 16B) prevented force 
development in response to Bay K8644.  Inhibition of ROCK by H-1152 (Figure 16C) 
also prevented force development.  PKC inhibition with Bis (Figure 16D) did not 
significantly alter Bay K8644-stimulated force.  The rise in force, as well as the leveling 
phase, was similar to that seen during Bay K8644 treatment alone. Pre-treatment with the 
MAP kinase kinase inhibitor U0126 (Figure 16E) produced greater force than in 
response to Bay K8644 stimulation alone; however, the effect was not statistically 
significant. As can be seen at the zero time points in all panels of Figure 16, basal, 
unstimulated force was approximately 10% of the maximum response to 110 mM KCl.  
This passive unstimulated force has been previously shown to produce a pre-load that 
approximates Lo, the length at which the tissue produces maximal force (Herlihy and 
Murphy 1973). 
Steady-state force at 120 minutes after addition of Bay K8644 is quantified in 
Figure 17.  This was the final time point in all experiments and represents the point at 
which biochemical measurements were performed.  The anteceding Western blots intend 
to visualize intracellular events at that moment of sustained, sub-maximal force.  Bay 
K8644-stimulated tissue achieved a steady state of force that is approximately 60-70% of 
a maximal KCl contraction.  Pre-treatment with nifedipine, ML-7, or H-1152 
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significantly decreased steady-state force compared to Bay K8644 alone.  The PKC 
inhibitor Bis had no significant effect on force development.  The MAP kinase inhibitor 
U0126 significantly increased Bay K8644 steady state force.  Taken together, these 
results show that LTCC activity, MLC kinase activity, and ROCK activity are required 
for force development.  It rules out PKC as a significant contributor to Bay K8644-
stimulated force and suggests that MAP kinase plays an inhibitory role in vascular 
smooth muscle contraction based on the observation that inhibition of MAP kinase 
increased force development.   
 
Myosin light chain phosphorylation 
Myosin light chain phosphorylation at Serine19 was assessed by urea/glycerol-
PAGE (Figure 18).  The glycerol content of the gel and the high concentration of urea in 
the sample buffer creates a condition where modified forms of the same protein have 
different electrophoretic mobility.  Consequent Western blotting showed that the 
phosphorylated MLC had a greater electrophoretic mobility as compared to 
unphosphorylated MLC.  Representative Western blots demonstrate that opening of 
LTCCs with Bay K8644 resulted in MLC phosphorylation at the Serine19 residue.  
Nifedipine and ML-7 treatment prevented the Bay K8644-induced increase in MLC 
phosphorylation. The MAP kinase inhibitor U0126 significantly increased MLC 
phosphorylation above that measured in response to Bay K8644 stimulation alone.  MLC 
phosphorylation levels during Bay K8644 stimulation in the presence of the PKC 
inhibitor, Bis, were not significantly different compared to Bay K8644-stimulated tissue 
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in the absence of Bis.  Treatment with the ROCK inhibitor H-1152 resulted in decreased 
MLC phosphorylation compared to the level seen during Bay K8644 stimulation alone.  
 
MYPT1 and CPI-17 phosphorylation 
 To determine the involvement of MLC phosphatase in the Bay K8644-induced 
contraction, the phosphorylation status of the MLC phosphatase myosin binding subunit, 
MYPT1, was visualized (Figure 19A).  The level of MYPT1 phosphorylation in tissues 
treated with Bay K8644 was lower than in basal, unstimulated tissues (not shown).  
Inhibition of MAP kinase with U0126 significantly increased MYPT1 phosphorylation 
compared to treatment with Bay K8644 alone (Figure 19B).  The ROCK inhibitor H-
1152 completely abolished MYPT1 phosphorylation, as ROCK is responsible for 
MYPT1 phosphorylation.  Additionally, Figure 19C shows that ML-7 and Bis had no 
effect on MYPT1 phosphorylation, as the levels were the same as that measured during 
Bay K8644 stimulation alone.  Treatment with nifedipine significantly increased MYPT1 
phosphorylation compared with Bay K8644-stimulation.   
The MLC phosphatase inhibitor CPI-17 is phosphorylated by PKC (Eto, Ohmori 
et al. 1995).  It is common to see an increase in CPI-17 phosphorylation during 
contraction as it is one of the two Ca2+ sensitizing mechanisms that allow MLC to remain 
phosphorylated by inhibition of MLC phosphatase activity (Eto, Ohmori et al. 1995, K 
Kimura, Ito et al. 1996).  The lack of CPI-17 phosphorylation during Bay K8644 
stimulation with or without inhibitors (Figure 20A) suggests that PKC is not activated 
and that this particular pathway is not involved in the observed force and MLC 
phosphorylation results in response to Bay K8644. Phorbol-dibutyrate (PDBu) was used 
 74 
as a positive control for CPI-17 phosphorylation because it directly activates PKC.  
Quantification of CPI-17 phosphorylation (Figure 20B) demonstrates the magnitude of 
PDBu-stimulated CPI-17 phosphorylation compared against unstimulated basal and Bay 
K8644-stimulated tissues.  
 
p42/44 MAP kinase phosphorylation 
 The activity of p42/44 MAP kinase was assessed by measuring the 
phosphorylation level of p42/p44 MAP kinase during Bay K8644 stimulation in the 
presence and absence of inhibitors (Figure 21).  The effectiveness of the MAP kinase 
inhibitor, U0126, was demonstrated by its complete abolishment of MAP kinase 
phosphorylation. Inhibition of MLC kinase with ML-7 significantly increased MAP 
kinase phosphorylation during Bay K8644 stimulation.  This was an unexpected result, 
and a potential mechanism for this will be explored in Aim 3. 
 The effect of the other inhibitors (nifedipine, Bis, and H-1152) on p42/44 MAP 
kinase was also assessed (Figure 21C).  Inhibition of PKC with Bis significantly 
increased MAP kinase phosphorylation, a phenomenon that has previously been 
described by our laboratory (Trappanese 2012).  The exact mechanism for this is 
unknown, however the working hypothesis is that PKC activates a MAP kinase 
phosphatase, MKP-1.  Thus, inhibition of PKC with Bis blocks the MAP kinase 
phosphatase leading to an increase in MAP kinase phosphorylation.  Inhibition of LTCCs 
with nifedipine or inhibition of ROCK with H-1152 had no discernible effect on p42/44 
MAP kinase phosphorylation during the Bay K8644-stimulated contraction.  
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Caldesmon phosphorylation 
To determine whether the thin filament-associated protein caldesmon was 
involved in Bay K8644-stimulated force, caldesmon phosphorylation at Serine789 was 
examined. Caldesmon phosphorylation at Serine789 relieves inhibition of actin-myosin 
ATPase and allows force to develop (C-L Wang 2001).  Western blotting for caldesmon 
phosphorylation at Serine789 revealed no change during Bay K8644 stimulation regardless 
of the presence or absence of the various kinase inhibitors (Figure 22).  The level of 
phosphorylation is the same in basal unstimulated tissues as it was in Bay K8644-
stimulated tissues with or without inhibitors.   
 
Discussion. 
 The purpose of this Aim was to examine the intracellular signaling downstream of 
Ca2+ influx through LTCCs that contributes to stable force maintenance in vascular 
smooth muscle.  A better understanding of the signaling pathways that contribute to 
prolonged force will provide information for developing targeted therapeutics for 
conditions such as hypertension and vasospasm.  It is well established that Ca2+ influx or 
release from intracellular stores and the subsequent activation of MLC kinase are 
required for the initiation of vascular smooth muscle contraction (Menice, Hulvershorn et 
al. 1997).  However, other studies and findings in this Aim provide new lines of evidence 
suggesting that these events are far less important during a prolonged contraction 
resulting in steady-state force.  By using pharmacological inhibitors of signaling proteins 
known or suspected to be involved in modulating force, our main goal was to delineate 
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the signaling pathways involved in prolonged vascular contraction evoked by LTCC 
activation.  
 
Isometric force in response to Bay K8644 
Stimulation of LTCCs with 100 nM of the agonist Bay K8644 resulted in sustained force 
that was approximately 60-70% of a maximal contraction.  This magnitude in force was 
coupled to an increase in MLCSer19 phosphorylation, as expected.  The LTCC inhibitor 
nifedipine and the MLC kinase inhibitor ML-7 significantly prevented force 
development.  This was likely due to inhibition of two critical steps in the initiation of 
contraction, namely, Ca2+ entry through LTCCs and MLC kinase activity, respectively.  
Inhibition of ROCK with H-1152 also prevented force development.  This result suggests 
that ROCK activity is required for initiation of membrane depolarization-induced force. 
This outcome is inconsistent with many reports in the literature as ROCK is believed to 
be activated primarily by ligand binding to a receptor and is not believed to be Ca2+-
dependent (Sasahara, Okamoto et al. 2015, Urban, Berg et al. 2003).  ROCK, like LTCCs 
and MLC kinase, appeared to exhibit a basal level of activity that supports resting tension 
in unstimulated tissue.  The lack of effect by the PKC inhibitor Bis suggests that PKC is 
not critical in force development via opening of LTCC.  Because PKC phosphorylates a 
protein, CPI-17, that has an inhibitory effect on MLC phosphatase, use of the PKC 
inhibitor during a stimulated contraction was expected to decrease force.  The fact that 
Bay K8644-induced force during inhibition of PKC was comparable to force developed 
in response to Bay K8644 alone leads to the conclusion that CPI-17-mediated inhibition 
of MLC phosphatase activity does not contribute to sustained force.  The most interesting 
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result from the isometric force recordings was the significant increase in steady state Bay 
K8644-induced force in the presence of the MAP kinase inhibitor, U0126.  In neuronal 
cells, U0126 has been suggested to induce membrane depolarization by activating K+ 
channels (Pereira, Carvalho et al. 2002).  However pretreatment of carotid smooth muscle 
with 10µM U0126 did not increase force or MLC phosphorylation demonstrating that the 
observed effects attributed to U0126 were not via membrane depolarization.  Instead the 
force result suggests that MAP kinase has an inhibitory role on contraction, perhaps to 
keep the tissue from deleterious maximal contractions.  This effect will be explored 
further in Aims 2 and 3.   
 
MLC phosphorylation 
Stimulation of the tissue with Bay K8644 caused phosphorylation of MLC at 
Serine19 (Figure 18A).  Tissues treated with the MLC kinase inhibitor ML-7 or the 
LTCC inhibitor nifedipine showed a significant reduction in MLC phosphorylation.  This 
was expected because these inhibitors prevented force development, and MLC 
phosphorylation and force development are, in most cases, tightly coupled (Barany, 
Rokolya et al. 1991, Kamm and Stull 1985).  The MAP kinase inhibitor U0126 
significantly increased MLC phosphorylation, which agrees with the significantly 
increased force.  These results imply that active (non-inhibited) MAP kinase suppresses 
MLC phosphorylation and force development.  In the presence of the inhibitor, this 
suppression is relieved resulting in greater MLC phosphorylation and force development 
in response to LTCC stimulation.  The ROCK inhibitor H-1152 did not alter MLC 
phosphorylation levels compared to Bay K8644 stimulation alone.  This was surprising 
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given that ROCK inhibition prevented force development.  This result represents an 
uncoupling between MLC phosphorylation and contractile force that warrants further 
investigation.    
 
Ca2+ sensitization mechanisms 
Contraction by electromechanical or pharmacomechanical coupling is often 
accompanied by activation of Ca2+-sensitizing mechanisms that inhibit MLC phosphatase 
and allow MLC to remain phosphorylated without an additional influx of Ca2+ or increase 
in MLC kinase activity (Hartshorne, Ito et al. 1998, Mizuno, Isotani et al. 2008, Uehata, 
Ishizaki et al. 1997).  Ca2+ sensitization is determined by an increase in phosphorylation 
of the myosin-binding subunit of MLC phosphatase, MYPT1, and/or phosphorylation of 
the PKC-potentiated inhibitory protein of 17kDa, CPI-17.  Surprisingly there was no 
increase in MYPT1 phosphorylation during a Bay K8644-induced contraction (Figure 
19).  The ROCK inhibitor H-1152 significantly decreased MYPT1 phosphorylation, as 
ROCK is the kinase responsible for this event.  The MAP kinase inhibitor U0126 
significantly increased MYPT1 phosphorylation, and that may explain why force and 
MLC phosphorylation were both increased in the presence of Bay K8644 plus U0126.  
CPI-17 was not phosphorylated in any experimental condition (Figure 20).  This agrees 
with the observation that inhibition of PKC did not affect Bay K8644-induced force 
development (Figure 16D) or levels of MLC phosphorylation (Figure 18). 
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MAP kinase and caldesmon phosphorylation 
 p42/44 MAP kinase phosphorylation, an index of MAP kinase activity (Katoch 
and Moreland 1995), was measured during Bay K8644 stimulation.  The MAP kinase 
inhibitor U0126 completely abolished MAP kinase phosphorylation as expected (Figure 
21).  Inhibiting MLC kinase with ML-7 resulted in a significant increase in MAP kinase 
phosphorylation, suggesting that MAP kinase activity is dampened by an active MLC 
kinase.  Perhaps this is to block inappropriate cell proliferation in a contractile cell or 
abnormally high levels of contraction.  The mechanism responsible for this MAP kinase-
MLC kinase effect will be explored further in Aim 2.  If MAP kinase is involved in 
prolonged force maintenance, it is surprising that there was no appreciable difference in 
caldesmon Serine789 phosphorylation during Bay K8644 stimulation (Figure 22) in the 
presence as compared to the absence of MAP kinase inhibition.  An increase in 
caldesmon phosphorylation during contractile stimulation has been reported previously 
by our laboratory (Trappanese 2012).  At the very least, it was expected that inhibition of 
MAP kinase would result in inhibition of caldesmon phosphorylation as MAP kinase is 
recognized as the endogenous kinase for caldesmon (Adam and Hathaway 1993).  
Caldesmon physically associates with the actin filament and inhibits myosin ATPase 
activity and therefore crossbridge cycling (Ngai and Walsh 1984).  This suggests that thin 
filament disinhibition by caldesmon phosphorylation is not involved in sustained LTCC-
mediated contraction in vascular smooth muscle.  It is possible that caldesmon 
disinhibition is not a ubiquitous event in vascular smooth muscle contraction and will not 
occur during all forms of stimulation and the development of force.  Caldesmon may 
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require specific stimulation conditions in order to be involved in a contractile event of 
smooth muscle. 
The lack of involvement of either Ca2+ sensitization or thin filament disinhibition 
steers the course of this study into an entirely unexpected direction.  The following two 
Aims will attempt to further define the signaling between MLC kinase and MAP kinase 
and explain how they contribute to prolonged force during an LTCC-mediated 
contraction in vascular smooth muscle.     
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Figures: Specific Aim 1   
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Figure 15.  Time course of force development with 100nM Bay K8644 in swine carotid 
artery. 
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Figure 15.  Time course of force development with 100 nM Bay K8644 in swine carotid 
artery. 
Addition of 100 nM of the LTCC inhibitor Bay K8644 resulted in a steady rise in 
force for the first 60 minutes that leveled off and was maintained at approximately 60-
70% of a maximal contraction in response to 110 mM KCl for the next 60 minutes, until 
termination of the experiment.  The contraction was carried out for 120 minutes in order 
to study the signaling involved in maintaining steady state force. 
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Figure 16. Effect of inhibitors on Bay K8644-stimulated force.   
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Figure 16. Effect of kinase inhibitors on Bay K8644-stimulated force.   
Kinase inhibitors were added 20 minutes prior to contraction with Bay K8644 to 
allow for permeation into the tissue strip.  A. Inhibition of LTCCs with 1 µM nifedipine 
prevented force development, as expected.  B. Inhibition of MLC kinase with 10 µM 
ML-7 also prevented force development as expected.  C.  Surprisingly, inhibition of 
ROCK with 1 µM H-1152 prevented force development.  D.  Inhibition of PKC with 3 
µM Bis had no appreciable effect on force development, as the results are nearly identical 
to force with Bay K8644 alone.  E. Inhibition of MAP kinase kinase with 10 µM U0126 
increased steady state force (the plateau region) but not the rate of rise of force 
development.  This indicates that MAP kinase may play a role in the inhibition of force 
maintenance.  A One-Way Repeated Measures ANOVA was performed to determine 
statistical significance.   ** p<0.001 
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Figure 17. Steady-state force 120 minutes after the addition of Bay K8644.  
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Figure 17. Steady-state force 120 minutes after addition of Bay K8644.   
This bar graph depicts the magnitude of Bay K8644-induced force compared to 
the maximal contraction in response to 110 mM KCl in the presence of each of the kinase 
inhibitors.  As depicted in the previous figure, inhibition of LTCCs, MLC kinase, and 
ROCK led to significant decreases in steady state force.  There was no significant effect 
in the presence of Bis.  U0126 significantly increased Bay K8644-stimulated force, 
though only during the steady state.  Nifedipine: LTCC inhibitor; ML-7: MLC kinase 
inhibitor; H-1152: ROCK inhibitor; Bis: PKC inhibitor; U0126: MAP kinase inhibitor.  
Bars represent mean ± SEM.  To determine significance, a One-Way ANOVA was 
performed with multiple comparisons versus Bay K8644 stimulation alone (Holm-Sidák 
Method).  ** p<0.01  n = 12 
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Figure 18.  MLC phosphorylation during a sustained Bay K8644-induced contraction. 
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Figure 18. MLC phosphorylation during a sustained Bay K8644-induced contraction. 
A. Representative Western blot of urea/glycerol-PAGE showing MLC 
phosphorylation at Serine19.  B. Quantified results of several blots of MLC 
phosphorylation at Serine19 as shown in panel A.  Bay K8644-induced MLC 
phosphorylation was inhibited by nifedipine and ML-7.  Bis had no appreciable effect on 
MLC phosphorylation.  U0126 significantly increased levels of MLC phosphorylation.  
The effect of H-1152 was variable but is suggested in this figure to produce as a decrease 
of phosphorylation.  Bars represent mean +/- SEM. Significance was determined using a 
One Way ANOVA with multiple comparisons versus Bay K8644 stimulation alone 
(Holm-Sidák Method).  * p<0.05   n = 8-10 
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Figure 19.  MYPT1 phosphorylation during a sustained Bay K8644-stimulated 
contraction. 
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Figure 19. MYPT1 phosphorylation during a sustained Bay K8644-stimulated 
contraction. 
The involvement of MLC phosphatase inhibition via MYPT1 phosphorylation 
was assessed by Western blot.  A. Representative Western blot of MYPT1Thr850 
phosphorylation during Bay K8644 stimulation alone and in the presence of the MAP 
kinase kinase inhibitor U0126 and the ROCK inhibitor H-1152.  B. Quantification of 
several blots as shown in panel A demonstrate that U0126 significantly increased 
MYPT1 phosphorylation, which could explain the increase in Bay K8644-stimulated 
force.  Treatment with H-1152 nearly abolished MYPT1 phosphorylation because ROCK 
is the primary kinase believed to phosphorylate MYPT1.  Bars represent mean +/- SEM.  
Significance was determined using a One Way ANOVA with multiple comparisons 
against Bay K8644 stimulation alone (Holm-Sidák Method).  * p<0.05   n = 4 
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Figure 20. CPI-17 phosphorylation during a sustained Bay K8644-stimulated 
contraction. 
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Figure 20. CPI-17 phosphorylation during a sustained Bay K8644-stimulated 
contraction. 
Another index of MLC phosphatase inhibition is phosphorylation of CPI-17 at 
Threonine38.  A. Representative Western blot showing CPI-17 phosphorylation during 
Bay K8644 stimulation alone or in the presence of the MAP kinase kinase inhibitor 
U0126 and the ROCK inhibitor H-1152.  Phorbol 12,13-dibutyrate (PDBu) was used as a 
positive control as it directly activates PKC.  B. Quantification of several blots as shown 
in Panel A.  CPI-17 phosphorylation is not elevated in response to Bay K8644 in the 
presence or absence of the kinase inhibitors.  CPI-17 phosphorylation is significantly 
elevated in response to stimulation with the PKC activator, PDBu.  Bars represent mean 
+/- SEM.  Significance was determined using a One Way ANOVA with multiple 
comparisons versus PDBu-stimulated control (Holm-Sidák Method).  ** p<0.001  n = 4 
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Figure 21. p42/44 MAP kinase phosphorylation during a sustained Bay K8644-
stimulated contraction. 
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Figure 21. p42/44 MAP kinase phosphorylation during a sustained Bay K8644-
stimulated contraction. 
MAP kinase activity was visualized to determine its potential role in a sustained 
Bay K8644 stimulated contraction.  A. Representative Western blot of dual p42/44 MAP 
kinase phosphorylation during Bay K8644 stimulation and in the presence of the MLC 
kinase inhibitor ML-7 and the MAP kinase inhibitor U0126.  B. Quantification of p42/44 
MAP kinase phosphorylation from several blots shown in Panel A.  ML-7 significantly 
increased p42/p44 MAP kinase phosphorylation, a finding not reported previously in the 
literature.  U0126 abolished p42/p44 MAP kinase phosphorylation as expected.  Bars 
represent mean +/- SEM.  A One Way ANOVA determined significance with multiple 
comparisons versus Bay K8644-stimulation alone (Holm-Sidák Method).  ** p<0.001 
compared to  p42 MAP kinase phosphorylation in response to Bay K8644 stimulation 
alone.  † p < 0.05 and †† p < 0.001 compared to p44 MAP kinase phosphorylation in 
response to Bay K8644 stimulation alone.  n = 8 
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Figure 22. Caldesmon phosphorylation during a sustained Bay K8644-stimulated 
contraction. 
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Figure 22.  Caldesmon phosphorylation during a sustained Bay K8644-stimulated 
contraction. 
 Caldesmon phosphorylation at Serine789 was visualized to determine what role it 
may play in a sustained, LTCC-mediated contraction.  There was no change in caldesmon 
phosphorylation during a Bay K8644-stimulated contraction alone or in the presence of 
kinase inhibitors.  This rules out the involvement of caldesmon in maintaining a sustained 
contraction.  n = 4 
  
 98 
 
 
Specific Aim 2: 
To determine the role of MAP kinase on MLC kinase activity and MLC phosphorylation 
during a sustained vascular smooth muscle contraction. 
 
  
 99 
Introduction. 
  
The results of Specific Aim 1 suggest there is crosstalk between MLC kinase and 
p42/44 MAP kinase as inhibiting one increased the activity of the other.  Inhibiting MLC 
kinase significantly increased p42/44 MAP kinase phosphorylation (Figure 21A).  
Interestingly, inhibition of p42/44 MAP kinase resulted in greater Bay K8644-stimulated 
force than Bay K8644 alone (Figure 16E).  This increase in force was correlated with a 
significant increase in MLC phosphorylation (Figure 18A).  This suggested that the 
increase in force during inhibition of p42/p44 MAP kinase was MLC phosphorylation-
dependent.  Taken together these results imply that, when fully functional in vascular 
smooth muscle tissue, MLC kinase has an inhibitory or suppressive effect on MAP kinase 
and MAP kinase has an inhibitory or suppressive effect on force via decreases in levels of 
MLC phosphorylation.  The ability of MAP kinase to inhibit force via effects on MLC 
kinase may serve to direct the energy of the cell to proliferative mechanisms, stimulated 
by MAP kinase activation, and decrease contractile mechanisms stimulated by MLC 
kinase.  Given that the typical force modulatory mechanisms of Ca2+ sensitization via 
MYPT1 and CPI-17 phosphorylation (Figures 19 and 20, respectively) and caldesmon 
disinhibition by phosphorylation (Figure 22) were found not be involved in Bay K8644-
dependent force development in Aim 1, the inhibitory effect of p42/44 MAP kinase is a 
possible mechanism for the modulation of force.  This current Aim sought to define the 
interaction(s) between MLC kinase and MAP kinase and to suggest a potential 
mechanism for the observed effects as summarized in Figure 23.  To better understand 
the role of MAP kinase in this experimental model, the following provides a brief review 
of the plethora of functions attributed to MAP kinase(s). 
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Cellular roles of MAP kinases  
MAP kinases are intermediary signaling proteins responsible for transducing 
extracellular signals to nuclear transcription factors that regulate, in part, protein 
synthesis.  The three primary MAP kinases are p42/44 (also known as extracellular 
regulated kinase, or ERK 1/2), p38 MAP kinase, and c-Jun amino terminal kinase/stress-
activated protein kinase (JNK/SAPK)—all three kinases are expressed in vascular smooth 
muscle tissue to various degrees (Childs and Mak 1993, Hedges, Yamboliev et al. 1998, 
Zhan, Kim et al. 2003).  Figure 9 shows canonical MAP kinase signaling.  There is a 
homologous, tiered pattern of activation that begins with an extracellular signal such as a 
growth factor or cytokine and ends with a biological response such as cell growth, cell 
differentiation, or apoptosis (Cargnello and Roux 2011).  The sequential phosphorylation 
events allow for amplification of the initiating signal as it is transduced inward, a 
common feature in physiological pathways.  Because of the demonstrated importance of 
MAP kinases as key regulators of cell growth and death, the components of the MAP 
kinase signaling pathway are often studied in the context of cancer and developmental 
biology (Dhillon, Hagan et al. 2007).  MAP kinases also operate signaling leading to cell 
migration that is used by cells to avoid toxins, seek nutrients, and perform specific 
cellular roles.  Cell migration requires interaction between actin and myosin molecules, 
similar to the cross-bridge cycling that occurs in muscle cells (Klemke, Cai et al. 1997).  
Figure 24 illustrates how p42/44 MAP kinase, or ERK1/2, regulated signaling bifurcates 
in order to regulate both cell proliferation and cell movement.  In fact, research has 
shown considerable crosstalk between pathways responsible for growth and contraction.  
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Growth factors are able to induce smooth muscle contraction (Berk and Alexander 1989) 
and well-known smooth muscle agonists like angiotensin II and endothelin-1 can activate 
cell growth through MAP kinase signaling (Dessy, Kim et al. 1998, Watanabe, Pakala et 
al. 2001).  The ability of smooth muscle cells to respond to diverse stimuli is typified by 
its ability to modulate cellular phenotype. 
 
Phenotypic diversity 
Vascular smooth muscle cells have a complex lineage.  Rather than a single 
origin, vascular smooth muscle cells develop from different progenitors depending on 
their terminal location (Majesky 2007).  This makes the vasculature a mosaic of cells of 
diverse origins.  It is believed that local signals from the surrounding tissue lead to the 
expression of smooth muscle-specific proteins as illustrated in Figure 25.  Smooth 
muscle cells are unique in that their fate as a cell is not fixed.  They have the ability to 
phenotypically modulate from a contractile cell to a migratory/secretory cell and back to 
a contractile phenotype (Campbell and Campbell 1985).  The differentiated or contractile 
phenotype is defined by high expression of contractile proteins and ion channels such as 
LTCCs, and very little production of extracellular matrix proteins (Davis-Dusenbery, Wu 
et al. 2011, Gollasch, Haase et al. 1998).  Conversely, the dedifferentiated phenotype 
shows reduced expression of contractile proteins, reduced expression of many membrane 
associated ion channels, high rates of migration and proliferation, and increased 
production of extracellular matrix.  This diversity allows smooth muscle cells to 
phenotypically change with the phenotype determined by the physiological or 
pathophysiological stimuli or environment (Owens 1995).  Figure 26 illustrates some of 
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the influences that can drive the smooth muscle cell phenotype from a contractile to a 
migratory phenotype as well as the microRNAs that are important to each.  The shift 
from a contractile phenotype to a migratory/secretory phenotype typically occurs during 
vessel remodeling, vessel injury, and hypoxic conditions.  In response to an injury to the 
vessel lumen, growth factors and inflammatory cells induce smooth muscle cells to 
dedifferentiate and migrate to the lumen in an attempt at repair the injury (Gimbrone 
1999, H Yu, Clarke et al. 2011).  An overabundance of smooth muscle cell proliferation 
in the lumen leads to the formation of an atherosclerotic lesion that may eventually result 
in myocardial infarct, stroke, and/or sudden cardiac death (Lusis 2000).  Environmental 
factors such as exposure to nicotine (Yoshiyama, Chen et al. 2014) and diseases such as 
diabetes (Beckman, Creager et al. 2002) can stimulate this phenotypic switch and 
accelerate atherosclerotic disease progression.   
MAP kinase pathways appear to regulate two distinct signaling events, one 
leading to contraction and another leading to cell migration and proliferation.  MAP 
kinases play an important role in activating nuclear transcription factors that can increase 
or decrease specific protein expression levels and, by extension, the function of the cell 
(Cargnello and Roux 2011, Cobb, Boulton et al. 1991, Zhan, Kim et al. 2003).  They also 
act in contractile pathways, as discussed next.  
 
MAP kinases in contraction 
p42/44 MAP kinase, or extracellular signal-regulated kinase (ERK1/2), is 
activated by dual phosphorylation at Tyrosine185 and Threonine187 (Cobb, Boulton et al. 
1991).  MAP kinase activation has been observed concurrently with smooth muscle 
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contraction in response to Ca2+ influx through voltage-sensitive calcium channels (Rosen, 
Ginty et al. 1994), membrane depolarization (Katoch and Moreland 1995), serotonin 
(Florian and Watts 1998, Hershenson, Chao et al. 1995), endothelin-1 (Kwon, Lee et al. 
2003), phenylephrine (Dessy, Kim et al. 1998, Tsai and Jiang 2005), increase in 
intraluminal pressure (Lagaud, Lam et al. 1999, Spurrell, Murphy et al. 2003), and stretch 
(Franklin, Wang et al. 1997).  The multitude of stimuli that induce both smooth muscle 
contraction and concomitant activation of MAP kinase demonstrates that MAP kinase is 
an integral signaling protein in smooth muscle tissue.  MAP kinase has also been shown 
to contribute to Ca2+ sensitization in intestinal smooth muscle by inhibiting MLC 
phosphatase activity (Ihara, Yu et al. 2015). However, the results of the previous Aim 
demonstrate that this particular function of MAP kinase is not involved in the 
experimental model utilized in this project, based on the evidence that the two indices of 
MLC phosphatase inhibition, phosphorylation of CPI-17 (Figure 20) and 
phosphorylation of MYPT1 (Figure 19), were not involved in a Bay K8644-induced 
muscle contraction.   
p38 MAP kinase and JNK are structurally and functionally similar to the p42/44 
isoform (Cargnello and Roux 2011, Cobb, Boulton et al. 1991).  It is unlikely but entirely 
possible that they play a role in sustained vascular contractions.  This hypothesis was 
tested by measuring the phosphorylation levels of p38 MAP kinase and JNK during 
sustained Bay K8644-stimulated.  If phosphorylation levels of p38 MAP kinase and/or 
JNK change significantly during a Bay K8644-mediated contraction, inhibitors of these 
kinases can be used to further determine their importance in the development of sustained 
force. 
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The results of Specific Aim 1 revealed an inhibitory signaling crosstalk between 
MLC kinase and MAP kinase in vascular smooth muscle that has not been previously 
described.  Unraveling the mechanisms of the potential crosstalk between p42/44 MAP 
kinase and MLC kinase are important to the understanding of the development of tone in 
vascular smooth muscle as this is likely a novel regulatory mechanism of smooth muscle 
contraction.  The interplay between p42/p44 MAP kinase and MLC kinase may therefore 
be involved in the regulatory mechanisms of Ca2+ sensitization, thin filament regulation, 
and actin cytoskeleton dynamics in modulating force.  At an organismal level, this 
additional pathway of regulation would allow fine-tuning of contractile force in response 
to different stimuli.  
 Given the observations in Aim 1 showing that inhibition of p42/44 MAP kinase 
increases contractile force and that inhibition of MLC kinase increases p42/44 MAP 
kinase phosphorylation, the next step was to determine whether these effects were 
isoform-specific (p42/p44 MAP kinase) or attributable to all members of the MAP kinase 
family (p42/p44 MAP kinase, p38 MAP kinase, and/or JNK).  Thus, the goal of this Aim 
was to investigate the role of p42/44, p38, JNK MAP kinase, and MLC kinase in 
sustained vascular smooth muscle contraction stimulated by LTCC activation.   
 
Rationale. 
 MAP kinase signaling in smooth muscle cells can modulate contraction. 
However, a direct link between p42/44 MAP kinase activity and MLC kinase activity 
during a sustained contraction is not known.  This Aim explored the relationship between 
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MLC kinase and MAP kinase activity during a Bay K8644-mediated contraction.  The 
MLC kinase inhibitor ML-7 and the MAP kinase inhibitor U0126 were used separately 
and together.  As before, the inhibitors were added 20 minutes prior to stimulation with 
100 nM Bay K8644.  Western blot analysis of tissue samples taken at the final time point 
during the sustained contraction (120 min) was performed to further characterize the 
MLC kinase-MAP kinase effect.  The phosphorylation of MLC and p42/44 MAP kinase 
was also quantified.  It was of interest to see how the magnitude of force, MLC 
phosphorylation, and MAP kinase phosphorylation change when inhibitors of both MLC 
kinase and MAP kinase were used together.  Phosphorylation of MLC kinase at Serine1760 
decreases affinity of the C-terminal end of the kinase for the Ca2+/CaM complex and 
represents deactivation of the kinase (Conti and Adelstein 1981).  Phosphorylation of 
MLC kinase was quantified to show whether MAP kinase was affecting force and MLC 
phosphorylation through MLC kinase.    
In order to determine whether this effect is specific to the p42/44 isoform and rule 
out involvement of other MAP kinases, Western blots of p38 and JNK/SAPK 
phosphorylation were performed. 
 
Results. 
Isometric force with Bay K8644 
ML-7 prevented Bay K8644-stimulated force as shown in Aim 1 (Figure 27, 
closed triangles).  When U0126 was added along with ML-7, there was a significant 
increase in force development (Figure 27, open triangles) compared to force 
development in response to Bay K8644 plus only ML-7.  This appears to be a “rescue” 
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by U0126 of force that would otherwise have been prevented by ML-7.  This result 
indicated that U0126 increased force in a manner that was independent of MLC kinase 
activity. 
 
MLC phosphorylation 
 Phosphorylation of MLC at the Serine19 residue was visualized using 
urea/glycerol-PAGE (Figure 28).  Quantification of the optical densitometry results 
revealed that, compared to Bay K8644-stimulation alone, ML-7 produced a significant 
decrease (or prevented an increase) in MLC phosphorylation as would be expected by the 
addition of an inhibitor of the MLC kinase.  U0126 appeared to increase phosphorylation 
compared to Bay K8644 stimulation alone; however, the effect was not statistically 
significant.  When both U0126 and ML-7 were used together during Bay K8644-
dependent stimulation, it appeared that the ML-7 effect dominated in terms of MLC 
phosphorylation, and an increase in levels of MLC phosphorylation was prevented.  
 
p42/44 MAP kinase phosphorylation   
 The crosstalk between MLC kinase and p42/44 MAP kinase was further 
examined by measuring p42/44 MAP kinase phosphorylation.  Western blots of p42/44 
MAP kinase confirmed that inhibiting MLC kinase with ML-7 significantly increased 
MAP kinase phosphorylation during a Bay K8644-induced contraction (Figure 29).  The 
MAP kinase inhibitor U0126 inhibited p42/44 phosphorylation whenever present, 
regardless of the inclusion of ML-7 or Bay K8644.  Taking into consideration the 
previous two figures, the p42/44 MAP kinase phosphorylation results suggested that the 
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elevation of Bay K8644-stimulated force in the presence of U0126 is independent of 
MAP kinase phosphorylation.  
 
MLC kinase phosphorylation 
 MLC kinase phosphorylation at Serine1760 results in decreased affinity of the 
MLC kinase for the Ca2+/CaM complex and therefore reduces MLC kinase activity 
(Tansey, Luby-Phelps et al. 1994).  In Aim 1 and the present Aim, inhibition of MAP 
kinase increased levels of force and MLC phosphorylation but it is unclear if these effects 
are through MLC kinase.  Therefore, MLC kinase phosphorylation was visualized in 
order to determine what, if any, effect U0126 may have directly on MLC kinase.  There 
was little to no MLC kinase phosphorylation in the unstimulated sample (Figure 30A). 
However, MLC kinase phosphorylation increased greatly in the presence of Bay K8644.  
ML-7 plus Bay K8644 significantly decreased MLC kinase phosphorylation (Figure 
30B).  U0126 plus Bay K8644 did not alter MLC kinase phosphorylation levels, and 
there was no statistically significant difference between U0126 plus Bay K8644 and Bay 
K8644 alone.  U0126 plus ML-7 in the presence of Bay K8644 showed a significant 
decrease in MLC kinase phosphorylation compared to Bay K8644 stimulation alone; 
however, the amount of phosphorylation was greater than in the sample treated with ML-
7 plus Bay K8644.  This result is similar to the force data (Figure 27), where U0126 plus 
ML-7 had significantly greater force than ML-7 alone but not as much force as Bay 
K8644 alone.  
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p38 MAP kinase and JNK phosphorylation 
 Experiments in this present Aim and in Aim 1 demonstrated that inhibiting p42/44 
MAP kinase activity altered signaling and force development in vascular smooth muscle.  
It was of interest to determine whether this effect is specific to the p42/44 isoform of 
MAP kinase or a general MAP kinase superfamily effect.  p38 MAP kinase and c-Jun 
kinase (JNK) are in the MAP kinase superfamily alongside p42/44 MAP kinase.  p38 
MAP kinase and JNK phosphorylation levels were visualized to determine whether the 
MAP kinase-MLC kinase effect applied to other MAP kinase isoforms (Figure 31).  p38 
MAP kinase and JNK phosphorylation levels were unchanged during Bay K8644 
stimulation in the absence or presence of kinase inhibitors.  p38 MAP kinase appears to 
be constitutively phosphorylated while there is no JNK phosphorylation across tissues in 
any condition tested.  
 
Discussion. 
 The goal of this aim was to explore the observed effect of MLC kinase inhibition 
on MAP kinase phosphorylation and the effect of MAP kinase inhibition on MLC kinase 
and MLC phosphorylation during sustained contraction stimulated by Bay K8644. The 
results in Aim 1 showed that Bay K8644-stimulated force is enhanced in the presence of 
the MAP kinase inhibitor U0126 (Figure 16E) and is prevented by the MLC kinase 
inhibitor ML-7 (Figure 16B).  Furthermore, ML-7 significantly increased p42/44 MAP 
kinase phosphorylation (Figure 21), while U0126 significantly increased MLC 
phosphorylation (Figure 18B).  This interplay between MLC kinase and p42/44 MAP 
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kinase was examined further by using the inhibitors ML-7 and U0126 alone or together, 
during a Bay K8644-induced contraction.  
 
Isometric force and MLC phosphorylation 
Bay K8644-induced force was inhibited by the MLC kinase inhibitor ML-7 and 
increased by the MAP kinase inhibitor U0126.  When the inhibitors were applied 
together, the effect of U0126 overcame the effect of ML-7 such that significant levels of 
force were developed in contrast to the almost complete inhibition of force in the 
presence of ML-7 alone.  This suggested that inhibition of MAP kinase increases force by 
a mechanism that is independent of MLC kinase activity (Figure 27).  Quantification of 
MLC phosphorylation levels (Figure 28) revealed that the combined use of U0126 and 
ML-7 resulted in a significant decrease in Bay K8644-stimulated MLC phosphorylation, 
although force was enhanced.  This is of great interest because it represents an 
uncoupling between force and MLC phosphorylation.  The tissues treated with ML-7 plus 
U0126 during Bay K8644 stimulation had significantly higher levels of force than tissues 
subjected to Bay K8644 plus ML-7; however there was no significant increase in MLC 
phosphorylation above that in response to Bay K8644 alone or Bay K8644 plus ML-7. 
This suggests that the effect of ML-7 on MLC phosphorylation overcame the effect of 
U0126 on MLC phosphorylation and again suggests that U0126 increases Bay K8644-
induced force by a MLC kinase-independent mechanism.   
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Phosphorylation of MAP kinases 
p42/44 MAP kinase phosphorylation was significantly increased in the presence 
of the MLC kinase inhibitor ML-7 and decreased significantly in the presence of the 
MAP kinase inhibitor U0126 (Figure 29).  Use of both inhibitors resulted in significantly 
decreased MAP kinase phosphorylation suggesting that the effect of U0126 overcame 
that of ML-7.  Several studies have reported the activation and involvement of p38 MAP 
kinase and JNK in smooth muscle contraction, but only in disease states such as 
atherosclerosis and hypertension and not in the regulation or function of smooth muscle 
in normal state (Kwon, Fang et al. 2004, C Wang, Chang et al. 2015, J Yu, Ok et al. 
2015).  This is likely because p38 MAP kinase and JNK are stress-response proteins that 
change cellular activity depending on cues from the extracellular milieu.  In any case, it 
was still important to rule out their involvement in the current experimental design in 
general, and in the signaling between MLC kinase and p42/44 MAP kinase, in particular.  
The lack of change in p38 MAP kinase or JNK phosphorylation levels in basal versus 
Bay K8644-stimulated tissues, along with the lack of change in the presence of inhibitors, 
provide more evidence supporting the existence of the novel MLC kinase-p42/44 MAP 
kinase effect observed in this Aim and in Aim 1.   
 
MLC kinase phosphorylation 
 MLC kinase phosphorylation at Serine1760 results in inactivation of the kinase 
(Tansey, Luby-Phelps et al. 1994).  At the conclusion of a 2-hour contraction evoked 
with Bay K8644, MLC kinase phosphorylation had increased.  This seems 
counterintuitive, because phosphorylation inhibits MLC kinase activity and MLC kinase 
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activity is thought to be essential to smooth muscle contraction.  The increased 
phosphorylation (and therefore inhibition) of MLC kinase during Bay K8644-stimulation 
suggests that continued MLC kinase activity is not required for sustained contraction.  It 
is possible that this phosphorylation event is an internal brake that prevents uncontrolled 
contraction.  Once stimulated to contract by the opening of LTCCs and the influx of 
extracellular Ca2+, MLC kinase phosphorylation may be increased to modulate the force 
of contraction in order to conserve energy and/or maintain blood flow.  MLC kinase 
phosphorylation significantly decreased in the presence of the MLC kinase inhibitor ML-
7, though MLC kinase is not known to auto-phosphorylate.  It is possible that binding of 
ML-7 to MLC kinase prevented the Bay K8644-mediated increase in MLC kinase 
phosphorylation.  The MAP kinase inhibitor U0126 did not affect the Bay K8644-
induced increase in MLC kinase phosphorylation, suggesting that p42/44 MAP kinase 
has no role in the phosphorylation of MLC kinase.  When both U0126 and ML-7 were 
used together, the effect of U0126 dominated resulting in a more MLC kinase 
phosphorylation than in the presence of ML-7 alone but significantly less 
phosphorylation compared to Bay K8644 alone.  
 The next Aim will investigate whether p21-activated kinase 1 (PAK1) regulates 
MLC kinase to suppress p42/44 MAP kinase activity and MAP kinase to suppress MLC 
phosphorylation and force in vascular smooth muscle.    
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Figure 23. Observed effects between MLC kinase and p42/44 MAP kinase during a 
steady state contraction in response to Bay K8644 stimulation. 
. 
A. Normal tissue, no inhibitors: 
 
 
B.  MLC kinase inhibited with ML-7: 
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Figure 23. Observed effects between MLC kinase and p42/44 MAP kinase during a 
steady state contraction in response to Bay K8644. 
Arrows indicate an excitatory effect, blunted lines indicate an inhibitory effect.  
(A) During sustained force maintenance in normal tissue in the absence of inhibitors of 
MLC kinase or MAP kinase, MLC kinase decreases MAP kinase activity and MAP 
kinase decreases MLC phosphorylation presumably due to effects on MAP kinase   (B) 
The suppressive effect of MLC kinase on MAP kinase phosphorylation was revealed with 
the use of the MLC kinase inhibitor ML-7.  In the presence of ML-7, MAP kinase 
phosphorylation was significantly increased.  (C) The suppressive effect of MAP kinase 
on force was revealed with the use of the MAP kinase inhibitor U0126.  In the presence 
of U0126, steady state force significantly increased with an increase in MLC 
phosphorylation.   
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Figure 24. Regulation of cell migration and contraction by MAP kinase.  
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In fact, half-maximal ERK-activated MLCK required two
to threefold less calmodulin than MLCK not activated by
ERK. Together, these findings reveal that phosphoryla-
tion of MLCK by MAP kinase leads to increased MLCK
activity and a decreased requirement for calmodulin.
MAP Kinase–induced Cell Migration Requires MLCK 
Activity and MLC Phosphorylation
To establish a role for MLCK in the MAP kinase–induced
cell migration response, COS cells transfected with MEK1
were allowed to migrate in the presence or absence of the
MLCK inhibitor KT5926 (Nakanishi et al., 1990). As shown
in Fig. 7 A, upper panel, KT5926 not only blocked the MEK-
induced migration response but also prevented the phos-
phorylation of MLC in these cells in response to the ex-
pression of MEK1 (Fig. 7 A, lower panel). These findings
suggest that MLCK plays a pivotal role in the MAP ki-
nase–induced cell migration response.
To further establish that MLCK activity is required for
MAP kinase–induced cell migration, COS-7 cells express-
ing MEK1 were transfected with a mutationally inacti-
vated form of rabbit smooth muscle MLCK (MLCK[Mut])
containing a single in frame deletion at K725. Residue
K725 is predicted by alignment with other ser/thr kinases
to have a key role in binding ATP and thereby acting as a
dominant-negative enzyme (Hanks et al., 1988; Zoller et al.,
1981; Knighton et al., 1991). This recombinant enzyme ex-
pressed in COS cells has no detectable catalytic activity,
even at ATP concentrations that are 10-fold greater than the
KmATP determined for smooth muscle MLCK (Gallagher
et al., 1993). This enzyme was incapable of phosphorylat-
ing MLC in COS cells even though its calmodulin binding
capacity was identical to the wild-type enzyme (Gallagher,
P.J., unpublished results). Importantly, this mutant enzyme
expressed in COS cells not only blocked cell migration in-
duced by mutationally active MEK (Fig. 7 B, upper panel),
but it also prevented the MEK-induced MLC phosphory-
lation in these cells (Fig. 7 B, lower panel). In addition,
when EGF (100 ng/ml) was used to stimulate COS cell mi-
gration on collagen, expression of the mutant MLCK com-
pletely blocked the EGF-induced migration response (data
not shown). These results are consistent with the notion
that this mutant form of MLCK acts in a dominant-nega-
tive manner when introduced into MEK1 COS cells. It is
noteworthy that the activity of MAP kinase in the MEK1
cells was not significantly impacted by either the mutation-
ally inactive MLCK or the MLCK inhibitor KT5926 (Fig. 7),
suggesting that MLCK and MLC phosphorylation are down-
stream of MAP kinase and necessary for the migration of
these cells.
Model Depicting Role of MAP Kinase in Cell Migration
Based on the experiments described above and the work
of others, it is now possible to develop a model that depicts
the signaling pathway leading from integrin and/or growth
factor ligation to myosin activation and cell migration (Fig.
8). This model identifies a signaling pathway involving the
ability of MAP kinase to directly phosphorylate MLCK,
which in turn is better able to phosphorylate MLC. Impor-
tantly, this pathway is independent of the ability of MAP
kinase to translocate to the nucleus where it activates gene
transcriptional events involved in cell proliferation and
differentiation.
Discussion
Cellular recognition of growth factors and adhesive pro-
teins within the extracellular matrix influences whether a
cell undergoes proliferation, differentiation, or migration.
It is now clear that growth factor/cytokine receptors as
well as adhesion receptors influence the activity of one or
more members of the MAP kinase family of signaling mol-
ecules that have been implicated in a wide range of cell bi-
ological events. While MAP kinase signaling has been as-
sociated with the regulation of gene transcriptional events,
we now present evidence that MAP kinase can promote
cell migration on the extracellular matrix in a transcrip-
tion-independent manner. We propose that MAP kinase
can directly phosphorylate MLCK, thereby increasing its
ability to phosphorylate MLC, which promotes cytoskele-
tal contraction necessary for cell movement (Sellers and
Adelstein, 1987; Tan et al., 1992). While cell migration de-
pends on cell adhesion as well as deadhesion of cell surface
receptors and may be influenced by cell shape (Crowley and
Horwitz, 1995), our findings that MAP kinase induction of
MLCK activity has little or no influence on cell adhesion
or spreading suggests these events may be differentially
regulated. In fact, stress fiber formation and membrane
ruffling has been associated with activation of small G pro-
Figure 8. Model depicting role of MAP kinase in cell migration.
Proposed signaling pathway leading from integrin or growth fac-
tor receptor ligation to activation of cell migration. This model
takes into account that MAP kinase can be activated by integrins
and/or growth factors. As shown in this study, once activated,
MAP kinase can phosphorylate MLCK, which in turn shows en-
hanced activity as measured by its ability to phosphorylate MLC.
This model assumes that this phosphorylated MLC regulates the
cell’s actin-myosin motor function, thereby facilitating contrac-
tion leading to cell movement on the extracellular matrix.
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Figure 24. Regulation of cell migration and contraction by MAP kinase.   
MAP kinases are at the center of two signaling pathways, one leading to gene 
transcription and one leading to contraction.  The activity of a smooth muscle cell- 
whether if is in a proliferative or contractile phenotype- depends on its state of 
differentiation.  Differentiation depends on the extracellular milieu, local signals such as 
inflammatory cytokines, and the internal genetic program of the cell.  Precisely the 
degree to which MAP kinase has control of the determination of the cellular phenotype, 
and therefore differentiation or dedifferentiation, of the cell is still controversial.  In other 
words, does MAP kinase dictate instructions resulting in the phenotype of the cell or is 
MAP kinase activity altered in response to these instructions?  (Klemke, Cai et al. 1997).  
Reprinted with permission from Rockefeller University Press. 
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Figure 25. Development of a smooth muscle cell into a contractile phenotype  
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FIG. 1. Ontongeny of expression of smooth muscle cell (SMC) differentiation markers in developing vascular SMCs. 
Results shown illustrate earliest developmental stage that marker has been detected. To avoid confusion, I have not 
cited published reports that did not adequately distinguish non-smooth muscle (SM) versus SM isoforms of proteins 
that serve as SMC differentiation markers (e.g., SM a-tropomyosin versus skeletal or nonmuscle cr-tropomyosin, h- vs. 
1-caldesmon, y-vinculin vs. cu-, a’-, and P-vinculin) or did not comprehensively examine when in development the marker 
is first expressed. * lE12 is a monoclonal antibody recently developed against lo-day-old embryonic quail dorsal aorta 
by Hungerford and Little. (122). lE12 recognizes an as yet unidentified antigen that appears to be specific for SM and 
is first detectable in presumptive SMCs that surround dorsal aortic endothelium at embryonic day 3. ** Frid et al. (74) 
reported that major increases in expression of calponin and h-caldesmon occurred very late in development of humans 
(>22-24 wk of gestation). However, both calponin and h-caldesmon were detectable in the 9- to lo-wk-old human 
fetus, the earliest developmental stage examined. Glukhova and co-workers (87, 88) also reported late expression of 
h-caldesmon and metavinculin in humans with levels detectable but low in the lo-wk-old fetus. To my knowledge, 
developmental changes in expression of metavinculin and y-vinculin (a SM-selective isoform) have not been systemati- 
cally characterized in other species. *** Study by Muthuchamy et al. (177) was based on analysis in whole mouse 
embryos and did not resolve SM ar-tropomyosin in specific tissues. For purposes of this figure, I have assumed (unproven) 
that expression occurred in vascular SMCs. **** Studies of Miano et al. (164) relied on in situ hybridization with a 
probe that did not distinguish SM-1 and SM-2 myosin heavy chain (MHC) isoforms. However, on the basis of immunolabe- 
ling studies in rabbits (139) and humans (1) showing that SM-1 expression occurs much earlier that SM-2, it is likely 
that earliest SM MHC isoform detected by Miano et al. (164) was SM-1. e.d., Embryonic day (chicken or quail); p.c., 
days postcoitus (mouse). 
muscle tissue and cells as well as immature SMCs (252, 
275). Neither caldesmon isoform is detectable in adult 
skeletal and cardiac muscle. However, h-caldesmon is ex- 
pressed in B&H1 skeletal myoblasts following serum 
depletion and density-dependent differentiation (275). 
B&H1 cells, which were originally derived from a mouse 
brain tumor, were at one time thought to be of a smooth 
muscle lineage based on observations that they were con- 
tractile, expressed smooth muscle cu-actin, and were 
mononucleate. However, there is now compelling evi- 
dence that this is not the case, in that the cell expresses 
a multitude of skeletal muscle-specific proteins and most 
likely represents a fusion defective skeletal myoblast cell 
line (269). Whereas further studies are needed to deter- 
mine whether h-caldesmon is also transiently expressed 
by skeletal myoblasts in vivo, it is clear that h-caldesmon 
expression, like smooth muscle a-actin, smooth muscle 
MLCs, and calponin is not strictly limited to SMCs. As 
such, it cannot be used as an unambiguous marker for 
identification of SMC lineages to the exclusion of all other 
cell types. 
Expression of caldesmon is developmentally regu- 
lated in vascular as well as nonvascular smooth muscle. 
Duband et al. (64) first detected h-caldesmon in the dorsal 
aorta on embryonic day 6 in the chick. In developing 
gizzards, 1-caldesmon was detected in lo-day-old chick 
embryos (the earliest time point examined), whereas h- 
caldesmon was first detectable between 10 and 13 days of 
development (275). Expression of h-caldesmon increased 
progressively from day 13 in parallel with increases in 
desmin, myosin, and ,&tropomyosin. In contrast, expres- 
sion of 1-caldesmon decreased progressively to undetect- 
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Figure 25. Development of a smooth muscle cell into a contractile phenotype.   
This process of differentiation of a smooth muscle cell into the contractile 
phenotype begins with expression of smooth muscle (SM) a-actin.  Proteins that are 
specific to the contractile phenotype of smooth muscle cells begin to be expressed 
including calponin, h-caldesmon, and myosin heavy chain (MHC).  With the increased 
expression of contractile proteins, the shape of the cell changes from that of a fibroblast 
to an elongated, spindle-shaped cell.  The smooth muscle cell is not terminally 
differentiated and can revert back to the fibroblast-like shape under certain circumstances 
(Owens 1995).  Reprinted with permission from The American Physiological Society. 
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Figure 26.  Phenotypic modulation of smooth muscle cells. 
 
 
 
 
  
transcription factor serum response factor (SRF) binds to the
CArG box as a homodimer and activates gene transcription.
The affinity of SRF for the CArG boxes of VSMC contractile
genes is strongly enhanced by the cofactors myocardin and
myocardin-related transcription factors A and B (MRTF-A
and MRTF-B)1 (Figure 1B). Moreover, transcription of con-
tractile genes can be negatively regulated by Kru¨ppel-like
factor 4 (KLF4). KLF4 is a potent repressor of contractile genes
and functions through multiple mechanisms, including remod-
eling the chromatin of CArG box-containing promoters, seques-
tering SRF, and reducing myocardin expression1 (Figure 1B).
Diverse mechanisms have been identified to regulate contractile
Figure 1. Regulation of vascular smooth muscle cell (VSMC) phenotype. A, In response to a variety of stimuli, VSMCs switch between
contractile phenotype and synthetic phenotype. Although not mutually exclusive, contractile phenotype is characterized by high expres-
sion of contractile genes and low rates of proliferation and migration. Conversely, synthetic VSMCs express low levels of contractile
genes and have increased rates of proliferation and migration. MicroRNAs (miRs) reported to promote contractile and synthetic pheno-
type are indicated. B, Transcriptional regulation of VSMC contractile gene expression involves binding of serum response factor (SRF)
and either myocardin or myocardin-related transcription factor (MRTF)-A/B to CArG box elements located within the promoter of con-
tractile genes. Kru¨ppel-like factor 4 (KLF4) is a potent repressor of myocardin/MRTF-A/B activity.
Davis-Dusenbery et al Regulation of VSMCs by miRNAs 2371
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Figure 26.  Phenotypic modulation of smooth muscle cells.   
Diverse extracellular signals such as injury, stress, hypoxia, or growth signals can 
influence a cell to modulate from a contractile phenotype to a secretory/migratory 
phenotype.  This switch is accompanied by the increased expression of microRNAs that 
are believed to orchestrate the reprogramming of the cell.  There is an entire field 
dedicated to studying the mechanisms responsible for phenotypic switching in smooth 
muscle cells as it is a definitive event in disease processes such as atherosclerosis (Davis-
Dusenbery, Wu et al. 2011).  Reprinted with permission from Wolters Kluwer Health, 
Inc. 
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Figure 27.  Sustained contraction with Bay K8644 in the presence of the MAP kinase 
inhibitor U0126, the MLC kinase inhibitor ML-7, and both inhibitors. 
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Figure 27. Sustained contraction with Bay K8644 in the presence of the MAP kinase 
inhibitor U0126, the MLC kinase inhibitor ML-7, and both inhibitors.   
Bay K8644-stimulated development of force was prevented in the presence of the 
MLC kinase inhibitor ML-7.  The addition of the MAP kinase inhibitor U0126 
significantly increased Bay K8644-induced force.   In the presence of both U0126 and 
ML-7, force increased to levels significantly above basal but significantly less than Bay 
K8644-induced force alone.  Therefore, inhibition of MAP kinase activity “rescues” the 
force that was decreased by inhibition of the MLC kinase.  This suggests that inhibition 
of MAP kinase with U0126 increased Bay K8644-stimulated force in a MLC kinase-
independent way.  Significance was determined using a One Way Repeated Measures 
ANOVA.   * p<0.05  ** p<0.001 compared to Bay K8644 stimulation.  n = 5-15 
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Figure 28. MLC phosphorylation in the presence of U0126, ML-7, and U0126 plus ML-
7 during a Bay K8644-stimulated contraction. 
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Figure 28. MLC phosphorylation in the presence of U0126, ML-7, and U0126 plus ML-
7 during a Bay K8644-stimulated contraction. 
The addition of the MLC kinase inhibitor ML-7 significantly decreased MLC 
phosphorylation during Bay K8644-stimulated force.  The MAP kinase inhibitor U0126 
did not significantly affect Bay K8644-stimulated force.  The use of both ML-7 and 
U0126 together during a Bay K8644-dependent contraction resulted in a significant 
decrease in MLC phosphorylation as compared to Bay K8644 alone but similar to that 
obtained in the presence of ML-7 during a Bay K8644 stimulated contraction.  Note that 
as shown in Figure 27, the addition of U0126 in the presence of ML-7 increased force as 
compared to ML-7 alone during Bay K8644 stimulation.  This suggests that the effect of 
ML-7 overcame the effect of U0126 in terms of MLC phosphorylation but U0126 
"rescued" the ML-7-dependent inhibition of force.   
Bars represent mean ± SEM.  Significance was determined with a One Way ANOVA 
with multiple comparisons to Bay K8644 stimulation using the Holm-Sidák Method.   
*** p<0.001   n = 8 
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Figure 29.  Dual phosphorylation of p42/44 MAP kinase during stimulation with Bay 
K8644 stimulation in the presence of ML-7, U0126, or ML-7 plus U0126. 
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Figure 29.  Dual phosphorylation of p42/44 MAP kinase during stimulation with Bay 
K8644 in the presence of ML-7, U0126, or ML-7 plus U0126. 
Inhibiting MLC kinase with ML-7 significantly increased MAP kinase 
phosphorylation.  The MAP kinase inhibitor U0126 inhibited p42/44 phosphorylation, 
regardless of the inclusion of ML-7.  This confirms the earlier result that inhibition of 
MLC kinase significantly increases p42/44 MAP kinase phosphorylation during a 
sustained Bay K8644 contraction.  Bars represent mean ± SEM.  Significance was 
determined with a One Way ANOVA with multiple comparisons o Bay K8644 
stimulation with the Holm-Sidák Method.  ** p <0.01 compared to Bay K8644-
stimulated phosphorylation of p42.  †† p <0.01 compared to Bay K8644-stimulated 
phosphorylation of p44.  n = 6 
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Figure 30.  MLC kinase phosphorylation during sustained Bay K8644 contraction in the 
presence of ML-7, U0126, or ML-7 plus U0126. 
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Figure 30.  MLC kinase phosphorylation during sustained Bay K8644 contraction in the 
presence of ML-7, U0126, or ML-7 plus U0126. 
(A) Phosphorylation of MLC kinase at the Serine1760 residue increased during a 
sustained Bay K8644-stimulated contraction.  (B) The MLC kinase inhibitor significantly 
decreased MLC kinase phosphorylation compared to phosphorylation during a Bay 
K8644-stimulated contraction.  The MAP kinase inhibitor U0126 did not affect Bay 
K8644-induced MLC kinase phosphorylation.  When both inhibitors (ML-7 and U0126) 
were present, the effect of U0126 reversed the inhibitory effect of ML-7 on MLC kinase 
phosphorylation.  In the presence of both inhibitors, MLC kinase phosphorylation 
remained elevated and similar to that in the presence of Bay K8644 alone.  Bars represent 
mean ± SEM.  Significance was determined with a One Way ANOVA with multiple 
comparisons o Bay K8644 stimulation with the Holm-Sidák Method.  * p <0.05  *** p 
<0.001 compared to Bay K8644-induced MLC kinase phosphorylation.  n = 4 
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Figure 31. Phosphorylation of p38 MAP kinase and JNK isoforms of the MAP kinase 
family during sustained Bay K8644-stimulated contraction in the absence and presence of 
ML-7 or U0126. 
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Figure 31. Phosphorylation of p38 MAP kinase and JNK isoforms of MAP kinase family 
during sustained Bay K8644-stimulated contraction in the absence or presence of ML-7 
or U0126. 
 JNK phosphorylation was visualized at Threonine183/Tyrosine185 during a 
sustained Bay K8644-induced contraction in the presence and absence of ML-7, U0126, 
and ML-7 plus U0126.  There was no detectable JNK phosphorylation during any 
condition examined.  Visualization of total JNK protein confirmed the kinase was present 
in the tissue sample.  p38 MAP kinase phosphorylation was visualized at 
Threonine180/Tyrosine182 during the same conditions described above.  There was a 
stable, unaltered degree of p38 MAP kinase phosphorylation in all samples regardless of 
treatment.  These results were interpreted as a lack of involvement of JNK and p38 MAP 
kinases in sustained contraction stimulated by LTCC opening.  n = 4.    
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Specific Aim 3:  
To determine the involvement of p21-activated kinase in regulating p42/44 MAP kinase 
and MLC kinase activity during sustained vascular smooth muscle contraction. 
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Introduction. 
The results of Aims 1 and 2 suggest the presence of a unique signaling pathway 
involved in developing prolonged vascular smooth muscle force stimulated by opening of 
LTCC in response to Bay K8644 stimulation.  In Aim 1, inhibition of MAP kinase with 
U0126 increased sustained force (Figure 16E) and levels of MLC phosphorylation 
(Figure 18B).  Conversely, inhibition of MLC kinase with ML-7 increased MAP kinase 
phosphorylation and therefore MAP kinase activity (Figure 21).  When the inhibitors of 
MAP kinase and MLC kinase were used together in Aim 2, sustained force was preserved 
(Figure 27) but MLC phosphorylation levels were significantly decreased (Figure 28), 
representing an uncoupling between force and MLC phosphorylation.  This suggests that 
the ability of U0126 to increase Bay K8644-stimulated force can be associated with an 
increase in MLC phosphorylation (Aim 1), but when MLC kinase is inhibited with ML-7, 
U0126 “rescues” force in the absence of a significant increase in MLC phosphorylation 
(Aim 2).  Considering that MLC kinase inhibition significantly increased MAP kinase 
phosphorylation, there appears to be crosstalk between MLC kinase and MAP kinase 
during a sustained LTCC-mediated contraction in vascular smooth muscle.  The results of 
Aim 1 revealed this interplay between Bay K8644-stimulated force, MLC 
phosphorylation, and p42/44 MAP kinase phosphorylation.  The results of Aim 2 
explored this effect further and showed that the effect is selective to the p42/44 isoform 
of MAP kinase.    
MAP kinases have several substrates, most of which are nuclear transcription 
factors (Cargnello and Roux 2011).  A known MAP kinase substrate that affects smooth 
muscle contraction is caldesmon (Childs and Mak 1993), though its involvement in 
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sustained contraction in response to LTCC opening has already been ruled out (Figure 
22).  However, searching for a signaling link between MLC kinase and MAP kinase 
resulted in uncovering PAK1, a signaling protein present in vascular smooth muscle that 
is upstream of both MLC kinase and p42/44 MAP kinase.  
p21-activated kinase (PAK1) is a ubiquitous signaling protein that has diverse 
cellular functions and has demonstrated importance in muscle contraction.  PAK1 
consists of a protein binding domain, an autoinhibitory domain, and a catalytic kinase 
domain (Sheehan, Ke et al. 2007).  PAK1 exists in its inactivated form as a dimer in the 
cytosol and binding of GTP-bound Rac1 or Cdc42 activates PAK1 by dissociating 
dimerization allowing PAK1 monomers to autophosphorylate and become activated 
(Knaus, Wang et al. 1998, Parrini, Lei et al. 2002).  Once activated, PAK1 can 
phosphorylate a number of substrates depending on the cell type and the initiating 
extracellular signal.  PAK1 typically mediates cell growth, proliferation, motility, and 
actin cytoskeleton dynamics (Q Li, Spinelli et al. 2006, Sells, Knaus et al. 1997, Smith, 
Jaffer et al. 2008).  Its expression and activity are significantly dysregulated in cancers 
such as bladder (Huang, Chen et al. 2014), pancreatic (Zhou, Jubb et al. 2014), and breast 
cancer (Shrestha, Schafer et al. 2012).  For these reasons PAK1 is an attractive target for 
cancer therapeutics.   
 PAK1 activity is necessary for glucose uptake in skeletal muscle (Tunduguru, 
Chiu et al. 2014) and intracellular Ca2+ homeostasis in cardiac muscle (Y Wang, Tsui et 
al. 2014), both functions that are profoundly important for cell survival.  In smooth 
muscle cells, PAK1 signaling appears to regulate a number of contraction-related events.  
PAK1 phosphorylates the thin filament-associated protein caldesmon in isolated smooth 
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muscle cells, potentially a signaling pathway that may increase contractility (Foster, Shen 
et al. 2000).  PAK1 has also been shown to increase MYPT1 phosphorylation at the 
Threonine696 residue in intestinal smooth muscle, another potential pathway to increase 
contractility (Chu, Pham et al. 2013).  
 
PAK1 effects on MLC kinase and p42/44 MAP kinase 
PAK1 has been shown to inhibit MLC kinase activity (via phosphorylation) in 
isolated smooth muscle cells (Sanders, Matsumura et al. 1999) and intact guinea pig 
smooth muscle preparations (Wirth, Schroeter et al. 2003).  In the intact smooth muscle 
model, Wirth et al also found that PAK1 did not phosphorylate MLC or the thin filament-
associated protein caldesmon during a steady state contraction.  These findings contradict 
previous research that found PAK1 phosphorylates MLC (Chew, Masaracchia et al. 
1998) and caldesmon (Takizawa, Koga et al. 2002) during contraction in smooth muscle.  
The contradictory results could be explained by differences in the experimental models 
used or could indicate isoform-specific functions.  In addition to its effects on MLC 
kinase, PAK1 has been shown to phosphorylate and activate MAP kinase kinase, MEK 
(Frost, Steen et al. 1997); however this was determined in cultured HEK (human 
embryonic kidney) cells and not smooth muscle cells.  The collective effects of PAK1 on 
MLC kinase, p42/44 MAP kinase, and contraction were the focus of this Aim.  
The goal of this Aim was to test the hypothesis that p21-activated kinase is the 
upstream signaling molecule that regulates the activity of both MAP kinase and MLC 
kinase (as depicted in Figure 32) in vascular smooth muscle during sustained contraction 
stimulated by LTCC opening with Bay K8644. 
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Rationale. 
The results of Aims 1 and 2 suggested a signaling crosstalk between MLC kinase 
and p42/44 MAP kinase during the development of sustained vascular smooth muscle 
contraction.  What mediates this effect is unknown.  After consulting several protein 
kinase substrate databases accessible online (Human Protein Reference Database, 
PhosphoNetworks, Reactome, Kinase Substrate Database, Uniprot Proteome, the 
MaxQuant Database) to determine if there are any recorded upstream or downstream 
substrates shared by MLC kinase and MAP kinase, the focus turned to PAK1 because of 
its presence in smooth muscle, its role as a regulator of diverse intracellular signaling 
pathways including contraction (Foster, Shen et al. 2000, Sanders, Matsumura et al. 1999, 
Sells, Knaus et al. 1997, B Webb, Zhou et al. 2006), and most importantly its potential 
role in phosphorylation and therefore regulation of both MLC kinase and MAP kinase 
(Park, Eblen et al. 2007, Wirth, Schroeter et al. 2003).  A commercially available 
inhibitor of PAK1 was used to test its effects during sustained vascular smooth muscle 
contraction.  The inhibitor, IPA-3, targets the auto-regulatory domain of PAK1 and 
promotes the inactive conformation (Deacon, Beeser et al. 2008).   
PAK1 was inhibited during a sustained Bay K8644-induced contraction, and the 
force output was correlated with the intracellular signaling events MLC phosphorylation, 
p42/44 MAP kinase phosphorylation, MLC kinase phosphorylation, and PAK1 
phosphorylation.  Force is the physiological output to which all intracellular activities 
were related.  Tissues were rapidly frozen during a sustained contraction in order to 
capture the signaling events at that particular moment of contraction.  MLC 
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phosphorylation at Serine19 was visualized with urea/glycerol-PAGE as before.  p42/44 
MAP kinase phosphorylation at Tyrosine185/Threonine187 was visualized as an index of 
MAP kinase activity.  As in the previous Aim, MLC kinase phosphorylation at Serine1760 
was measured to determine whether PAK1 is involved in the phosphorylation, and 
therefore inhibition, of MLC kinase.  Finally, PAK1 phosphorylation at Serine144 was 
visualized as an index of PAK1 activity.  Phosphorylation of PAK1 at the Serine144 
residue, located in the kinase inhibitory domain, substantially contributes to PAK1 
activation (Chong, Tan et al. 2001).  
 
Results. 
Sustained isometric force in response to Bay K8644 in the presence of PAK1 inhibition 
 The small molecule PAK1 inhibitor, IPA-3, was used to determine if PAK1 is 
involved in sustained vascular smooth muscle force.  Bay K8644-stimulated force was 
significantly decreased in tissues treated with IPA-3 (Figure 33, open circles). As shown 
previously, Bay K8644-induced steady state force was greater in the presence of the 
MAP kinase inhibitor U1026 (Figure 33, closed triangles) than with Bay K8644 
stimulation alone (Figure 33, closed circles).  When the inhibitors of MAP kinase and 
PAK1 were used together, the effect of U0126 overcame that of IPA-3-dependent 
inhibition of force resulting in significantly increased force development (Figure 33, 
open triangles).  
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MLC phosphorylation and inhibition of PAK1  
 MLC phosphorylation at Serine19 was assessed by urea/glycerol-PAGE.  
Inhibition of PAK1 with IPA-3 decreased the degree of MLC phosphorylation during a 
Bay K8644 contraction (Figure 34, left set of bars).  The presence of the MAP kinase 
inhibitor U0126 did not change MLC phosphorylation levels compared to Bay K8644 
stimulation alone, but there appeared to be a slight increase.  When IPA-3 was used 
together with U0126 during Bay K8644-induced contraction, MLC phosphorylation did 
not change compared to U0126 and Bay K8644 alone (Figure 34, right set of bars).   
 
MAP kinase phosphorylation during PAK1 inhibition 
 Inhibiting PAK1 with IPA-3 decreased p42/44 MAP kinase phosphorylation 
during sustained Bay K8644-stimulated contraction.  When IPA-3 was used together with 
the MAP kinase inhibitor U0126 during Bay K8644-stimulated contraction, p42/44 MAP 
kinase phosphorylation was further and significantly decreased as compared to the 
addition of IPA-3 (Figure 35).  The MAP kinase inhibitor U0126 inhibited nearly all 
MAP kinase phosphorylation as demonstrated earlier in Aim 1 (Figure 21) and Aim 2 
(Figure 29). 
 
MLC kinase phosphorylation during inhibition of PAK1 and MAP kinase 
 As shown previously, MLC kinase phosphorylation increased during a steady 
state contraction stimulated by the LTCC agonist Bay K8644 (Figure 36A).  PAK1 
inhibition with IPA-3 increased MLC kinase phosphorylation at Serine1760 (Figure 36B). 
Tissues treated with Bay K8644 plus U0126 resulted in MLC kinase phosphorylation 
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levels comparable to that measured during Bay K8644 stimulation alone.  The use of 
IPA-3 and U0126 together resulted in greater MLC kinase phosphorylation compared to 
Bay K8644 stimulation alone, though the effect was not significant.  The general trend 
was that MLC kinase phosphorylation increased in the presence of the PAK1 inhibitor 
IPA-3 suggesting that active PAK1 suppresses or inhibits this effect in vascular smooth 
muscle. 
 
PAK1 phosphorylation at Serine144 during Bay K8644-induced sustained force 
 PAK1 phosphorylation was examined at the Serine144 residue because 
phosphorylation at this site has been shown to significantly contribute to PAK1 activation 
(Chong, Tan et al. 2001).  In basal unstimulated tissues, there is PAK1 Serine144 
phosphorylation indicating constitutive PAK1 function (Figure 37A).  The presence of 
IPA-3 decreased Serine144 phosphorylation compared to Bay K8644 stimulation, 
evidence that IPA-3 inhibited PAK1 activity as expected.  The inhibitor IPA-3 did not 
fully abolish PAK1 phosphorylation.  The addition of U0126 did not alter the level of 
PAK1 phosphorylation compared to Bay K8644 alone (Figure 37B).  
 
Discussion. 
 The goal of this Aim was to determine whether PAK1 is a regulator of the 
observed MAP kinase-MLC kinase effect shown in Aim 1 and explored further in Aim 2.  
The small molecule inhibitor of PAK1, IPA-3, was used to inhibit PAK1 activity during 
sustained vascular smooth muscle contraction stimulated with Bay K8644.   
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Isometric force  
Force was significantly decreased by PAK1 inhibition demonstrating that PAK1 
activity plays a role in initiating and maintaining contraction.  The action of PAK1 to 
prevent force development was reversed by the addition of the MAP kinase inhibitor 
U0126.  Bay K8644-induced force was significantly increased in the presence of both 
IPA-3 and U0126 compared to force developed and maintained in the presence of IPA-3 
alone.  This indicates that MAP kinase inhibition affects force by a PAK1-independent 
mechanism.  This suggests that inhibition of MAP kinase with U0126 rescued Bay 
K8644-stimulated force in a PAK1-independent way similarly to what was seen in Aim 2 
when U0126 rescued force in a MLC kinase-independent way (Figure 27).  Therefore, 
p42/44 MAP kinase activity and inhibition of this activity are affecting force in a way 
that is not reliant on any identified pathway or protein.  This adds further credibility to 
the fact that the p42/44 MAP kinase effect on vascular smooth muscle contraction is a 
novel mechanism.  One possibility is that, during Bay K8644-dependent steady state 
force maintenance, MAP kinase has a suppressive effect on force and acts downstream of 
PAK1 and MLC kinase.  Inhibition of p42/44 MAP kinase with U0126 shows profound 
effects on force, not only increasing Bay K8644-stimulated force but increasing force that 
is prevented by inhibition of two kinases, PAK1 or MLC kinase, that are necessary for 
contraction.  This could be interpreted as demonstrating the presence of a constitutively 
active p42/44 MAP kinase that inhibits increases in MLC phosphorylation and force in 
arterial smooth muscle. 
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MLC phosphorylation 
Similar to the results showing the effect of inhibition of PAK1 on force, inhibition 
of PAK1 with IPA-3 decreased MLC phosphorylation during a Bay K8644-stimulated 
contraction.  MAP kinase inhibition with U0126 appeared to increase MLC 
phosphorylation but the effect was not statistically significant.  This increase in MLC 
phosphorylation was unaffected by the use of IPA-3 and U0126 together, as MLC 
phosphorylation levels were comparable to that measured in the presence of only U0126.  
Perhaps U0126 is able to maintain levels of MLC phosphorylation that would otherwise 
be decreased in the presence of IPA-3.  However this would oppose the earlier finding 
that U0126 rescued force inhibited by ML-7 without a concomitant increase in levels of 
MLC phosphorylation (Figures 27 and 28).  U0126 can significantly increase Bay 
K8644-stimulated force even when force development was inhibited by the MLC kinase 
inhibitor ML-7 or the PAK1 inhibitor IPA-3.  The high variability of the MLC 
phosphorylation results that do not correlate with the recorded force results suggests that 
perhaps these two events are not as tightly coupled as previously thought, at least during 
a sustained contraction. The effect of inhibition of MAP kinase with U0126 may be 
interpreted as a compensatory effect to maintain elevated MLC phosphorylation levels 
and hence force.  The inhibitory effect of IPA-3 on force was reversed by the addition of 
U0126.   However the inhibition of MAP kinase with U0126 is affecting force, it does not 
appear to be affected by inhibition of MLC kinase or PAK1. 
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MAP kinase and MLC kinase phosphorylation 
Inhibition of PAK1 with IPA-3 decreased p42/44 MAP kinase phosphorylation 
which agrees with a study that determined PAK1 activates MEK, the kinase upstream of 
p42/44 MAP kinase activation (Park, Eblen et al. 2007).  This result adds to the evidence 
that PAK1 is upstream of p42/44 MAP kinase and contributes at least partially to MAP 
kinase phosphorylation and activation.  The presence of U0126 decreased MAP kinase 
phosphorylation and there appeared to be an additive decrease in MAP kinase 
phosphorylation when U1026 and IPA-3 were used concurrently.   
Phosphorylation of MLC kinase at Serine1760, an indication that MLC kinase 
activity is inhibited, was significantly increased during a sustained Bay K8644-induced 
contraction.  This may be a protective measure to prevent unregulated force generation.  
The Bay K8644-induced increase in MLC kinase phosphorylation was further increased 
by inhibition of PAK1 with IPA-3.  This is inconsistent with the literature stating that 
PAK1 inhibits MLC kinase activity via phosphorylation (Goeckeler, Masaracchia et al. 
2000, Sanders, Matsumura et al. 1999).  If uninhibited PAK1 phosphorylates MLC kinase 
then inhibition of PAK1 should result in a decrease and not an increase in MLC kinase 
phosphorylation.  The inclusion of U0126 did not affect MLC kinase phosphorylation 
indicating that p42/44 MAP kinase may not be involved in MLC kinase phosphorylation.  
The results suggest that p42/44 MAP kinase affects MLC phosphorylation in a MLC 
kinase-independent way. 
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PAK1 phosphorylation 
PAK1 phosphorylation at Serine144 decreased to approximately 60% of that 
recorded during sustained Bay K8644-stimulated contraction in the presence of the PAK1 
inhibitor IPA-3.  Because the inhibitor IPA-3 did not completely abolish PAK1 
phosphorylation at Serine144 the implication is that IPA-3 did not effectively inhibit 
PAK1 activity.  This is unlikely as IPA-3 did have significant inhibitory effects on Bay 
K8644-induced force and p42/44 MAP kinase phosphorylation.  The MAP kinase 
inhibitor U0126 also had no discernible effect on PAK1 phosphorylation compared to 
Bay K8644 stimulation alone.  This suggests that MAP kinase does not affect PAK1 
phosphorylation and activation, and agrees with MAP kinase being downstream of 
PAK1.  
 
 In summary, PAK1 is an important regulator of sustained vascular smooth muscle 
force and is upstream of both MLC kinase and p42/44 MAP kinase. The pathway shown 
in Figure 38 illustrates the interactions between the various kinases.  PAK1 contributes 
to p42/44 MAP kinase activation.  Once activated, p42/44 MAP kinase has a suppressive 
effect on both MLC phosphorylation and the magnitude of sustained force in response to 
LTCC opening with Bay K8644.  PAK1 also prevents MLC kinase from being 
phosphorylated, an event that inhibits MLC kinase activity. This agrees with the decrease 
in MLC phosphorylation seen during PAK1 inhibition because MLC kinase 
phosphorylation decreases its' affinity to Ca2+/calmodulin and would hence decrease 
MLC phosphorylation These two functions of PAK1 have opposite effects on force but it 
is likely there are additional components to this pathway that direct the signaling down 
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one cascade instead of the other.  Taken together the results provide evidence of a novel 
modulatory pathway that regulates sustained vascular smooth muscle that has not been 
described previously.   
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Figures: Specific Aim 3 
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Figure 32.  PAK1 as a regulator of MLC kinase and MAP kinase activity in sustained 
smooth muscle contraction. 
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Figure 32.  PAK1 as a regulator of MLC kinase and MAP kinase activity in sustained 
smooth muscle contraction. 
 Based on the evidence in the literature that PAK1 is expressed in smooth muscle 
cells, affects contraction, and upstream of both MLC kinase and p42/44 MAP kinase, we 
hypothesized that the effects seen in the previous two Aims may be mediated by PAK1 
acting through MLC kinase and p42/44 MAP kinase.  Arrows indicate an excitatory 
effect and blunted lines indicate an inhibitory effect.  We sought to determine the effect 
of PAK1 inhibition on sustained Bay K8644-mediated force and the downstream 
parameters of MLC phosphorylation, MLC kinase phosphorylation, and MAP kinase 
phosphorylation.    
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Figure 33.  Time course of Bay K8644-induced force in the presence of IPA-3,U0126, 
and both IPA-3 and U1026 
 
 
 
  
* 
** ** 
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Figure 33.  Time course of Bay K8644-induced force in the presence of IPA-3,U0126, 
and both IPA-3 and U0126 
Bay K8644 stimulation resulted in a slow rise in force that plateaued at 
approximately 60-70% of a maximal 110mM KCl-induced contraction (closed circles).  
Inhibition of MAP kinase with U0126 resulted in a higher steady state force than in 
response to Bay K8644 alone (closed triangles).  Inhibition of PAK1 with IPA-3 
significantly decreased Bay K8644-stimulated force (open circles).  This decrease in 
force was significantly reversed by inclusion of the MAP kinase inhibitor U0126 (open 
triangles).  A One Way Repeated Measures ANOVA was performed to determine 
significance between Bay K8644 stimulation alone with Bay K8644 stimulation in the 
presence of inhibitors.  * p < 0.05  ** p < 0.01 compared to Bay K8644-stimulation 
alone.   n = 5-15 
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Figure 34.  The effect of IPA-3, U0126, and IPA-3 plus U0126 on Bay K8644-induced 
MLC phosphorylation. 
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Figure 34.  The effect of IPA-3,U0126, and IPA-3 plus U0126 on Bay K8644-induced 
MLC phosphorylation. 
Bay K8644-induced MLC phosphorylation was decreased by inhibition of PAK1 
with IPA-3.  Inhibition of MAP kinase with U0126 slightly increased MLC 
phosphorylation, though not significantly.  The use of IPA-3 and U0126 together did not 
decrease MLC phosphorylation compared to U0126 plus Bay K8644 indicating that 
U0126 increased (or reversed the inhibition) of MLC phosphorylation in the presence of 
IPA-3.  No significance was detected with a One Way ANOVA with multiple 
comparisons against Bay K8644 stimulation alone. n = 5 
 
 
  
 151 
Figure 35.  The effect of IPA-3, U0126, and IPA-3 plus U0126 on p42/44 MAP kinase 
phosphorylation. 
 
A. 
 
 
B. 
 
 
 
  
ba
sa
l 
Ba
yK
 
+U
01
26
 
ba
sa
l 
Ba
yK
 
+U
01
26
 
+ 100µM IPA-3 
p42/44 
MAPK 
phospho 
total 
†† 
†† 
** 
** 
†† 
* 
 152 
Figure 35.  The effect of IPA-3, U0126, and IPA-3 plus U0126 on p42/44 MAP kinase 
phosphorylation. 
Inhibition of PAK1 with IPA-3 significantly decreased p42 and p44 MAP kinase 
phosphorylation during a sustained Bay K8644-stimulated contraction.  The MAP kinase 
kinase inhibitor U0126 abolished MAP kinase phosphorylation.  There appears to be an 
additive effect on MAP kinase phosphorylation inhibition in the presence of U0126 plus 
IPA-3, suggesting that PAK1 is upstream of MAP kinase.  A One Way ANOVA with 
multiple comparisons against Bay K8644 stimulation alone was performed. 
* p < 0.05  ** p < 0.001 compared to p42 isoform of Bay K8644 stimulation alone. 
†† p < 0.001 compared to p44 isoform of Bay K8644 stimulation alone.  n = 5 
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Figure 36.  The effect of IPA-3, U0126, and IPA-3 plus U0126 on MLC kinase 
phosphorylation. 
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Figure 36.  The effect of IPA-3, U0126, and IPA-3 plus U1026 on MLC kinase 
phosphorylation. 
The increase in MLC kinase phosphorylation during a sustained Bay K8644-
stimulated contraction was further enhanced by inhibition of PAK1 with IPA-3.  
Inhibition of MAP kinase with U0126 had no discernible effect on MLC kinase 
phosphorylation.  A One Way ANOVA with multiple comparisons against Bay K8644 
stimulation alone revealed no significant differences.  n = 5 
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Figure 37.  The effect of IPA-3, U0126, and IPA-3 plus U0126 on PAK1 
phosphorylation. 
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Figure 37. The effect of IPA-3, U0126, and IPA-3 plus U0126 on PAK1 
phosphorylation. 
PAK1 was phosphorylated at Serine144 during a sustained Bay K8644-stimulated 
contraction.  This phosphorylation was markedly decreased in the presence of the PAK1 
inhibitor IPA-3.  Inhibition of MAP kinase with U0126 had no effect on PAK1 
phosphorylation and the results are comparable to that which was measured with Bay 
K8644 alone.  A One Way ANOVA with multiple comparisons against Bay K8644 
stimulation alone revealed no significant differences.  n = 5 
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Figure 38. Progression of the signaling pathway involving PAK1, MAP kinase, and 
MLC kinase during a sustained contraction in vascular smooth muscle in response to Bay 
K8644. 
A.      B. 
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Figure 38.  Proposed signaling pathway involving PAK1, MAP kinase, and MLC kinase 
during a sustained contraction in vascular smooth muscle in response to Bay K644. 
Based on the results of the three Aims of this thesis, we hypothesize that sustained 
vascular smooth muscle contraction induced by opening of LTCC involves PAK1 as a 
regulator of both MLC kinase and p42/44 MAP kinase.  In the following figures, arrows 
indicate an excitatory effect and blunted lines indicate an inhibitory effect.  A. Aims 1 
and 2 demonstrated that inhibition of MLC kinase significantly increased MAP kinase 
phosphorylation while inhibition of MAP kinase significantly increased contractile force 
and MLC phosphorylation.  B. Aim 3 tested the hypothesis that PAK1 regulates the 
signaling between MLC kinase and MAP kinase.  We believe PAK1 inhibits the 
phosphorylation of MLC kinase, keeping MLC kinase active and favoring force.  PAK1 
also activates MAP kinase, which has a dampening effect on force and MLC 
phosphorylation.  C. Put into the context of the other known modulatory mechanisms of 
force, PAK1 has two signaling arms with opposing actions.  In this way PAK1 maintains 
force and prevents uncontrolled contraction.  The modulatory mechanisms that can affect 
force through inhibiting MLC phosphatase via ROCK and PKC are not involved, 
indicated by the gray lines.  Disinhibition of caldesmon is also not involved.  The results 
indicate that PAK1 is upstream of MLC kinase and p42/44 MAP kinase with MLC kinase 
favoring contraction and p42/44 MAP kinase inhibiting contraction.  There may be 
additional components to this pathway that direct the signaling down one cascade instead 
of the other.  Taken together the results provide evidence of a novel modulation pathway 
that regulates sustained vascular smooth muscle that has not been described previously.   
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Discussion 
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Overview 
A unique feature of vascular smooth muscle is its ability to maintain an intrinsic 
level of contractile force, or tone (Folkow 1989, Meininger and Davis 1992).  The ability 
of vascular smooth muscle to develop force and maintain it for long periods of time is 
essential to the physiological role of the vasculature (Akata 2007, Moosmang, Schulla et 
al. 2003, Pelham, Ketsawatsomkron et al. 2012, Schepelmann, Yarova et al. 2015).  As 
such it is important to uncover the mechanisms involved.  The goal of this project was to 
mimic a state of increased tone in carotid vascular smooth muscle tissue by sub-
maximally activating L-type Ca2+ channels in order to elucidate the intracellular events 
responsible for maintaining long-term contraction or tone.  To this end, the following 
Specific Aims were completed:  
 
Specific Aim 1: To determine the intracellular signaling in vascular smooth 
muscle cells during sustained sub-maximal contraction in response to opening of L-type 
Ca2+ channel stimulation. 
Specific Aim 2: To determine the role of MAP kinase on MLC kinase activity 
and MLC phosphorylation during a sustained vascular smooth muscle contraction. 
Specific Aim 3: To determine the involvement of p21-activated kinase in 
regulating p42/44 MAP kinase and MLC kinase activity during sustained vascular 
smooth muscle contraction. 
 
The smooth muscle layer of the swine carotid artery was used as a model system 
to study signaling pathways and the phosphorylation state of proteins downstream from 
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opening LTCCs.  LTCC dysfunction is implicated in pathological states like hypertension 
(Joseph, Thakali et al. 2013, Kudryavtseva, Herum et al. 2014, Lawton, Brown et al. 
2012, Navedo, Cheng et al. 2010, Pratt, Bonnet et al. 2002).  The potent LTCC agonist 
Bay K8644 was used to mimic tone (Alonso, Rico et al. 1989) and produce a sustained 
contraction.  Pharmacological inhibitors against signaling proteins known or suspected to 
be involved in the development and maintenance of contraction were used to determine 
the intracellular signaling that regulates steady state force.  Phosphorylation of proteins of 
interest was visualized using Western blot and fluorescent secondary antibodies.   
The results revealed a lack of involvement of several known force-modulating 
pathways and a novel signaling pathway involving MLC kinase, p42/44 MAP kinase, and 
PAK1 during a sustained contraction induced by Bay K8644.  The kinases, MLC kinase, 
p42/44 MAP kinase, and PAK1, all affected phosphorylation of MLC, either directly or 
indirectly, and therefore contributed to steady state force.  PAK1 appears to be a regulator 
of MAP kinase and MLC kinase activity based on the finding that inhibition of PAK1 led 
to decreased activity of MAP kinase and MLC kinase, visualized with Western blots of 
phosphorylatable activation sites or downstream substrates.   
 
Investigating force modulatory mechanisms 
Surprisingly, the signaling events that are known to modulate contractile force 
were found to not be involved.  Calcium sensitization due to inhibition of MLC 
phosphatase was determined by measuring phosphorylation of the myosin-binding 
subunit, MYPT1, and a small phosphatase inhibitor protein, CPI-17.  Stimulation of 
LTCCs increases intracellular Ca2+ (Alvarez, Miner et al. 2010) and it was assumed that 
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Ca2+ sensitization mechanism would be involved in this sustained contraction.  MYPT1 
phosphorylation did not change during a sustained Bay K8644-induced contraction 
suggesting the ROCK-MYPT1 pathway is not required for the maintenance of force in 
vascular smooth muscle, at least not in response to calcium influx through LTCC (Figure 
19).  However, MYPT1 phosphorylation was significantly increased by inhibition of 
MAP kinase with U0126, a point discussed in greater detail below.  The PKC substrate 
CPI-17 was also not phosphorylated during a Bay K8644-induced contraction (Figure 
20).  These results suggest that inhibition of MLC phosphatase by either of these 
mechanisms (MYPT1 and CPI-17) did not contribute to the sustained Bay K8644-
mediated contraction.  The simplest explanation is that, with a constant leak of Ca2+ into 
the cell, Ca2+ sensitization mechanisms were not needed.   
Thin filament regulation by the actin-associated protein caldesmon was 
determined by measuring levels of caldesmon phosphorylation (Figure 22).  Caldesmon 
phosphorylation remained unchanged during the sustained contraction in response to 
stimulation of Bay K8644 alone or in the presence of any of the various inhibitors used in 
this study.  This indicates that thin filament-mediated force modulation by calcium does 
not play a role in this regulation of sustained force due to the influx of calcium through 
LTCC.  
 
Inconsistency of MLC phosphorylation  
 Typically the magnitude of force correlates with the relative amount of MLC 
phosphorylation at Serine19.  However there are conditions where force can be developed 
in the absence of MLC phosphorylation such as in response to PDBu, an activator of 
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PKC (Fulginiti, Singer et al. 1993) and during the “latch state” where slowly cycling 
force-bearing crossbridges are supported by low levels of MLC phosphorylation (Dillon, 
Aksoy et al. 1981).  In this thesis, there were several instances when an apparent 
uncoupling between force and MLC phosphorylation was found.  This occurred during 
the reversal of the ML-7 inhibition of Bay K8644-induced force by the presence of the 
MAP kinase inhibitor U0126.  The significant increase Bay K8644-induced force that 
was prevented by ML-7 was reversed by U0126 without a concomitant increase in MLC 
phosphorylation (Figure 28A).  Another example was the ROCK inhibitor H-1152 that 
prevented Bay K8644-dependentforce but did not significantly decrease levels of MLC 
phosphorylation (Figure 18B).  The results of this study suggest that MLC 
phosphorylation, although an important activator of smooth muscle contraction, is not 
reliable as an intracellular index of developed force, at least in this particular model and 
those previously cited.  It is probably, based on the latch state hypothesis, that during the 
long time course of the Bay K8644-induced force studied, MLC phosphorylation levels 
were transient as cross-bridges continually cycle to maintain force levels and transitioned 
from highly phosphorylated rapidly cycling crossbridges to slowly cycling, 
dephosphorylated latchbridges (Hai and Murphy 1989). 
 
p42/44 MAP kinase reduces maintained contractile force in response to Bay K8644 
dependent opening of LTCC  
 Inhibition of MAP kinase with U0126 resulted in significantly elevated force 
during steady state sustained force stimulated by prolonged opening of LTCCs in 
response to the addition of Bay K8644 (Figure 16E).  The ability of U0126 to increase 
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force reversed the inhibition of force by the addition of ML-7, the MLC kinase inhibitor, 
and IPA-3, the PAK1 inhibitor.  Bay K8644-stimulated force was prevented by the MLC 
kinase inhibitor ML-7 (Figure 16B) however ML-7 in the presence of U0126 to inhibit 
MAP kinase resulted in a significant increase in developed force (Figure 27).  Similarly, 
force development was significantly decreased by the PAK1 inhibitor IPA-3 but 
“rescued” in the presence of U0126 (Figure 33).  This indicates that U0126 affected Bay 
K8644-stimulated force in a MLC kinase- and PAK1-independent manner.  One possible 
explanation for this is the significant increase in the phosphorylation of MYPT1 
measured in the presence of U0126 and Bay K8644 (Figure 19).  The higher MYPT1 
phosphorylation levels results in greater levels of MLC phosphatase inhibition and 
greater levels of sustained MLC phosphorylation and hence force.  This would be a 
reasonable explanation for how U0126 increased force during Bay K8644-stimulated 
contraction however there was not always a significant increase in MLC phosphorylation 
during U0126 treatment.  There is evidence that MAP kinase can partially regulate 
contraction without MLC phosphorylation (Kwon, Lee et al. 2003) and that mechanism 
may be present in this model.  When U0126 was used with ML-7, there was significantly 
increased force but almost no MLC phosphorylation.  This inconsistency requires a closer 
look.  The mechanism(s) responsible for the ability of U0126 to increase force can only 
be speculated at this time but are clearly of great importance in determining how steady 
state force is maintained and the magnitude of the force maintained. 
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MLC kinase phosphorylation in response to Bay K8644-stimulation 
 Phosphorylation of MLC kinase inhibits its activation by calmodulin binding.  It 
was interesting to see that MLC kinase phosphorylation was very high during a 
prolonged contraction mediated by Bay K8644 compared to the unstimulated basal 
sample (Figures 30A and 36A).  This would suggest that MLC kinase activity is 
inhibited during a sustained contraction.  The Bay K8644-induced increase in MLC 
kinase phosphorylation can be interpreted as a protective measure against deleterious 
high levels of force generation.  The major discrepancy with the observed high level of 
MLC kinase phosphorylation during a Bay K8644-stimulated increase in force is that 
MLC phosphorylation levels were similarly elevated.  Future studies are needed to 
reconcile this apparent inconsistency.   
 
PAK1 is upstream of p42/44 MAP kinase and MLC kinase 
 The results suggesting that PAK1 is upstream of MLC kinase and MAP kinase 
agrees with reports from the literature that PAK1 is upstream of both MLC kinase 
(Goeckeler, Masaracchia et al. 2000, Sanders, Matsumura et al. 1999) and p42/44 MAP 
kinase (Park, Eblen et al. 2007).  Inhibiting PAK1 during a Bay K8644-induced 
contraction resulted in significantly decreased force (Figure 33), suggesting an important 
role for PAK1 in initiating and maintaining Bay K8644-stimulated force.  PAK1 was 
shown to be a key regulator of MLC phosphorylation and p42/44 MAP kinase 
phosphorylation because inhibiting PAK1 decreased both, though the effect on MAP 
kinase phosphorylation (Figure 35B) was more significant than on MLC phosphorylation 
(Figure 34B).  Concluding that PAK1 is upstream of MLC kinase and MAP kinase adds 
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another layer of complexity to the mechanisms of smooth muscle contraction, both the 
development and maintenance of force.   
   
Limitations 
Several limitations of this study deserve consideration and are addressed below:   
• The use of smooth muscle from a large conduit vessel allowed for isolation of an 
intact tissue strip that was primarily composed of smooth muscle cells however 
this tissue lacks spontaneous tone.  Tone had to be created with the application of 
an agonist, Bay K8644 (Alonso, Rico et al. 1989, Gopalakrishnan, Park et al. 
1985).  Small resistance arteries do exhibit spontaneous tone and their use may 
have made the model more physiologically relevant (Meininger and Davis 1992). 
• In order to isolate the effects of the inhibitors on vascular smooth muscle 
contraction, the endothelial layer of the vessel was removed.  Denuding the 
endothelium helps isolate the effects being observed but makes the model less 
physiological.  In vivo, the endothelium plays a critical role in mediating vascular 
smooth muscle contraction (Sandoo, van Zanten et al. 2010).  Duplicating all 
experiments with an intact endothelium would have added another layer of 
understanding to the mechanisms.     	
• The statistical  tests used may be too stringent and increase the probability of a 
Type II error.  Also, the required statistical power was not met for some of the 
analyses because of a low n.   
• It is known that LTCC activity can be regulated by intracellular protein kinases 
such as PKA (Chik, Li et al. 1996), PKC (Wu, Chen et al. 2009), and others 
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(Grueter, Abiria et al. 2006, Hosey, Chien et al. 1996, Xiong and Sperelakis 
1995).  The phosphorylation of intracellular subunits of LTCC was not measured 
but it could have provided valuable information about the involvement of LTCCs 
in prolonged contraction.    
 
These issues notwithstanding, the results of this thesis are compelling.  A 
progression of the results is depicted in Figure 38.  Panel A shows the results of Aim 1 
that MLC kinase had an inhibitory or suppressive effect on p42/44 MAP kinase and 
p42/44 MAP kinase has an inhibitory or suppressive effect on MLC phosphorylation and 
force.  The interaction between MLC kinase and p42/44 MAP kinase was explored in 
Aim 2 and was found to be exclusive to the p42/44 isoform of MAP kinase.  Aim 2 led to 
the hypothesis depicted in panel B.  PAK1, a ubiquitous kinase that has shown 
involvement in smooth muscle contraction (Chu, Pham et al. 2013, Gerthoffer and Gunst 
2001, Wirth, Schroeter et al. 2003), was hypothesized to regulate the interaction between 
MLC kinase and p42/44 MAP kinase.  Panel C shows this novel pathway in the greater 
context of other modulatory pathways of smooth muscle contraction.  Neither Ca2+ 
sensitization mechanisms of ROCK and PKC nor the disinhibition of caldesmon (CaD) 
were involved in the sustained contraction.  This novel pathway adds another layer of 
complexity to our understanding of what mechanisms mediate large artery smooth 
muscle contraction.  
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Clinical significance  
Vascular smooth muscle is unique in its ability to maintain contractile force 
without fatigue.  This function provides smooth muscle the ability to maintain adequate 
organ perfusion in resistance vessels and to provide support against high pressure in 
conduit vessels.  The question of how force is sustained in the absence of a contractile 
stimulus is of great interest to human health and disease because the systemic perfusion 
of blood regulated by vascular smooth muscle contractile state is vital to life.  Clarifying 
the mechanisms behind the ability of vascular smooth muscle to maintain force is 
necessary to understand the pathophysiologic changes in diseased tissue.   
 
Structural vs. functional changes 
Dysfunction in the vasculature can be of two forms, structural and functional.  
Structural changes are most associated with large arteries and functional changes with 
small arteries.  Thickening of the vessel wall, a common structural alteration, is attributed 
to increased production of ECM components like collagen and elastin (Arribas, Hinek et 
al. 2006) which can occur in response to extrinsic factors such as neuroendocrine 
signaling, blood glucose, and dietary salt (Zieman, Melenovsky et al. 2005).  Functional 
changes like increased contractility and/or sensitivity to contractile agonists are attributed 
to small arteries.  The causes of increased contractility include increased Ca2+ channel 
expression and activity, increased ROCK activity, dysfunctional PKC signaling, 
increased MLC kinase expression and activity, and many more intracellular signaling 
dysfunctions that are too numerous to detail here (Han, Hu et al. 2006, Joseph, Thakali et 
al. 2013, Lawton, Brown et al. 2012, Linde, Antos et al. 2012, Pesic, Madden et al. 2004, 
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Salamanca and Khalil 2005, Seko, Ito et al. 2003, Uehata, Ishizaki et al. 1997).  
Functional changes of smooth muscle in small arteries is also tightly coupled to 
endothelial cell dysfunction (Ribeiro, Antunes et al. 1992, Zhong, Chen et al. 2003). 
 
Vascular stiffening 
Thickening of the vascular wall reduces the elasticity and compliance of large 
arteries, depleting their ability to dampen pulse pressure of blood leaving the heart 
(McEniery, Wilkinson et al. 2007).  Carotid intimal medial thickness (cIMT) has become 
an early indicator of cardiovascular diseases such as coronary artery disease and stroke 
(O'Leary, Polak et al. 1999, Oren, Vos et al. 2003).  Vascular stiffening is part of normal 
ageing however it can be exacerbated by hypertension, dyslipidemia, and diabetes (Kim, 
Park et al. 2016, McEniery, Wilkinson et al. 2007, Oltman, Richou et al. 2006).  Current 
treatments for vascular stiffening are lifestyle changes meant to slow its progression—
namely diet and exercise (Zieman, Melenovsky et al. 2005).  Pharmacological 
interventions for vascular stiffening include diuretics, nitrates, and inhibitors of the renin-
angiotensin-aldosterone system, all of which act to reduce systemic blood pressure 
(Zieman, Melenovsky et al. 2005).  These drugs may help slow the progression of 
vascular stiffening but do not address the main issue of vessel remodeling.   
While stiffening affects the mechanical properties of the vessel as a whole, it is 
less clear how it affects functioning of the smooth muscle layer and intracellular 
signaling within smooth muscle cells.  Determining a baseline for large artery function 
and the interplay between plasma membrane-bound LTCCs and intracellular kinases lay 
a groundwork to study changes in these signaling pathways in diseased arterial tissue.  
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Identifying changes in kinase and LTCC functioning and the time course of said changes 
would provide a context for developing targeted therapies.   
 
The role of intracellular signaling 
 Studying intracellular signaling brings to light possible drug targets.  There has 
been success in treating hypertension with ROCK inhibitors (Abe, Shimokawa et al. 
2004, Doggrell 2005, Fukumoto, Yamada et al. 2013).  ROCK has shown to be an 
integral signaling node within vascular smooth muscle cells that communicates with 
membrane-bound LTCCs (Ouyang, Han et al. 2014, Ureña and Lopez-Barneo 2012) as 
well as proteins that directly affect actin cytoskeletal remodeling (Corteling, Brett et al. 
2007, Sumi, Matsumoto et al. 2001).  
PKC is a known modulator of vascular smooth muscle function (Ansari, Teng et 
al. 2009, Salamanca and Khalil 2005, Throckmorton, Packer et al. 1998).  It has been 
shown to be important for tone (Cobine, Callaghan et al. 2007) though its involvement 
was questionable in the present model.  This is surprising given evidence that PKC can 
modify LTCC function by phosphorylating its intracellular subunits (Chik, Li et al. 1996, 
Ren, Zhang et al. 2010, Wu, Chen et al. 2009).  It is possible that this mechanism is 
absent in large conduit arteries and only exists in small resistance vessels.  Another 
possibility is that its function in large arteries only becomes apparent in a disease state, 
not in normal healthy tissue. 
MAP kinase has a recognized role in smooth muscle contraction (Franklin, Wang 
et al. 1997, Hershenson, Chao et al. 1995, Katoch and Moreland 1995, Lagaud, Lam et al. 
1999).  Its involvement in the present study may seem unexpected because MAP kinase 
 171 
is not known to be Ca2+-activated but at least one study found MAP kinase activation in 
response to LTCC opening (Rosen, Ginty et al. 1994).  MAP kinase can also be activated 
by stretch (Hosokawa, Aiuchi et al. 2002, Spurrell, Murphy et al. 2003) and the intact 
muscle strips in this model were subjected to stretch in order to generate force. 
PAK1 also participates in vascular smooth muscle contraction in health and 
disease (Hinoki, Kimura et al. 2010).  Its ability to phosphorylate MAP kinase (Coles and 
Shaw 2002, Park, Eblen et al. 2007) and MLC kinase (Goeckeler, Masaracchia et al. 
2000, Sanders, Matsumura et al. 1999) fit well with the present study.  Further research 
should also include its effects on actin polymerization (Sells, Knaus et al. 1997, B Webb, 
Zhou et al. 2006), another critical component of vascular smooth muscle contraction.  
This would lead to a more complete picture of intracellular signaling dynamics during 
prolonged LTCC opening and may relate to stiffening of individual cells within the 
vessel wall.   
The roles of LTCCs and the feedback by intracellular kinases such as ROCK, 
PKC, MAP kinase, and PAK1 in determining large artery contractility and structure are 
still to be determined but this thesis provides relevant information for further exploration.   
 
Conclusion 
Large arteries, far from being inert conduits, are dynamic vessels that have not 
received as much attention as small resistance vessels.  The present study sought to 
determine the intracellular signaling coupled to LTCC activity during sustained 
contraction in carotid artery smooth muscle.  An extension of this work would be to 
compare the present results with the results from a diseased carotid artery with increased 
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cIMT.  The focus thus far has been on mechanical influences on the structural changes 
and less on intracellular signaling that may contribute to structural and functional 
changes.  It would be important to determine whether structural changes cause 
intracellular dysfunction or aberrant intracellular signaling cause structural changes.  
Such information would contribute to understanding what goes awry in disease states, 
creating opportunities to identify therapeutic targets in the hope of treating or reversing 
large artery dysfunction in disease states. 
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